var title_f11_11_11440="Gastric leiomyoma Endosc";
var content_f11_11_11440=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F58068&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F58068&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gastric leiomyoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 315px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopy shows a protuberance in the antrum with overlying normal appearing mucosa (arrow). The diagnosis of a gastric leiomyoma was made during a subsequent endoscopic ultrasound.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Laurence Bailen, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_11_11440=[""].join("\n");
var outline_f11_11_11440=null;
var title_f11_11_11441="Chagas heart disease Angio";
var content_f11_11_11441=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F79255&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F79255&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chronic Chagas' heart disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 309px; height: 363px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Coronary angiography and left ventriculography from a patient with chronic Chagas' disease complaining of chest pain. Myocardial perfusion imaging showed a large defect involving the anterolateral, apical, and posterolateral walls. Coronary angiography (upper panel) demonstarted normal right and left coronary arteries. However, the left ventriculogram in the right anterior oblique (RAO, middle panel) and left anterior oblique (LAO, bottom panel) views show normal global left ventricular function but mild hypokinesis of the anterolateral, apical, and posterolateral walls (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_11_11441=[""].join("\n");
var outline_f11_11_11441=null;
var title_f11_11_11442="Normal trachea MRI";
var content_f11_11_11442=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F73228&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F73228&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal trachea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 290px; height: 468px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Magnetic resonance image of a normal trachea seen on T1-weighted coronal spin echo sequence.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_11_11442=[""].join("\n");
var outline_f11_11_11442=null;
var title_f11_11_11443="Abortus pentalogy of Cantrell";
var content_f11_11_11443=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F58812&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F58812&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Abortus specimen showing an extensive anterior abdominal wall and thoracic defect typical of Pentalogy of Cantrell",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 326px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ana Monteagudo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_11_11443=[""].join("\n");
var outline_f11_11_11443=null;
var title_f11_11_11444="Contents: Primary care infectious disease";
var content_f11_11_11444=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Primary care infectious disease",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Primary care infectious disease",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Bacterial infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/48/39688\">",
"           Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/15/2297\">",
"           Acute sinusitis and rhinosinusitis in adults: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/46/23274\">",
"           Allergy to penicillins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/38/6758\">",
"           Antibiotic failure in the treatment of streptococcal tonsillopharyngitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/37/20058\">",
"           Antimicrobial therapy of native valve endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/3/15417\">",
"           Aseptic meningitis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/14/11494\">",
"           Blood cultures for the detection of bacteremia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/37/23129\">",
"           Clinical features and diagnosis of acute bacterial meningitis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/42/9895\">",
"           Clinical features and management of sepsis in the asplenic patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/19/38199\">",
"           Clinical manifestations and diagnosis of Legionella infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/52/37704\">",
"           Clinical manifestations of meningococcal infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/30/27110\">",
"           Complications of streptococcal tonsillopharyngitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/23/375\">",
"           Diagnosis of intravascular catheter-related infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/41/27285\">",
"           Diagnosis of meningococcal infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/24/41352\">",
"           Diagnostic approach to infective endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/58/32680\">",
"           Epidemiology and pathogenesis of Legionella infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/32/27145\">",
"           Epidemiology and pathogenesis of Pseudomonas aeruginosa infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/8/8327\">",
"           Epidemiology and pathogenesis of acute rheumatic fever",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/29/6616\">",
"           Epidemiology, clinical manifestations, and diagnosis of streptococcal toxic shock syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/31/14840\">",
"           Epidemiology, risk factors and microbiology of infective endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/38/5738\">",
"           Evaluation of acute pharyngitis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/23/31094\">",
"           Infective endocarditis: Historical and Duke criteria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/17/22810\">",
"           Initial therapy and prognosis of bacterial meningitis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/9/1177\">",
"           Prevention of sepsis in the asplenic patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/27/14775\">",
"           Pseudomonas aeruginosa bacteremia and endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/50/11049\">",
"           Septic arthritis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/0/2055\">",
"           Suppurative (septic) thrombophlebitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/56/20360\">",
"           Synovial fluid analysis and the diagnosis of septic arthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/15/33015\">",
"           Treatment and prevention of Legionella infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/0/25609\">",
"           Treatment and prevention of meningococcal infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/38/2666\">",
"           Treatment and prevention of streptococcal tonsillopharyngitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/20/7498\">",
"           Treatment of intravascular catheter-related infections",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Central nervous system infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/37/23129\">",
"           Clinical features and diagnosis of acute bacterial meningitis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/41/27285\">",
"           Diagnosis of meningococcal infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/17/22810\">",
"           Initial therapy and prognosis of bacterial meningitis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/6/19561\">",
"           Lumbar puncture: Technique; indications; contraindications; and complications in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/0/25609\">",
"           Treatment and prevention of meningococcal infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/3/38968\">",
"           Viral encephalitis in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Gastrointestinal infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/13/24790\">",
"           Acute cholangitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/17/32025\">",
"           Approach to the adult with acute diarrhea in developed countries",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/40/38535\">",
"           Clinical manifestations and diagnosis of Shigella infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/0/7172\">",
"           Clinical manifestations of spontaneous bacterial peritonitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/39/29305\">",
"           Clostridium difficile in adults: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/29/20954\">",
"           Clostridium difficile in adults: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/0/12296\">",
"           Diagnosis of spontaneous bacterial peritonitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/44/24265\">",
"           Differential diagnosis of microbial foodborne disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/14/43241\">",
"           Epidemiology, clinical manifestations and diagnosis of norovirus and related viruses",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/28/33224\">",
"           Epidemiology, clinical manifestations, and diagnosis of giardiasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/19/14649\">",
"           Microbiology and epidemiology of salmonellosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/19/18745\">",
"           Microbiology, pathogenesis, epidemiology, and prevention of enterohemorrhagic Escherichia coli (EHEC)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/25/34197\">",
"           Pathogenesis of spontaneous bacterial peritonitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/4/37960\">",
"           Pathogenic Escherichia coli",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/29/29145\">",
"           Travelers' diarrhea",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/26/39334\">",
"           Treatment and prevention of Shigella infection in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/1/4121\">",
"           Treatment and prophylaxis of spontaneous bacterial peritonitis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hepatitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/30/15847\">",
"           Approach to patients with chronic hepatitis C virus infection and normal serum aminotransferases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/13/32980\">",
"           Atypical manifestations of hepatitis A virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/50/31530\">",
"           Clinical manifestations and natural history of chronic hepatitis C virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/26/30122\">",
"           Clinical manifestations and natural history of hepatitis B virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/57/14230\">",
"           Diagnosis of hepatitis D virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/7/2169\">",
"           Epidemiology and transmission of hepatitis C virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/31/4602\">",
"           Epidemiology, transmission, and prevention of hepatitis B virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/8/15498\">",
"           Extrahepatic manifestations of hepatitis C virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/24/7557\">",
"           GB virus C (hepatitis G) infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/38/1641\">",
"           Hepatitis A virus vaccination and postexposure prophylaxis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/11/33976\">",
"           Hepatitis E virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/2/15402\">",
"           Liver transplantation for chronic hepatitis B virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/5/16474\">",
"           Liver transplantation for hepatitis C virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/59/35768\">",
"           Mechanism of action and efficacy of standard interferon alfa for the treatment of chronic hepatitis C virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/45/43735\">",
"           Overview of the management of chronic hepatitis C virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/11/15543\">",
"           Pathogenesis, epidemiology, natural history, and clinical manifestations of hepatitis D virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/59/38841\">",
"           Patient selection for antiviral therapy for chronic hepatitis C virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/55/41849\">",
"           Screening for and diagnosis of chronic hepatitis C virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/18/42279\">",
"           Serologic diagnosis of hepatitis B virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/60/14281\">",
"           Standard and pegylated interferon for chronic hepatitis B virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/3/22583\">",
"           Treatment and prevention of hepatitis D virus infection",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         HIV",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/7/43129\">",
"           Acute and early HIV infection: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/46/18151\">",
"           Acute and early HIV infection: Pathogenesis and epidemiology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/17/22808\">",
"           Acute and early HIV infection: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/43/20154\">",
"           Approach to the HIV-infected patient with pulmonary symptoms",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/25/7577\">",
"           Clinical presentation and diagnosis of Pneumocystis infection in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/46/12009\">",
"           Diagnosis of latent tuberculosis infection in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/55/20345\">",
"           Diagnostic assays for HIV infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/10/1194\">",
"           Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/32/40458\">",
"           HIV protease inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/25/37273\">",
"           Immunizations in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/47/7930\">",
"           Management of healthcare personnel exposed to HIV",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/37/42584\">",
"           Management of tissue wasting in patients with HIV infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/50/22312\">",
"           Pituitary and adrenal gland dysfunction in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/50/11047\">",
"           Pneumococcal immunization in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/42/33450\">",
"           Primary prevention of opportunistic infections in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/52/2889\">",
"           Prophylaxis against Pneumocystis infection in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/52/21320\">",
"           Techniques and interpretation of measurement of the CD4 cell count in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/2/13353\">",
"           The stages and natural history of HIV infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/31/38388\">",
"           Thyroid gland dysfunction in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/60/27593\">",
"           Treatment of Pneumocystis infection in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/12/4298\">",
"           Treatment of latent tuberculosis infection in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/35/19002\">",
"           Treatment of pulmonary tuberculosis in the HIV-infected patient",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Infective endocarditis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/57/34712\">",
"           Antimicrobial therapy of prosthetic valve endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/52/18249\">",
"           Complications and outcome of infective endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/40/2697\">",
"           Epidemiology, clinical manifestations, and diagnosis of prosthetic valve endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/17/40215\">",
"           Infective endocarditis in injection drug users",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/49/22297\">",
"           Surgery for native valve endocarditis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Non-HIV immune deficiency",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/27/8633\">",
"           Medical management of immune deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/24/7561\">",
"           Secondary immune deficiency due to miscellaneous causes",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/62/39913\">",
"           Acute otitis media in adults (suppurative and serous)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/35/8760\">",
"           Acute otitis media in children: Diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/60/29642\">",
"           Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/11/31927\">",
"           Approach to the adult with fever of unknown origin",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/10/24745\">",
"           Approach to the patient with eosinophilia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/54/7017\">",
"           Biology and genetics of prions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/10/17576\">",
"           Cerebrospinal fluid: Physiology and utility of an examination in disease states",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/26/1450\">",
"           Chronic otitis media, cholesteatoma, and mastoiditis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/24/30090\">",
"           Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/53/20313\">",
"           Complications, diagnosis, and treatment of odontogenic infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/48/28425\">",
"           Diagnosis of Lyme disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/28/31176\">",
"           Diseases of the central nervous system caused by prions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/30/16873\">",
"           Epidemiology, pathogenesis, and clinical manifestations of odontogenic infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/4/15431\">",
"           Etiologies of fever of unknown origin in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/41/26263\">",
"           Evaluation of a tick bite for possible Lyme disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/24/39304\">",
"           Evaluation of fever in the returning traveler",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/62/32743\">",
"           External otitis: Pathogenesis, clinical features, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/10/12456\">",
"           External otitis: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/21/18777\">",
"           Gingivitis and periodontitis in adults: Classification and dental treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/34/26152\">",
"           Important sites and pathogens causing infections in long-term care facilities",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/51/40759\">",
"           Lyme carditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/41/19096\">",
"           Marine toxins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/7/9336\">",
"           Musculoskeletal manifestations of Lyme disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/10/8361\">",
"           Pathophysiology and treatment of fever in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/30/489\">",
"           Principles of infection control in long-term care facilities",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/43/20152\">",
"           Skin lesions in the returning traveler",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/54/27498\">",
"           Treatment of Lyme disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Prevention",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/36/585\">",
"           Antimicrobial prophylaxis for bacterial endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/44/41670\">",
"           Approach to immunizations in healthy adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/38/1641\">",
"           Hepatitis A virus vaccination and postexposure prophylaxis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/60/31690\">",
"           Hepatitis B virus vaccination",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/0/13322\">",
"           Immunizations for healthcare providers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/21/2394\">",
"           Immunizations for travel",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/47/7930\">",
"           Management of healthcare personnel exposed to HIV",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/55/23416\">",
"           Management of healthcare workers exposed to hepatitis B virus or hepatitis C virus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/12/21705\">",
"           Pneumococcal vaccination in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/55/3960\">",
"           Prevention of Lyme disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/3/13370\">",
"           Prevention of malaria infection in travelers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/13/44249\">",
"           Prevention of seasonal influenza in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/26/37289\">",
"           Prevention of varicella-zoster virus infection: Chickenpox",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/22/36200\">",
"           Prevention of varicella-zoster virus infection: Herpes zoster",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/8/37002\">",
"           Seasonal influenza vaccination in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/54/7014\">",
"           Tetanus-diphtheria toxoid vaccination in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/48/8967\">",
"           Travel advice",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/1/31767\">",
"           Treatment and prevention of parvovirus B19 infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/40/36488\">",
"           Treatment of herpes simplex virus type 1 infection in immunocompetent patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/20/33096\">",
"           Treatment of herpes zoster in the immunocompetent host",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/36/23110\">",
"           Treatment of varicella-zoster virus infection: Chickenpox",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Respiratory infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/38/29289\">",
"           Acute bronchitis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/6/10341\">",
"           Adherence to tuberculosis treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/43/20154\">",
"           Approach to the HIV-infected patient with pulmonary symptoms",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/18/31017\">",
"           Aspiration pneumonia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/47/39673\">",
"           Clinical manifestations and evaluation of pulmonary tuberculosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/36/38473\">",
"           Community-acquired pneumonia in adults: Risk stratification and the decision to admit",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/23/21881\">",
"           Diagnosis and treatment of pulmonary histoplasmosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/26/26026\">",
"           Diagnostic approach to community-acquired pneumonia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/57/12183\">",
"           Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/38/5738\">",
"           Evaluation of acute pharyngitis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/43/7866\">",
"           Management of infection in acute exacerbations of chronic obstructive pulmonary disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/38/23143\">",
"           Microbiology and pathogenesis of Streptococcus pneumoniae",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/5/3162\">",
"           Mycoplasma pneumoniae infection in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/4/13386\">",
"           Pneumococcal pneumonia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/12/21705\">",
"           Pneumococcal vaccination in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/6/7270\">",
"           Pneumonia caused by Chlamydophila (Chlamydia) pneumoniae in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/56/7050\">",
"           Respiratory syncytial virus infection: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/17/15640\">",
"           Respiratory syncytial virus infection: Prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/27/38327\">",
"           Respiratory syncytial virus infection: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/11/17591\">",
"           Sputum cultures for the evaluation of bacterial pneumonia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/35/38455\">",
"           Symptomatic treatment of acute pharyngitis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/22/35176\">",
"           Tonsillectomy in adults: Indications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/38/6761\">",
"           Tonsillectomy in adults: Surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/24/24969\">",
"           Treatment of community-acquired pneumonia in adults in the outpatient setting",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/21/19802\">",
"           Treatment of pulmonary tuberculosis in HIV-negative patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/26/29096\">",
"           Tuberculosis in pregnancy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Sexually transmitted disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/15/12538\">",
"           Approach to the patient with genital ulcers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/49/36633\">",
"           Approach to women with symptoms of vaginitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/56/30602\">",
"           Bacterial vaginosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/1/15386\">",
"           Candida vulvovaginitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/28/10696\">",
"           Chancroid",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/0/1032\">",
"           Clinical features and diagnosis of pelvic inflammatory disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/63/37876\">",
"           Desquamative inflammatory vaginitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/35/26166\">",
"           Diagnosis of gonococcal infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/44/39624\">",
"           Diagnostic testing for syphilis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/56/3976\">",
"           Disseminated gonococcal infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/10/9386\">",
"           Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/20/38217\">",
"           Epidemiology, pathogenesis, and clinical manifestations of Neisseria gonorrhoeae infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/18/18728\">",
"           Genital Chlamydia trachomatis infections in men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/46/42728\">",
"           Genital Chlamydia trachomatis infections in women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/25/18837\">",
"           Laboratory monitoring of patients undergoing treatment for syphilis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/36/21063\">",
"           Lymphogranuloma venereum",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/44/26312\">",
"           Neurosyphilis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/45/11992\">",
"           Pathogenesis of and risk factors for pelvic inflammatory disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/9/37017\">",
"           Pathogenesis, clinical manifestations, and treatment of early syphilis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/48/776\">",
"           Pathogenesis, clinical manifestations, and treatment of late syphilis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/55/12150\">",
"           Pathophysiology, transmission, and natural history of syphilis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/63/35832\">",
"           Treatment of pelvic inflammatory disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/3/19514\">",
"           Treatment of uncomplicated gonococcal infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/53/1881\">",
"           Trichomonas vaginalis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Soft tissue and bone infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/50/12071\">",
"           Approach to imaging modalities in the setting of suspected osteomyelitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/33/12825\">",
"           Cellulitis and erysipelas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/21/21846\">",
"           Impetigo",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/22/39269\">",
"           Pathogenesis of osteomyelitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/51/43831\">",
"           Skin abscesses, furuncles, and carbuncles",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/24/28038\">",
"           Soft tissue infections due to dog and cat bites",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/18/31013\">",
"           Soft tissue infections due to human bites",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/46/5865\">",
"           Technique of incision and drainage for skin abscess",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Urinary tract infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/42/4776\">",
"           Acute bacterial prostatitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/15/13561\">",
"           Acute uncomplicated cystitis and pyelonephritis in women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/19/42295\">",
"           Approach to the adult with asymptomatic bacteriuria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/60/23496\">",
"           Chronic bacterial prostatitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/24/5514\">",
"           Recurrent urinary tract infection in women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/24/44422\">",
"           Urinary tract infection associated with urethral catheters",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/41/24214\">",
"           Urine sampling and culture in the diagnosis of urinary tract infection in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Viral infections (other than HIV)",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/44/33480\">",
"           Clinical features of varicella-zoster virus infection: Chickenpox",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/20/40265\">",
"           Clinical manifestations and diagnosis of herpes simplex virus type 1 infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/54/22377\">",
"           Clinical manifestations and pathogenesis of human parvovirus B19 infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/1/18456\">",
"           Clinical manifestations of seasonal influenza in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/20/2378\">",
"           Clinical manifestations of varicella-zoster virus infection: Herpes zoster",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/11/43192\">",
"           Clinical presentation and diagnosis of measles",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/4/77\">",
"           Diagnosis of varicella-zoster virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/8/23688\">",
"           Epidemiology and pathogenesis of varicella-zoster virus infection: Herpes zoster",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/58/15272\">",
"           Epidemiology of influenza",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/48/22278\">",
"           Epidemiology of varicella-zoster virus infection: Chickenpox",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/10/9386\">",
"           Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/14/33001\">",
"           Genital herpes simplex virus infection and pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/18/31018\">",
"           Infectious mononucleosis in adults and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/33/1558\">",
"           Pathogenesis and diagnosis of viral arthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/6/21608\">",
"           Postherpetic neuralgia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/15/21751\">",
"           Prevention of genital herpes virus infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/13/44249\">",
"           Prevention of seasonal influenza in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/26/37289\">",
"           Prevention of varicella-zoster virus infection: Chickenpox",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/22/36200\">",
"           Prevention of varicella-zoster virus infection: Herpes zoster",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/14/26855\">",
"           Rubella",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/51/23354\">",
"           Specific viruses that cause arthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/55/24440\">",
"           The common cold in adults: Diagnosis and clinical features",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/52/30537\">",
"           The common cold in adults: Treatment and prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/1/31767\">",
"           Treatment and prevention of parvovirus B19 infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/32/7690\">",
"           Treatment of genital herpes simplex virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/40/36488\">",
"           Treatment of herpes simplex virus type 1 infection in immunocompetent patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/20/33096\">",
"           Treatment of herpes zoster in the immunocompetent host",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/46/22250\">",
"           Treatment of seasonal influenza in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/36/23110\">",
"           Treatment of varicella-zoster virus infection: Chickenpox",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/28/33225\">",
"           Varicella-zoster virus infection in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/3/38968\">",
"           Viral encephalitis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/41/9879\">",
"           Viral myositis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/53/26455\">",
"           Virology of human papillomavirus infections and the link to cancer",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-8933FE757E-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f11_11_11444=[""].join("\n");
var outline_f11_11_11444=null;
var title_f11_11_11445="Technique of below-knee amputation with medial-based flap";
var content_f11_11_11445=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F65706&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F65706&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 481px\">",
"   <div class=\"ttl\">",
"    Technique of below-knee amputation with medial-based flap",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 461px; height: 667px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_11_11445=[""].join("\n");
var outline_f11_11_11445=null;
var title_f11_11_11446="Z-plasty";
var content_f11_11_11446=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Z-plasty",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/11/11446/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/11/11446/contributors\">",
"     Jesse Selber, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/11/11446/contributors\">",
"     Ashley K Christiani, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/11/11446/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/11/11446/contributors\">",
"     Charles E Butler, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/11/11446/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/11/11446/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/11/11446/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The basic Z-plasty is composed of a central limb incision and two lateral limb incisions which form a 'Z'. The lengths of the three limbs and the angles formed between the central and lateral limbs are equal. The incisional pattern creates two triangular tissue flaps that are transposed, changing both the length and orientation of a wound or scar.",
"   </p>",
"   <p>",
"    This topic will review the indications and technique for Z-plasty. Simple wound closure with sutures and staples is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18553?source=see_link\">",
"     \"Closure of skin wounds with sutures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33124?source=see_link\">",
"     \"Closure of minor skin wounds with staples\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary reasons to perform a Z-plasty are to improve contour, release scar contracture, relieve skin tension, and mobilize tissue for reconstructive surgery. This technique is rarely needed for the acute management of open wounds.",
"   </p>",
"   <p>",
"    Z-plasty has four main tissue effects:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Redirection of scar - The new scar reorients from the axis of the central limb to a line connecting the tips of the lateral limbs. Z-plasty is used to redirect scar into \"relaxed skin tension lines\" (ie, Langer's lines) (",
"      <a class=\"graphic graphic_figure graphicRef57566 \" href=\"UTD.htm?9/21/9558\">",
"       figure 1",
"      </a>",
"      ), natural skin folds, or along the border of an aesthetic unit (ie, nasolabial fold) to improve cosmetic or functional outcome.",
"     </li>",
"     <li>",
"      Lengthening of scar - Z-plasty lengthens the initial wound or scar. It is used to release flexion contractures (usually due to burns) occurring in the axilla, neck, antecubital fossa, or popliteal fossa [",
"      <a class=\"abstract\" href=\"UTD.htm?11/11/11446/abstract/1-4\">",
"       1-4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The amount of lengthening is related to the angle between the central and lateral limbs. Larger angles produce the most lengthening, but can be difficult to close because of skin tension. Narrow angles (&lt;45&ordm;) are easier to close, but produce minimal lengthening and have a higher risk of flap necrosis due to their precarious blood supply [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11446/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     Central/lateral",
"    </span>",
"    limb angle: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;30&ordm; &nbsp; &nbsp; 45&ordm; &nbsp; &nbsp; 60&ordm; &nbsp; &nbsp; 75&ordm; &nbsp; &nbsp; &nbsp; 90&ordm;",
"    <br/>",
"    Theoretical gain in length: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;25% &nbsp; &nbsp;50% &nbsp; &nbsp;75% &nbsp; &nbsp;100 % &nbsp; 120%",
"   </p>",
"   <p>",
"    The 60 degree Z-plasty (ie, classic Z-plasty) is most commonly used because it provides the optimal balance between lengthening and ease of closure.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tissue mobilization - Z-plasty mobilizes adjacent tissue to close skin defects that might otherwise have required a skin graft (eg, deepen finger digital web spaces, or correction of syndactyly), lobular transposition in congenital microtia (ie, small ears) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/11/11446/abstract/6\">",
"       6",
"      </a>",
"      ], vaginal reconstruction [",
"      <a class=\"abstract\" href=\"UTD.htm?11/11/11446/abstract/7\">",
"       7",
"      </a>",
"      ], management of pilonidal cysts [",
"      <a class=\"abstract\" href=\"UTD.htm?11/11/11446/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Tissue realignment - Z-plasty realigns tissue (eg, male cervicoplasty), and can be used to shift topographical structures (eg, nasal ala in craniofacial clefts [",
"      <a class=\"abstract\" href=\"UTD.htm?11/11/11446/abstract/9\">",
"       9",
"      </a>",
"      ], release epicanthal folds in the Asian eyelid).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no absolute contraindications to Z-plasty. Factors adversely affecting skin vascularity, wound healing, and skin mechanics are relative contraindications. These include severe peripheral vascular disease, smoking, poorly controlled diabetes mellitus, collagen vascular disease, and prior skin irradiation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TYPES OF Z-PLASTY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple Z-plasty configurations are available. The choice depends on the nature of the",
"    <span class=\"nowrap\">",
"     wound/scar",
"    </span>",
"    being repaired, and laxity of the surrounding skin.",
"   </p>",
"   <p>",
"    The classic Z-plasty consists of three limbs of equal length (",
"    <a class=\"graphic graphic_figure graphicRef61176 \" href=\"UTD.htm?4/14/4335\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11446/abstract/10\">",
"     10",
"    </a>",
"    ]. The angles between the central limb and each lateral limb are also equal and measure 60&ordm;. When used for lengthening a scar, the central limb is oriented along the long axis of the",
"    <span class=\"nowrap\">",
"     scar/wound",
"    </span>",
"    to be repaired. Transposition of the skin flaps results in a new central limb that is perpendicular to the original; the orientation of the Z-plasty limbs does not change. The classic Z-plasty theoretically lengthens a scar by 75 percent, but the actual gain in central limb length will be 55 to 84 percent of predicted values, depending on tissue elasticity [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11446/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional lengthening can be achieved by using larger angles",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    longer limbs. As discussed above, large angles (&gt;75&ordm;) cause greater skin tension, which increases the risk of flap breakdown. Large angle Z-plasties work with only extremely lax tissue.",
"   </p>",
"   <p>",
"    Longer Z-plasty limbs produce greater degrees of lengthening; however, these larger flaps also produce greater skin tension during closure and require greater tissue mobility [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11446/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Z-plasty produces elongation not only longitudinally in the plane of the skin, but also projecting away from the skin's surface (\"stereometric elongation\"), which may result in a poor cosmetic result when the skin surface is flat rather than curved [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11446/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. The use of large angles increases the amount of skin projection and can lead to the formation of dog ears.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Z-plasty variations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Variations of the classic Z-plasty technique are available to lengthen incisions without creating excessively angulated or elongated flaps and are used in situation where skin mechanics are altered. Z-plasties are combined in parallel or in series. Z-plasties in parallel (eg, four flap) lead to greater longitudinal lengthening but at the expense of transverse shortening and require more adjacent tissue to be available. On the other hand, Z-plasties in series (eg, double-opposing) do not require as much adjacent tissue, but offer less potential length gain.",
"   </p>",
"   <p>",
"    Different types of Z-plasty include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Double-opposing Z-plasty - The double opposing Z-plasty consists of two Z-plasty incisions placed next to each other as mirror images (",
"      <a class=\"graphic graphic_figure graphicRef74115 \" href=\"UTD.htm?3/20/3392\">",
"       figure 3",
"      </a>",
"      ). This technique is useful in scar contracture because skin lengthening is achieved in areas of limited adjacent skin laxity. Also, this technique may be more useful in areas of decreased vascularity (eg, burns) because the larger central flap is less prone to necrosis.",
"      <br/>",
"      <br/>",
"      The jumping man z-plasty is a variation of the double opposing Z-plasty (",
"      <a class=\"graphic graphic_figure graphicRef65939 \" href=\"UTD.htm?39/56/40832\">",
"       figure 4",
"      </a>",
"      ). It is used often used to reconstruct the epicanthal region.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unequal triangle Z-plasty - The unequal triangle Z-plasty, also call the half-Z, refers to a technique where one of the Z-plasty limbs is perpendicular (90&ordm;) to the central incision creating a fissure into which a triangular flap of normal skin is introduced (",
"      <a class=\"graphic graphic_figure graphicRef65672 \" href=\"UTD.htm?41/35/42558\">",
"       figure 5",
"      </a>",
"      ). This Z-plasty technique is particularly useful in areas where normal skin elasticity varies (eg, eyelid) or at a scar edge. In regions of compromised dermis (eg, burns, skin grafts) an S-plasty can be created with blunted flap tips, which are less prone to vascular compromise.",
"     </li>",
"     <li>",
"      Four flap Z-plasty - A four flap Z-plasty has two additional limbs coming off of the central limb (",
"      <a class=\"graphic graphic_figure graphicRef60824 \" href=\"UTD.htm?35/13/36063\">",
"       figure 6",
"      </a>",
"      ). This creates more length for a given angle compared to the classic Z-plasty and is useful in releasing severe scar contractures in areas of otherwise normal flexion, such as the neck.",
"     </li>",
"     <li>",
"      Six flap Z-plasty - The six flap Z-plasty is a four flap Z-plasty with additional limbs. It creates a symmetric zigzag and is used for release of short contracted bands. Because it recruits minimally from adjacent tissue, transposing the flaps can be difficult and dog-ears commonly occur (",
"      <a class=\"graphic graphic_figure graphicRef55030 \" href=\"UTD.htm?25/1/25616\">",
"       figure 7",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Multiple Z-plasty - Multiple Z-plasties are used to manage large wounds or scars not amenable to a single Z-plasty (",
"      <a class=\"graphic graphic_figure graphicRef71491 \" href=\"UTD.htm?20/45/21201\">",
"       figure 8",
"      </a>",
"      ). The theoretical advantage to multiple Z-plasties as opposed to a single large Z-plasty is that they provide the same amount of lengthening in the longitudinal axis with less transverse shortening. However, actual lengthening may be less than expected due to impingement of each Z-plasty upon its neighbor.",
"     </li>",
"     <li>",
"      Planimetric Z-plasty - The planimetric Z-plasty uses a 75&ordm; angle and limb incisions that are twice as long as the central incision (",
"      <a class=\"graphic graphic_figure graphicRef59417 \" href=\"UTD.htm?6/53/6993\">",
"       figure 9",
"      </a>",
"      ). The central incision is then elongated in both directions to twice the length of the limb incisions. The two triangular areas that are created are excised prior to flap transposition. Planimetric Z-plasties can also be linked as in the compound Z-plasty described above. This technique was developed to address issues of stereometric elongation, which predisposed to dog ears when performing Z-plasty on flat surfaces [",
"      <a class=\"abstract\" href=\"UTD.htm?11/11/11446/abstract/12,13\">",
"       12,13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PREOPERATIVE ISSUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Wound/scar evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment of the skin surrounding the wound or scar is necessary to determine the most appropriate technique. The direction of relaxed skin tension lines (ie, Langer's lines) should be noted (",
"    <a class=\"graphic graphic_figure graphicRef57566 \" href=\"UTD.htm?9/21/9558\">",
"     figure 1",
"    </a>",
"    ). A wound or scar that is already directed into these lines may not be appropriate for Z-plasty.",
"   </p>",
"   <p>",
"    The skin surrounding a scar or wound is pinched and lifted to assess its quality, quantity, and mobility. The degree of skin laxity impacts the ability to mobilize and transpose the skin flap. Larger flaps require more laxity and, if adequate laxity is not present, the closure will be under tension and at risk for scar widening or breakdown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Antibiotic prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard gram positive coverage for skin flora, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/37/37462?source=see_link\">",
"     cephalexin",
"    </a>",
"    , is appropriate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=see_link\">",
"     \"Overview of control measures to prevent surgical site infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;An anxiolytic (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    10 mg orally) can be given approximately one hour prior to the procedure to help the patient relax.",
"   </p>",
"   <p>",
"    Patients should avoid taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and nonsteroidal anti-inflammatory medications for seven days prior to the procedure, as these may increase the risk of perioperative bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/45/40666?source=see_link&amp;anchor=H25#H25\">",
"     \"Perioperative medication management\", section on 'Medications affecting hemostasis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Patient counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefits of Z-plasty include a significant potential for improved functional and cosmetic outcome. Important issues that should be discussed during the consent process include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The length of the wound or scar will be longer than the original and three scars will result instead of the one pre-existing scar or wound.",
"     </li>",
"     <li>",
"      Complications, such as bleeding or hematoma formation or infection, may lead to flap failure, resulting in an even less appealing scar than the original. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Complications'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      A hypertrophic scar may form and produce contracture or undesirable cosmetic results. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1847?source=see_link\">",
"       \"Keloids\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Local nerve injury can lead to a transient or permanent loss of sensation in the region.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Alternatives to performing Z-plasty include",
"    <span class=\"nowrap\">",
"     repair/excision",
"    </span>",
"    of wound or scar with side to side closure, skin graft, or wound healing by secondary intention (ie, packing). These options, however, are likely to produce cosmetic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    functional results which are inferior to Z-plasty in certain circumstances.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PROCEDURE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Z-plasty can be performed in either an appropriately equipped office or an ambulatory surgery setting.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Equipment",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Electrocautery unit",
"     </li>",
"     <li>",
"      Suction device",
"     </li>",
"     <li>",
"      Caliper or protractor for angle measurement",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Medications",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Local anesthetic: 1 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      with or without epinephrine (see",
"      <a class=\"local\" href=\"#H14\">",
"       'Anesthesia'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Materials",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Sterile gown, gloves, materials for skin preparation, and a fenestrated drape",
"     </li>",
"     <li>",
"      Sterile skin marking pen",
"     </li>",
"     <li>",
"      5 mL syringe with 16 to 20 gauge needle to draw up anesthetic and a 27 to 30 gauge needle for injection",
"     </li>",
"     <li>",
"      Instruments: number 15 scalpel, fine skin hooks, Adson forceps, smooth needle holder, suture scissors",
"     </li>",
"     <li>",
"      Suture: 4-0, 5-0, or 6-0 absorbable suture",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      4-0, 5-0, or 6-0 nonabsorbable suture",
"     </li>",
"     <li>",
"      Wound dressing: nonadherent dressing, semiocclusive dressing",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Preoperative marking",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to take the time to plan the incisions preoperatively. Careful surgical planning ensures optimal alignment of skin edges under minimal tension and successful wound closure.",
"   </p>",
"   <p>",
"    First, identify the orientation of the relaxed skin tension lines (",
"    <a class=\"graphic graphic_figure graphicRef57566 \" href=\"UTD.htm?9/21/9558\">",
"     figure 1",
"    </a>",
"    ) or the desired orientation of the new scar. Remember, the new central limb will be represented by a line connecting the distal tips of the two lateral limbs. This line should either lie along the relaxed lines of skin tension, or along the division between two aesthetic subunits, but preferably both. The final scar length for the classic (60&ordm; angle) Z-plasty will be approximately 1.75 times the original scar length.",
"   </p>",
"   <p>",
"    The flaps are rearranged mentally or, if needed, the pattern can be cut on a piece of paper or drape as a model prior to making the incisions. Z-plasty simulators are also available [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11446/abstract/14\">",
"     14",
"    </a>",
"    ]. Keep in mind that the planned geometry does not always translate to identical clinical results, likely due to the unpredictable mechanics of the skin [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11446/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Z-plasty is most commonly performed with local anesthetic, with or without sedation. The addition of epinephrine is preferred for most cutaneous surgeries, with the exception of surgery to an area perfused by terminal arteries (eg, fingers, toes, nose, and penis). More extensive wound management or revision may require general anesthesia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inpatient postoperative management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34618?source=see_link\">",
"     \"Procedural sedation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33689?source=see_link\">",
"     \"Infiltration of local anesthetics\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     General technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Z-plasty technique is similar regardless of the Z-plasty configuration chosen. With a number 15 blade, make or complete the central limb incision. For a scar revision or lesion excision, excise the linear scar or lesion in a narrow ellipse along its longitudinal axis. Next, make the incisions on the previously marked skin to create the lateral limbs of the Z (or variation thereof). Bevel the incisions away from the narrow angles of the Z to maximize flap tip thickness and, thereby, their vascularity. The tips can also be rounded slightly to decrease the chance of tip loss.",
"   </p>",
"   <p>",
"    Elevate the skin flaps. The flap plane is created below the subdermal vascular plexus and just into the subcutaneous fat with care to avoid damage to the nutrient vessels. Include some subcutaneous fat as dissection approaches the base of the flap to maintain a robust blood supply. Undermine the skin where the flap is attached to create additional flap mobility. Meticulously control any bleeding.",
"   </p>",
"   <p>",
"    Using fine skin hooks to handle the skin (avoid handling tissue with forceps which can crush the tissue), rotate the triangular flaps and cross them over each other. Place a suture at each of the flap tips to hold them in place. Complete the remainder of the wound closure with interrupted subdermal 3-0 or 4-0 absorbable suture (eg, Vicryl) and the close the skin with interrupted 3-0 or 4-0 nonabsorbable suture (eg, nylon). In children, use interrupted 5-0 absorbable (eg, plain gut) so that sutures do not have to be removed. If the limbs are long a running subcuticular suture may also be used. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18553?source=see_link\">",
"     \"Closure of skin wounds with sutures\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Place steri-strips, as needed, a non-adherent dressing, and a protective occlusive dressing. A thick overlying dressing of 4x4 inch gauze or other bandage is also placed for 24 hours to keep the underlying dressings clean and dry.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;For minor procedures, nonprescription pain relievers should suffice but the patient should refrain from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or other nonsteroidal anti-inflammatory medications for at least the first 24 hours following surgery. The patient may shower after 24 hours, but should keep the dressing dry.",
"   </p>",
"   <p>",
"    The surgical site should be examined in the physician's office within one to two days postoperatively. Generally, sutures are removed at specific intervals depending on location and extent of the surgery: three to five days for the face versus 10 to 14 days for the trunk or extremities.",
"   </p>",
"   <p>",
"    Bleeding or drainage, fever, excessive pain, or other concerns should be reported to the physician. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Special wound considerations",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Face - If the wound is on the face, the patient should be instructed to sleep with the head elevated the first two nights following the procedure and avoid sleeping on the affected side. The patient should also avoid bending forward with the head below the heart for the first 48 hours following surgery.",
"     </li>",
"     <li>",
"      Across joints - If Z-plasty is used to release joint contracture, the joint should be splinted in extension for at least a week. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15208?source=see_link\">",
"       \"Splinting of musculoskeletal injuries\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications are minimal with careful surgical planning, sterile technique and meticulous hemostasis. Early (within two weeks) postoperative complications include: bleeding, excessive pain, foreign body reaction to the chosen suture material, surgical site infection, and flap necrosis. Delayed problems include recurrent contracture or hypertrophic scar formation, alterations in skin pigmentation (hyper- or hypopigmentation), nerve injury, skin atrophy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hair loss, and trap door deformity (ie, lymphedema within the skin flaps).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Z-plasty is used extensively in plastic surgery to improve contour, release scar contracture, relieve skin tension, and close tissue defects. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Medical conditions affecting skin vascularity, wound healing, or skin mechanics (ie, smoking, prior skin irradiation, severe peripheral vascular disease, poorly controlled diabetes mellitus, and collagen vascular disease) may compromise Z-plasty results and represent relative contraindications to the procedure. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Z-plasty is composed of a central limb and two lateral limbs forming a 'Z'; two triangular skin flaps are created. Transposition of these triangular flaps reorients the central limb to a line connecting the tips of the lateral limbs; the orientation of the Z-plasty limbs does not change. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Types of Z-plasty'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For the classic Z-plasty, the angles between the central limb and lateral limbs measure 60&ordm;. The classic Z-plasty theoretically lengthens a scar by 75 percent. Other configurations are used in special circumstances. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Z-plasty variations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Z-plasty is performed with local anesthesia as an outpatient procedure. Postoperative pain is minimal and significant complications are uncommon. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Procedure'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11446/abstract/1\">",
"      Freiling D, Galla M, Lobenhoffer P. [Arthrolysis for chronic flexion deficits of the knee. An overview of indications and techniques of vastus intermedius muscle resection, transposition of the tibial tuberosity and z-plasty of the patellar tendon]. Unfallchirurg 2006; 109:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11446/abstract/2\">",
"      Aslan G, Tuncali D, Cigsar B, et al. The propeller flap for postburn elbow contractures. Burns 2006; 32:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11446/abstract/3\">",
"      Robson MC, Barnett RA, Leitch IO, Hayward PG. Prevention and treatment of postburn scars and contracture. World J Surg 1992; 16:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11446/abstract/4\">",
"      Ketchum LD. The use of the full thickness skin graft in Dupuytren's contracture. Hand Clin 1991; 7:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11446/abstract/5\">",
"      Furnas DW, Fischer GW. The Z-plasty: biomechanics and mathematics. Br J Plast Surg 1971; 24:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11446/abstract/6\">",
"      Olbricht S, Li&eacute;geois NJ. Closing surgical defects of the external ear. Semin Cutan Med Surg 2003; 22:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11446/abstract/7\">",
"      Farroha A, Hanna H. Reconstruction of symptomatic postoperative vaginal shortening using Z-plasty. Int J Gynaecol Obstet 2008; 102:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11446/abstract/8\">",
"      Pomazkin VI, Mansurov IuV. [Choice of operation for treatment of patients with pilonidal sinus]. Vestn Khir Im I I Grek 2008; 167:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11446/abstract/9\">",
"      Seyhan T, K&yacute;l&yacute;nr H. Median cleft of the lower lip: report of two new cases and review of the literature. Ann Otol Rhinol Laryngol 2002; 111:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11446/abstract/10\">",
"      Borges AF, Gibson T. The original Z-plasty. Br J Plast Surg 1973; 26:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11446/abstract/11\">",
"      Hudson DA. Some thoughts on choosing a Z-plasty: the Z made simple. Plast Reconstr Surg 2000; 106:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11446/abstract/12\">",
"      Roggendorf E. The planimetric Z-plasty. Plast Reconstr Surg 1983; 71:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11446/abstract/13\">",
"      Suzuki S, Um SC, Kim BM, et al. Versatility of modified planimetric Z-plasties in the treatment of scar with contracture. Br J Plast Surg 1998; 51:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11446/abstract/14\">",
"      Sillitoe AT, Platt A. The Z-plasty simulator. Ann R Coll Surg Engl 2004; 86:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11446/abstract/15\">",
"      Hove CR, Williams EF 3rd, Rodgers BJ. Z-plasty: a concise review. Facial Plast Surg 2001; 17:289.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6670 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-180.241.123.62-8D972B75FE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_11_11446=[""].join("\n");
var outline_f11_11_11446=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TYPES OF Z-PLASTY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Z-plasty variations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PREOPERATIVE ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Wound/scar evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Antibiotic prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Patient counseling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Preparation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Preoperative marking",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Anesthesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      General technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      POSTOPERATIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Special wound considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/6670\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/6670|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/21/9558\" title=\"figure 1\">",
"      Whole body Langers lines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/14/4335\" title=\"figure 2\">",
"      Classic z-plasty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/20/3392\" title=\"figure 3\">",
"      Double opposing z-plasty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/56/40832\" title=\"figure 4\">",
"      Jumping man z-plasty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/35/42558\" title=\"figure 5\">",
"      Unequal z-plasty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/13/36063\" title=\"figure 6\">",
"      Four flap z-plasty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/1/25616\" title=\"figure 7\">",
"      Six flap z-plasty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/45/21201\" title=\"figure 8\">",
"      Compound z-plasty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/53/6993\" title=\"figure 9\">",
"      Planimetric z-plasty",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33124?source=related_link\">",
"      Closure of minor skin wounds with staples",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18553?source=related_link\">",
"      Closure of skin wounds with sutures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33689?source=related_link\">",
"      Infiltration of local anesthetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1847?source=related_link\">",
"      Keloids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/45/40666?source=related_link\">",
"      Perioperative medication management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34618?source=related_link\">",
"      Procedural sedation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15208?source=related_link\">",
"      Splinting of musculoskeletal injuries",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_11_11447="Endobronchial electrocautery";
var content_f11_11_11447=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Endobronchial electrocautery",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/11/11447/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/11/11447/contributors\">",
"     Henri G Colt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/11/11447/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/11/11447/contributors\">",
"     Praveen N Mathur, MB, BS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/11/11447/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/11/11447/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/11/11447/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tracheobronchial obstruction due to malignant or benign processes can produce recurrent pneumonia, respiratory insufficiency, and death. Curative resection is not possible in the majority of cases, and treatment instead is focused upon palliation. Several techniques are available for the bronchoscopic treatment of obstructing tissue in the tracheobronchial tree, including electrocautery, laser therapy, cryosurgery, airway stents, brachytherapy, and balloon dilation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11447/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37351?source=see_link\">",
"     \"Diagnosis and management of central airway obstruction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Of these options, only laser resection and electrocautery produce rapid tissue destruction in a single sitting, and are therefore appropriate to treat lesions that are producing acute respiratory distress or hemoptysis. The neodymium yttrium aluminum garnet (Nd:YAG) laser generally is used in this situation in the United States, but expense limits the availability of laser equipment in many parts of the world. Electrocautery could be called \"the poor man's laser\" because it also produces rapid thermal destruction of tissue, but does so relatively inexpensively by means of electric current rather than laser light [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11447/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/25/32151?source=see_link\">",
"     \"Basic principles of medical lasers\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/47/38645?source=see_link\">",
"     \"Bronchoscopic laser resection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The technique of endobronchial electrocautery, also referred to as electrofulguration, diathermy, electrocoagulation, thermocoagulation, or electrosurgery, will be reviewed here. Other therapeutic bronchoscopy techniques are discussed separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTORICAL BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrocautery was first used in the 1930s to treat rectal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11447/abstract/5\">",
"     5",
"    </a>",
"    ]. Endoscopic electrocautery subsequently has found wide use in the treatment of gastrointestinal lesions, such as colonic polyps, bleeding vessels, and biliary stenosis.",
"   </p>",
"   <p>",
"    Initial reports of the potential utility of electrocautery in the treatment of tracheal and bronchial tumors also appeared in the 1930s [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11447/abstract/6-8\">",
"     6-8",
"    </a>",
"    ], but complications such as burns, tracheal perforation, and fatal hemoptysis dampened enthusiasm for the technique [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11447/abstract/9\">",
"     9",
"    </a>",
"    ]. Refinements of the electrodes and other hardware and the use of more sophisticated generators of high frequency current have improved the efficacy and safety of bronchoscopic electrocautery and have led to a renewed interest in the technique. Nonetheless, the literature describing palliative electroresection is limited, and most pulmonologists remain unfamiliar with its use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     BASIC PRINCIPLES OF ELECTROCAUTERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three effects may be observed when electric current flows through human tissue:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An electrolytic effect, in which chemical bonding is altered by the application of electrical energy",
"     </li>",
"     <li>",
"      A capacitance effect, in which the electrical potential difference of local structures is altered and which may stimulate nerves and muscles",
"     </li>",
"     <li>",
"      A thermal effect, due to the resistance of a tissue to the flow of electrical current",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The rise in temperature of a given tissue during electrocautery is proportional to the square of the applied electrical current times the intrinsic resistance of the tissue; the latter is largely a function of vascularity and water content, with bone and fat having a higher resistance than skin and muscle [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11447/abstract/10\">",
"     10",
"    </a>",
"    ]. Resistance and thermal effects are also increased by reducing the area of contact between the electrical probe and the patient, since the same quantity of current must then flow through less conducting tissue.",
"   </p>",
"   <p>",
"    The temperature rises at different rates in different areas within a given tissue due to inhomogeneity of tissue density and the irregular distribution of electrical current. As a rule, the density of the electric current is largest, and the rise in temperature greatest, in the contact area between the coagulation electrode and tissue, and decreases with greater distance from this point.",
"   </p>",
"   <p>",
"    Thermal destruction of tissue can be used to effect coagulation or resection:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Coagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thermal coagulation (or \"white coagulation\"), is caused by the relatively slow heating of tissue to approximately 70&ordm;C (",
"    <a class=\"graphic graphic_table graphicRef69047 \" href=\"UTD.htm?8/17/8475\">",
"     table 1",
"    </a>",
"    ). Above this temperature, the glucose-containing coagulum dehydrates and carbonizes. Three different coagulation modes are differentiated: soft coagulation, forced coagulation, and spray coagulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Soft coagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Soft coagulation is produced when no electric arcs pass between the coagulation electrode and the tissue; this prevents the tissue from becoming carbonized. The unipolar or bipolar electrode is brought into direct contact with the tissue to be coagulated, and less than 200 volts is employed. This mode is used when coagulation is needed solely to stop bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Forced coagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Forced coagulation results when electric arcs are generated between the coagulation electrode and the tissue in order to obtain deeper coagulation than is achieved with soft coagulation. The electrode is kept in contact with the tissue, a minimum of 500 volts is used, and cutting effects are avoided. This mode is used for vaporization of tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Spray coagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spray coagulation is characterized by the intentional generation of long electric arcs between a spray electrode and tissue without any direct contact between electrode and tissue. High voltages are necessary, and tissue destruction and carbonization are readily accomplished. This mode is used when a large area is to be cut and vaporized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tissue can only be cut when the voltage between the electrode and the tissue is sufficiently high to produce an electric arc, effectively concentrating the electric current onto specific points of the tissue. The temperature produced at the points at which electric arcs contact the tissue is so high that the tissue is immediately evaporated or burned away.",
"   </p>",
"   <p>",
"    Electric arcs cannot be triggered and tissue cannot be cut if less than 200 volts are used. Higher voltages are sometimes required, depending on the resistance characteristics of the tissue to be resected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     INDICATIONS AND EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrocautery is a bronchoscopic technique that is used to treat benign or malignant airway lesions that are endobronchial and involve the central airways [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11447/abstract/1,2,11-14\">",
"     1,2,11-14",
"    </a>",
"    ]. Treatment may be curative or palliative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Malignant tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endobronchial electrocautery is most commonly indicated for the treatment of symptomatic airway obstruction caused by bronchogenic carcinoma in patients who are not operative candidates [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11447/abstract/15-18\">",
"     15-18",
"    </a>",
"    ]. In such patients, airway patency is restored in more than 80 percent of patients and symptoms are relieved in more than 70 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11447/abstract/19\">",
"     19",
"    </a>",
"    ]. Endobronchial electrocautery has been used to treat other causes of malignant airway obstruction as well, including endobronchial metastases.",
"   </p>",
"   <p>",
"    The impact of endobronchial electrocautery on malignant airway obstruction has been illustrated by case series. In one series of 17 patients with locally advanced tracheobronchial malignancies who underwent endobronchial electrocautery, 15 patients had immediate reopening of the airway (89 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11447/abstract/15\">",
"     15",
"    </a>",
"    ]. Eleven of those patients had restoration of &gt;75 percent of the normal airway diameter, although only four patients had objective improvement in their physiological parameters. There were no deaths resulting from treatment, but minor bleeding occurred in one patient and aspiration pneumonia developed in another. Three patients required additional therapy.",
"   </p>",
"   <p>",
"    Indolent malignant tumors are less common, but may also be treated effectively with endobronchial electrocautery [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11447/abstract/12,14\">",
"     12,14",
"    </a>",
"    ]. This was illustrated by a series of 11 patients with intraluminal bronchial carcinoid tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11447/abstract/12\">",
"     12",
"    </a>",
"    ]. Electrocautery eradicated lesions in eight of the patients (73 percent). The remaining three patients could not be completely treated because the lesions were in the upper lobe bronchi.",
"   </p>",
"   <p>",
"    Intraluminal microinvasive lung cancer that is radiographically occult has also been treated using endobronchial electrocautery. Treatment is most likely to be successful in patients who have strict intraluminal disease, visible distal margins (detected using autofluorescence ), no invasion of the bronchial wall (identified by bronchoscopy), and no extraluminal growth (determined by high resolution computed tomography) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11447/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Benign lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endobronchial electrocautery can be used to treat benign obstructing lesions of the central airways (eg, granulation tissue, hamartomas, papillomas, lipomas). This was best demonstrated by a series of 38 patients who underwent endobronchial electrocautery [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11447/abstract/4\">",
"     4",
"    </a>",
"    ]. Twenty-five patients had benign lesions, while 13 patients had malignant tumors. A total of 47 procedures were performed, of which 42 were deemed successful (89 percent).",
"   </p>",
"   <p>",
"    Another setting in which endobronchial electrocautery is used to treat benign disease is when there is granulation tissue obstructing metal or hybrid stents. Electrocautery can be performed safely as long as certain precautions are adhered to, including avoiding supplemental oxygenation, avoiding direct applications of energy onto stent covering, and keeping energy applications to a minimum. These precautions are necessary because electrocautery can ignite the lining of covered metal stents, as well as break metal stents [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11447/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endobronchial lesions may cause hemoptysis or postobstructive pneumonia, both of which can be successfully treated with endobronchial electrocautery:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Effective treatment of hemoptysis requires an accessible, visible lesion. In such circumstances, we are able to gain immediate hemostatic control in approximately 75 percent of patients. Adequate visualization of the tumor is essential in this situation and rigid bronchoscopy may allow more effective suctioning of briskly bleeding structures. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30454?source=see_link\">",
"       \"Massive hemoptysis: Initial management\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7412?source=see_link\">",
"       \"Rigid bronchoscopy: Intubation techniques\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment (and prevention) of postobstructive pneumonia requires the restoration of at least partial airway patency. This can be achieved using endobronchial electrocautery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extrinsic compression of the airway is a contraindication to electrocautery. In this circumstance, there is no endobronchial tumor to remove, and electrocautery can produce a hole in the bronchus. Unipolar electrocoagulation to remove tumor ingrowth from metal stents must be applied with extreme caution in order to avoid any contact of the electrode with the steel filaments, because melting and fracture of the stent can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11447/abstract/23\">",
"     23",
"    </a>",
"    ]. Electrocautery with unipolar electrodes can deprogram cardiac pacemakers or implanted defibrillators, and should be undertaken with caution in such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11447/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     EQUIPMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchoscopic electrocautery requires electrocautery electrodes, a bronchoscope, and a generator of high frequency current.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Electrocautery electrodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unipolar electrodes are most commonly used, and may be rigid or flexible. The rigid blunt electrode is 70 cm long and 2.5 mm in diameter, while flexible devices are 190 cm long and 2 mm in diameter. Electrodes are available in several configurations: blunt probe, knife, forceps, or wire snare. Rigid probes are more effective for debulking large tumors, while flexible probes permit treatment of small tumors, particularly in the upper lobes.",
"   </p>",
"   <p>",
"    Electric current flows through the desired instrument, tissues, and through a grounded neutral plate electrode attached to the patient. The neutral electrode must have a sufficiently large contact surface with the patient to prevent a cutaneous burn at its point of attachment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Endoscope",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rigid electrocautery probes are used with a rigid bronchoscope, while flexible electrodes can be used through the working channel of a fiberoptic bronchoscope. The ability of an electrode to deliver electricity depends in part on its diameter; for this reason, a fiberoptic bronchoscope should be selected with as large an operative lumen as possible. The operative lumen of a rigid bronchoscope must have a diameter large enough for both the electrode and the rigid optic system.",
"   </p>",
"   <p>",
"    The fiberoptic bronchoscope currently in the widest use for endobronchial electrocautery is the Olympus 6 mm bronchoscope with a 2.6 mm working channel and an insulated and electrically grounded inner sheath. A new generation of insulated and grounded fiberoptic bronchoscopes will soon be commercially available [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11447/abstract/10,15,25-27\">",
"     10,15,25-27",
"    </a>",
"    ]. Most bronchoscopes in current use are not grounded, and there is a risk of the endoscopist receiving a shock if there is not a suitable low resistance pathway for current to pass through the patient to the neutral electrode. In addition, burns of the tracheobronchial tree may result if the bronchoscope makes contact with the patient near the point of electrocautery (",
"    <a class=\"graphic graphic_figure graphicRef59256 \" href=\"UTD.htm?29/46/30447\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     High frequency current generator",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most presently available generators are not configured in a manner that permits precise control of the power delivered to a lesion. Standard generators usually have power output settings that are graduated from 1 to 10; estimates about the actual power delivered at a given setting are often inaccurate, and the delivered voltage is variable. In addition, the resistance characteristics of a given tissue change as it is cauterized, and charring can foul the electrode. This promotes adhesion to the tissues, and the charring serves as an insulator that prevents coagulation from progressing.",
"   </p>",
"   <p>",
"    Newer high frequency generators are regulated with a microprocessor and a voltage stabilizer, which allow precise control of the thermal coagulation process. Most of these generators switch off automatically at 100&ordm;C in order to prevent the production of exploding steam pockets that can cause tissue perforation, rupture, and hemorrhage (the \"popcorn effect\"). Additional safety features, such as isolated outputs and precise control of delivered power (in watts), are also included.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;General precautions are required to prevent electrical injuries to the patient, clinician, and support staff. The patient should not have any contact with metal from the table, and sheets should be dry. The neutral plate electrode must be placed in its entirety on the patient. If the contact surface is not sufficient, the current will pass from the patient through smaller contact points which, by virtue of their lesser area and consequently higher resistance, may cause burns.",
"   </p>",
"   <p>",
"    At a minimum, cardiac rhythm and oxygen saturation should be continuously monitored and blood pressure frequently assessed during the procedure. Routine intraoperative monitoring protocols are generally used if the electrocautery is performed under general anesthesia. The procedure usually lasts between 20 and 60 minutes if performed through a rigid bronchoscope, and longer if a flexible fiberoptic scope is used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;General anesthesia is usually required if endobronchial electrocautery is performed through a rigid bronchoscope, although dissociative anesthesia with sedatives and neuroleptics is occasionally employed. Local anesthesia and conscious sedation can be used when the procedure is performed through a fiberoptic bronchoscope with flexible electrodes. Readministration of sedatives may be required during the procedure because a longer duration of sedation is needed than for a routine bronchoscopy.",
"   </p>",
"   <p>",
"    Flammable anesthetic agents should not be used during the procedure because of the risk of ignition. In addition, the fraction of inspired oxygen should be kept at the lowest level required to maintain adequate patient oxygenation in order to reduce the risk of tracheal fires. The maximal fractional concentration of inspired oxygen for use with electrocautery (or bronchoscopic laser resection) is 0.4.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fiberoptic endoscope can be introduced by either the nasal or oral route. The procedure is carried out under direct vision, with the electrode introduced within the tube of the rigid bronchoscope beside the optical system, or in the operating channel of the fiberoptic bronchoscope.",
"   </p>",
"   <p>",
"    The operator assesses the lesions to be treated, noting their position and the extent of stenosis or extrinsic compression, whether they are projecting or infiltrating, and whether they are hemorrhagic or bland. The electrode must protrude from the end of the bronchoscope by about 2 cm and is then placed in contact with the lesions to be destroyed. The high frequency generator is adjusted to automatic control of soft coagulation, with a power setting generally between 40 and 60 watts, or is adjusted to the visible coagulative effect if a first generation machine is used. Other modalities, such as forced or spray coagulation or cutting mode, are used as required, and different electrodes (eg, blunt electrode, wire snare, forceps or knife) are selected as needed. It is useful to clean the tip of the electrode frequently, because buildup may damage the electrode",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reduce the delivered power.",
"   </p>",
"   <p>",
"    Two main methods of electrocautery are used: debulking of tissue by means of a cutting loop, or direct electrodestruction of tissue. Both techniques are effective and provide good results, but smoke needs to be suctioned during resection, and an unpleasant burnt tissue smell is given off. Treatment is continued until sufficient patency of the airway lumen is restored",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bleeding arrested.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Resection of tissue generally is accomplished by the use of a unipolar wire snare apparatus similar to that used to excise colonic polyps. The technique is most suitable for narrow-based lesions causing incomplete bronchial obstruction, such that the instrument can be passed distal to the tumor and the base snared.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The device either is passed through the endotracheal tube alongside a fiberoptic bronchoscope, or inside the operating channel of the fiberoptic or rigid bronchoscope, looped around the base of the tissue to be resected, and then energized [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11447/abstract/11,16,28,29\">",
"     11,16,28,29",
"    </a>",
"    ]. Debrided tissue fragments are often too large to be removed through the bronchoscope, and must be grasped and removed in conjunction with it.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tissue can be directly destroyed with electrocautery to achieve an effect similar to that seen with Nd:YAG laser vaporization [",
"      <a class=\"abstract\" href=\"UTD.htm?11/11/11447/abstract/28,29\">",
"       28,29",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/47/38645?source=see_link\">",
"       \"Bronchoscopic laser resection\"",
"      </a>",
"      .) A blunt cautery probe is directly applied to burn, desiccate, and vaporize obstructing tissue. Unipolar probes have generally been used for this purpose, but a bipolar flexible electrocautery probe (BICAP) has been adapted for use through the operating channel of a fiberoptic bronchoscope [",
"      <a class=\"abstract\" href=\"UTD.htm?11/11/11447/abstract/30-32\">",
"       30-32",
"      </a>",
"      ]. BICAP has seen widespread use for the ablation of gastrointestinal lesions and offers the advantage of not requiring a grounding plate, because the current completes its arc through the two tips of the probe.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endobronchial electrocautery is usually well tolerated, although there have been few large series that documented complication rates. A number of complications have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11447/abstract/15,17,24,28,29,31,33-36\">",
"     15,17,24,28,29,31,33-36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Application of deep electrocautery too close to the bronchial wall may result in perforation and pneumothorax. Cartilaginous rings may be destroyed, leading to a loss of structural support, tracheo- or bronchomalacia,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      secondary stenoses.",
"     </li>",
"     <li>",
"      Electrocautery generates electric arcs and can cause tracheal fires or ignition of endotracheal tubes, fiberoptic bronchoscopes, or silicon endoprostheses. The risk of fire is increased if high fractions of inspired oxygen are used. The maximal fractional concentration of inspired oxygen for use with electrocautery (or bronchoscopic laser resection) is 0.4.",
"     </li>",
"     <li>",
"      Bleeding can result from penetration of the probe into the tumor, but generally stops quickly due to thermocoagulation. Significant bleeding occurs in approximately 2 percent of cases, and may be more common with vascular neoplasms such as carcinoid tumors and hamartomas.",
"     </li>",
"     <li>",
"      Aspiration pneumonia has been reported, either as a complication of anesthesia or due to aspiration of postobstructive pus into the contralateral lung immediately after debulking.",
"     </li>",
"     <li>",
"      Electrical shock",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      electrical burns to the patient or operator may occur if unipolar leads and a nongrounded apparatus are used (",
"      <a class=\"graphic graphic_figure graphicRef59256 \" href=\"UTD.htm?29/46/30447\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Ventricular fibrillation has occurred when electrocautery is used near the heart, and interference with the function of implanted cardiac pacemakers or defibrillators may occur.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Generally speaking, the complications of endobronchial electrocautery are similar to those encountered using bronchoscopic laser ablation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11447/abstract/37\">",
"     37",
"    </a>",
"    ], which are described elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/47/38645?source=see_link\">",
"     \"Bronchoscopic laser resection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Postoperative care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrocautery does not require any particular immediate follow-up care in the absence of complications. Patients usually can return home the same day.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Electrocautery is a bronchoscopic technique that is used to treat benign or malignant airway lesions that are endobronchial and involve the central airways. Treatment may be curative or palliative. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Indications and efficacy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Extrinsic compression of the airway is a contraindication to electrocautery. In this circumstance, there is no endobronchial tumor to remove, and electrocautery can produce a hole in the bronchus. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Contraindications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Endobronchial electrocautery is performed under local anesthesia and conscious sedation using a fiberoptic bronchoscope. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Anesthesia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Procedure'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Endobronchial electrocautery usually well tolerated and results in minimal morbidity, although complications have been reported. It does not require immediate follow-up care in the absence of complications and patients usually can return home the same day. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Complications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Postoperative care'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11447/abstract/1\">",
"      Bolliger CT, Mathur PN, Beamis JF, et al. ERS/ATS statement on interventional pulmonology. European Respiratory Society/American Thoracic Society. Eur Respir J 2002; 19:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11447/abstract/2\">",
"      Ernst A, Silvestri GA, Johnstone D, American College of Chest Physicians. Interventional pulmonary procedures: Guidelines from the American College of Chest Physicians. Chest 2003; 123:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11447/abstract/3\">",
"      Boxem Tv, Muller M, Venmans B, et al. Nd-YAG laser vs bronchoscopic electrocautery for palliation of symptomatic airway obstruction: a cost-effectiveness study. Chest 1999; 116:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11447/abstract/4\">",
"      Coulter TD, Mehta AC. The heat is on: impact of endobronchial electrosurgery on the need for Nd-YAG laser photoresection. Chest 2000; 118:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11447/abstract/5\">",
"      Strauss, AA, Strauss, SF, Crawford, RA. Surgical diathermy of carcinoma of the rectum. Its clinical end results. JAMA 1935; 104:1480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11447/abstract/6\">",
"      Gilfoy, FE. Primary malignant tumors of the lower third of the trachea: Report of a case with successful treatment by electrofulguration and deep x-rays. Arch Otolaryngol 1932; 16:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11447/abstract/7\">",
"      Kernan, JD. Carcinoma of the lung and bronchus: Treatment with radon implantations and diathermy. Arch Otolaryngol 1933; 17:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11447/abstract/8\">",
"      Moersch HJ, Bowing HH. PRIMARY CARCINOMA OF THE BRONCHUS TREATED SUCCESSFULLY WITH SURGICAL DIATHERMY. Ann Surg 1935; 102:989.",
"     </a>",
"    </li>",
"    <li>",
"     Soulas A, Mounier-Kuhn P. Bronchologie, Masson Ed, Paris 1956. p.703-704.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11447/abstract/10\">",
"      Barlow DE. Endoscopic applications of electrosurgery: a review of basic principles. Gastrointest Endosc 1982; 28:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11447/abstract/11\">",
"      Sagawa M, Sato M, Takahashi H, et al. Electrosurgery with a fiberoptic bronchoscope and a snare for endotracheal/endobronchial tumors. J Thorac Cardiovasc Surg 1998; 116:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11447/abstract/12\">",
"      Sutedja, G, Schramel, FMNH, Smit, HJF, Postmus, PE. A prospective study of bronchoscopic electrocautery (BE) in patients with intra luminal typical bronchial carcinoid (ITBC). Eur Respir J 1996; 23:258S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11447/abstract/13\">",
"      Frizzelli R. [Treatment by electrocoagulation in malignant tracheobronchial pathology]. Rev Pneumol Clin 1986; 42:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11447/abstract/14\">",
"      van Boxem TJ, Venmans BJ, Schramel FM, et al. Radiographically occult lung cancer treated with fibreoptic bronchoscopic electrocautery: a pilot study of a simple and inexpensive technique. Eur Respir J 1998; 11:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11447/abstract/15\">",
"      Sutedja G, van Kralingen K, Schramel FM, Postmus PE. Fibreoptic bronchoscopic electrosurgery under local anaesthesia for rapid palliation in patients with central airway malignancies: a preliminary report. Thorax 1994; 49:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11447/abstract/16\">",
"      Pedersen, U, Kristensen, S, Illum, P. Palliative resection with high-frequency cutting loop in malignant tracheobronchial diseases. J Bronchol 1994; 1:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11447/abstract/17\">",
"      Baldeyrou, P, Girard, P, Grunenwald, D. High-frequency thermocoagulation of tumors of the respiratory tract: Results of an initial study with broncho fiberscope. J Bronchol 1996; 3:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11447/abstract/18\">",
"      Sutedja, G, Schramel, FMNH, Smit, HJF, Postmus, PE. Bronchoscopic electrocautery as an alternative for ND-YAG laser in patients with intraluminal tumor (abstract). Eur Respir J 1996; 23:259S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11447/abstract/19\">",
"      Wahidi MM, Herth FJ, Ernst A. State of the art: interventional pulmonology. Chest 2007; 131:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11447/abstract/20\">",
"      Vonk-Noordegraaf A, Postmus PE, Sutedja TG. Bronchoscopic treatment of patients with intraluminal microinvasive radiographically occult lung cancer not eligible for surgical resection: a follow-up study. Lung Cancer 2003; 39:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11447/abstract/21\">",
"      Dalupang JJ, Shanks TG, Colt HG. Nd-YAG laser damage to metal and silicone endobronchial stents: delineation of margins of safety using an in vitro experimental model. Chest 2001; 120:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11447/abstract/22\">",
"      Colt HG, Crawford SW. In vitro study of the safety limits of bronchoscopic argon plasma coagulation in the presence of airway stents. Respirology 2006; 11:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11447/abstract/23\">",
"      Ell C, Fleig WE, Hochberger J. Broken biliary metal stent after repeated electrocoagulation for tumor ingrowth. Gastrointest Endosc 1992; 38:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11447/abstract/24\">",
"      Caramella JP, Dodinot B. [Cardiac pacemaker deprogramming by electrocautery. An update]. Ann Fr Anesth Reanim 1989; 8:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11447/abstract/25\">",
"      Homasson JP, Roden S, Angebault M, et al. [Treatment of bronchial tumors with high-frequency thermocoagulation. Preliminary studies]. Rev Pneumol Clin 1995; 51:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11447/abstract/26\">",
"      Petrou M, Kaplan D, Goldstraw P. Bronchoscopic diathermy resection and stent insertion: a cost effective treatment for tracheobronchial obstruction. Thorax 1993; 48:1156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11447/abstract/27\">",
"      Ledingham SJ, Goldstraw P. Diathermy resection and radioactive gold grains for palliation of obstruction due to recurrence of bronchial carcinoma after external irradiation. Thorax 1989; 44:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11447/abstract/28\">",
"      Hooper RG, Jackson FN. Endobronchial electrocautery. Chest 1985; 87:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11447/abstract/29\">",
"      Gerasin VA, Shafirovsky BB. Endobronchial electrosurgery. Chest 1988; 93:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11447/abstract/30\">",
"      Marsh BR. Bipolar cautery for the fiberoptic bronchoscope. Ann Otol Rhinol Laryngol 1987; 96:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11447/abstract/31\">",
"      Hooper RG, Jackson FN. Endobronchial electrocautery. Chest 1988; 94:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11447/abstract/32\">",
"      Cunningham L, Wendell G, Berkowitz L, et al. Treatment of tracheobronchial granular cell myoblastomas with endoscopic bipolar cautery. Chest 1989; 96:427.",
"     </a>",
"    </li>",
"    <li>",
"     Wakabayashi A. Thoracoscopic techniques. In: Minimally Invasive Techniques in Thoracic Medicine and Surgery, Hetzel MR (Ed), Chapman &amp; Hall, London 1995. p.269.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11447/abstract/34\">",
"      Hooper RG, Spratling L, Beechler C, Schaffner S. Endobronchial electrocautery. A role in bronchogenic carcinoma? Endoscopy 1984; 16:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11447/abstract/35\">",
"      Carpenter RJ 3rd, Neel HB 3rd, Sanderson DR. Comparison of endoscopic cryosurgery and electrocoagulation of bronchi. Trans Sect Otolaryngol Am Acad Ophthalmol Otolaryngol 1977; 84:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11447/abstract/36\">",
"      Verkindre C, Brichet A, Maurage CA, et al. Morphological changes induced by extensive endobronchial electrocautery. Eur Respir J 1999; 14:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11447/abstract/37\">",
"      Kvale PA, Selecky PA, Prakash UB, American College of Chest Physicians. Palliative care in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132:368S.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4396 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-298F256B3B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_11_11447=[""].join("\n");
var outline_f11_11_11447=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTORICAL BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      BASIC PRINCIPLES OF ELECTROCAUTERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Coagulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Soft coagulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Forced coagulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Spray coagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      INDICATIONS AND EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Malignant tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Benign lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      EQUIPMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Electrocautery electrodes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Endoscope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      High frequency current generator",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Anesthesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Postoperative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4396\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4396|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/46/30447\" title=\"figure 1\">",
"      Ungrounded electrocautery risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4396|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/17/8475\" title=\"table 1\">",
"      Temperature tissue denaturation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/25/32151?source=related_link\">",
"      Basic principles of medical lasers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/47/38645?source=related_link\">",
"      Bronchoscopic laser resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37351?source=related_link\">",
"      Diagnosis and management of central airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30454?source=related_link\">",
"      Massive hemoptysis: Initial management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7412?source=related_link\">",
"      Rigid bronchoscopy: Intubation techniques",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_11_11448="Atypical carcinoid necrosis";
var content_f11_11_11448=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F59297&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F59297&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Atypical pulmonary carcinoid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 389px; height: 261px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEFAYUDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDa0hvE9sZdI1HQlsNOsbwXbeWCPJUnfhZt2NpYlsDntwMAUvis0umtoc+nmXVNBvd6Xkdvd+TFNIuG8pyo4I5IDA9TjvXrV7o1v4nt7NL64uVktJN9ykDbY5S6glGHcY24PXH1rlbnVfDfgme9s5kuJLW/mRobSZHSNQh5fc+cjdjDe3Wto1pOd7fcex7RTVo35uqX+f4nnegaVFrvh4Sast5ab5ZUtHiuTuFm3SAuRiRAd3OO/BAOK7f4XajpeqPrXg6/SRkRC8MT5VZoMBXQY67Tg5PPJNcjdXfhGbW72fSbXX9F1ZUkdILqFTaSELnygFJ2k9j939KPhimqXHxE8M6xdyRN9qFxFKFQL8ojkUAHv0H5UqkdHJu/+fXa6NWlKi+VNNfoek/EzwtY3XhuRYryfS7FtkVysLEoFDDYQOdpB4yOMMc9sWbQzwafo8Nvay2sMUqxTWlwAGiC/ecHPIGMjGQQenatnxtepbeGrmNreW4kvD9kghCj95K2cLkggZx1PFUYLe6dIo77yHuriEEx7gVh+UbkDD75Hc8Z9hWDMKc26acvP+vldiaZPHqVlJJI9rFPHkCPzMmVBIdjZBzggAg4zz7VQ1Sa9i1SzMDR24a4ZnVVBuFtgMAJuBQKD1ZiMnp1FULHR49Wup5dE82yiV3huJLuL/j5lXAeNQ/zKuRnIH97HWoPEMunQTTaPqGo21msttmaK5yUWEOMSMegQvhQrMMk4X3ajJyskbJQT+L/AIBuahYQ3erR2h0+3v8ATjEJYDcNn94GOTgghBz265FM+2C4uBY2BljNr5kcFjaIBuCNswM4UDKnB44BAwc1zmt+NdL8JqDqTXlpci2RC9o6uGRlPkhLfJC8DI3FTgeppnw+0Ozmnn8RC61e6vrvEc9zqLB5riJl3hYkXAjVwwA5JGMDGc1bg0ry+RDl+H/B/P5Gt4o1BLfw1rcOmXpuRHBiS7U5ZHaQBwM4HQnAHHvXMX9xpmu/CuGzSJbrxLbRwRQTOuGlmV9sXU/MzqBuGeMkk8V2stqmp+Gl0zU4Zlj8rzbuVWXau0giMuCcsOh7ZU9qtQ2sNtBcXS6aIktbQyqsEWT5Q5CjuWIBHFEKnKkktb3LvFLW+n9fiVLQ2ulaXYaXcmTU9RtEC/aZGJhQ852jPzBeQCQScDrXM+IY11nSpYTqI0xLN1urppXBi3YJ8qUBueMEA8bl6Guv8WTxf8I/DqOmWpWaa2zBA0PzqSAQrJ1HHJ9Md68wi+G9slqDqeowaVElos9+LdBP5mZH8vlTyFGwE+vQ5rJzlF3WrNaEYShzSdtet2/kl5/iep+EtAtG0+wlF3HeKiKUmSTzfMTAADPwGOMZ49q7ILtA2gADsBXnXgzVbLRDo2hQOklsYFdLryzCJPMy3+rPKgZUYPJ5rrtX1V7C8gMMaXFqDtuWEoURZIC9e5JPHtSi9LnDiadR1LP5dNDUurdbu2mgcfLIu3OAcehGe4PI96z5dTtrTUrPTlmje5nOwruHyHaSM+7YPFQa3qRsNX0ywlS7kGoy+QPJGBHxy2fxH5GvKR9ps/E1+kOnxaZOl1L9mmtkbqC6K0meXJwCTyfm7A1Ss723DD4ZzV5PRq6/L8z3GIl8AjDjqg7e/wBK5jxnrmg+G5Y59ct1864gdUlREMpQHJXJIIHIPvXij3fiSy1VZ9V1G/u7uYqkU1tOWYHkHbwpA5Py89fbl2m+CLzxZr2va9qqNNZ2jM/+igSy3bRjOI0VsbmwcngZPAOeNeSOut0bRwXsmpzloereHvEWk+LtVuLryryxfT2+y2okAADOhLuCuV3FSF55AHHWuEu9DtvDHiCeXTp9QjgVlZpraTaJEAy0fyn5lJ7+nHarllqy+IJNPt/B+g6lpOmwSuLyS9t4xCHT94YY1JPzHnLY+XPvSeOfEsLXc3gxLS5sraGKGWK4gKu22UAlyM8jJx655zUOHM3b8zehLklaOz0s+n9a/e9S94r8b32leGdMt4YbbS9R1iYrYXO7etqhfG+TI+8oPPXHep/D3iZS2n+ENZvDPr8sbR31xZRDypHDnJDHBBEYycL1PbBq98P/AAVpZ8I3mmXV6dWtpJfMjZwUEDAMBtRiQpUnOPU854rgPFtolnprweC5A2oabN5n2lP3d/LbMv7xnONzDe/p93jpmm3zNQhour/r/OxMI0ZOas7r+lv+W+9j3dtPtYtRF1DEqTLEIXcdWUfdUnrgc8e9ZGr6pYaVp+q6hf3sEFnAgmkMuTgr/Dxk9RngckivLPCXxQuv+Fe3c+o3h/tW1uo7SJ2gLJIrDhn4yD1PuQOOamtdYh1zXtHntrSGVLkra3qeWTDLbk4kQhicj+LP4fWZrkeq0/AzpYSpNOTe336a/wBfcN1DX9dvbjD3kl9DrEIvtGna38tLONwSiuVGMZARsnjAPzZ58/m8N/EDW7mXT7+x1WYSDzpVunKJCgzjPIHBOehPAI75+nU0HSdL+13lvZxRu8SQKG/1ahRtjRV6KBkAAAViaXol3p+gWFjfXbarqsKMLi/kcrIOdwQtkk4JABz0HStViJR+FJf1/X/DkRq05RSXT5X76dum/U5b4e+H38JEPrkjz+IL9y5XYPJX+HjaMA9eccZ6Dmu5MF3/AGpKumxQwSSw4kkkJkVWU5CkZHUZ/Os0SHy3fT1kMkbswWMb1iAGDliRkk5/A57U2waWDVEfNvEwG3yS+GGO7ckLkdOx7Vi5OTu9ypJvXrb+v61Nu48zU7RJDbXVtf20iymFG6OvYnoVPP4GsR9VFzHLb2d7Zi+tDuuZjtCWpIJCsQSA3UfQdzzWb4iutQ169bTNAnKo7CK4ZpA4QjJw2OgOMnd1xxTLHw7a2Pmzi0gnvL11uTDGN37rHDMWPGTzk+mB3oem44U1Fe8/l/X9eZG+nWKa3D4hvZLW616NClmLVcwxxumAznALg5chj0zitzQLeHXdKuri+1FJ5ZmOY7dgotOM8nrxzwTjjAFY5Ypq1zeXFiI7JIFhkvFZVRDt5VI/vNxgZ7YIHemy26RXkX2ZXRp2DzERrG8hcngtwc5wNv1JqW7WRty8y0dnpr6dPy8xmi3+sDTJbrxP9it3vFEEcFjbkbWRmBLHnJZSpHpjpXES3l9omsJZ2wcaPfOt7Hp7S7QNjlHwDznIJ29PXOK9C8UNLZ3cdhdhPNmhWSNhJje5JXGOx9++a8r+I9heXxtr1JI4LmykUJLJLs8ldw+Zj2AY5/Gk21NSfpt/XrbyOnD2dN8qvfX7trefS5117qelx3txaoG+0JGCVG7qwODtGQqZxk8DJA7iug0DwduuNN1LW7qW6DN5sWm2oEKW82GPmSODukYA4GeBk4BrgbO+XV7jX7IpEtx5dm880sO4XSI37qSKRTheDznJZfQgmvWoNZvtY8LWF3pYtEu0Ma3TyE7I3GAVVepLdunUVtJ8tnF6nLXcmko7X3/rzMu8+H2iw6nfXEERtnWJbuDfOzRh1zuyhO0gcHJHGeKwtJMUusppiy20LbTNduhAFugXOcLgBm4+X3FdH4g8R3F3HqcGl2cV3FaFLa+vjMIIl3MAUjLZy2cA5OBnOelcv/xJ9C0DVr/TIbj7ZfebLcrK+6XMbHMSehyp5646cUNSteRNGc2rSev5ab/qVbrXXvL2NdHsryWFIGu5oV8rdBFG4DNKGGSSp4VCCCrdasaneFLuzUSyJpguQL54yVZYGUhJQRztDFCQOvQ1leD7S48ReCdQ8QImpWloIzayWtq+GvoEbLnzOMglnHA7Ed6uyajPot3DYRWyWmprEWd2k3eWCDsUE/3MgF+cYyM8VoktLLVF8yldRen/AACxompm5EtzaXNvc6cLyRbSaWFlluYwRtYhhuYdUyeDtzWpFf3GnJaarp+mzWmhXF2ZYd86gXE2x/mxnckRAIVDx04Gawfs3mSyXuoyyh4/mBkk8xmHJLZLELuPbngdulQMbZLnQbzS7G8vba6luFL2sCubUuysV7KCW4Dtzt47U1yyl/W4pQ0Vzb8V3EEuqXOsHW9PEcMcUuIJ8SQSKvztJFk5I5G1ckYHrVRfGOnX6wxzWV5bNBbsIYjEmSMjJVQflTBVsseQD9ap6h4OuLDUtPXU4ra6lgnj06xglm8qBWkVmMjbBkliuwNjJJXPODVfTNC1S/t9W1C88zT44bY6d5ckXmF3SUqsSfP8wUZDcAAEjnkjSMaUk3Lb+u3+RK0sk7/1ZGvNHpWsaXJf6fdPHNBaTebGq+WzglcRh+wJPO3BOOtYc+jRSor3d6kmnRpIki6cjzyZVf3cOOoB5B4xgDPqNH7DpUYhsLm5AU7vMydz57sU74bsO3AqX+xdctYNSmjllkvZbVrdJv3cccm1W8qRSADvwerdCMknOBnGainZ27XNnppcyBNe6HpNm9nao9xdFnuFfJEZAXCrtXHQ9cCin2HjGx02bdpTWa25tbeCZbq8e033CKfNkWEBioO9Rk4yUJGepK6fZP8AkT89f8zP2reti14al1fQYXudN8y1FzmaNbseZAyAc46FCMhgCTwQOoxXL6r4p1nxNr9lo/iLSrbUDJKdr+TJDcW6E4IJUhTGQAe4PXNbenzaJZTXUbCWS6lgGVdmZooxlgM9Av8AFwO/NVm8Q2cFjqGmwyAbI9rRHJZ1wSUBI7YJxnuamXO23GO/UXs1J36lzw3ZW1u91bwXbRXBVvsyTMGPHTZ9fQc1qfCGE2viOS31KSJSu9rGMD940jDEo/2VGCQD3YmuU8JeHdQ1/wAaT6nIkFhpulTQvcSPdq0TMuG2o445UEkdge3SvosIl4yzpGEyQySJjLDGOo9j+tctW6bj95niK8Uml1/D/h/67nJ+OFvbbW9J1K1mfyIpY45omXKqpbBkH90gkA+2elefP491eDxdc6HqmkWM2iNIyhIX/fxBs/vY5CfvHPfsO3WvQ/iVqFjpukLDqczr9oKxbmJjUKW+8X6cY6dSO1UtJ0bw1fahF4gtNL23phZjOu/ynUjBfb64Bxx74qItRvpuKm17GLmtv6/zLXiF/ENxo8r+Gns57qWIqklxKgKLtwWPJXce2OOeR2rlbbwRpUieGb3x6LBtYso/Jnlkb9zdurfufMPRlVflZiMMepNHivwnZarYWdprrvcWOl3LebqNk0as5cLsWZcZLYIGRwByTVLVrnTdR8QXfhWwMdlq+mrNb6cViE8UkD4MkbCXjfnoRyCOOOusUmuVvTr/AFuQo6dLf18vTTzLml6dBpus+KvEfi3R/P1hpCZ7aSPz0EbMqReVxymVyTzwo4FOs47+y1SW61e8j0Pw00+65kvJCL3WLp1BRCoGY4k3KBGuMBTnOcr01hZT6dNZRxCOW0Wy8lxOxKxFEUAHJJblQTkjJqlqejWOo+I9L1bWjHd6jpNsUUnd5ILMCHCk/f8AmxyOfwFYqe7e/wDX5Gk1zWUfLb8dPX8bbl3W/sX2Z7e8f/iTXE8EKpCH3XEhbCqpHAUbSSR1GPerryQSXaTyXjrbl/NbzGI27OxA64x+PvWbcapAbKG4SZLqGC+khSb5SjSKMFUyByGJXjqFI71eudQ0/wCzLcXMoaNIxHI0eGJJxnOPuknAwfXtS8uoKLsmtv6/E4fxJda7qHi/TYNK1jSZ/wC0JiYBEo8tQpJk85f4mwpUn+LHyitbxXqCXnjm/wDDKaDdQ3lxDGI9RddkN3FGvmGOME9VbZ9zcc7gQAM0zwfPazfFcW+LYQw6Rvtoo5Y3Fs+VGBt5WQLuU9yvtXSeNLq3tI7W5UQS3ul3MUkL3CrvVXOH2sw6bQSSDxgZxUK7cm0azk41KcIdF993pfy2PPvDMF5q+r2hW5MV415cwxT7NwhUISpUHgjBAx/tCpL/AMcS+HvBWlWWr2x1XUracwTacIzbzSBS2xnAByn3e2SQDzmtzXFsPDkba5a6pHFo6bblZl3u0fnFlXaiKcnIwCePlAPGatajqVr4psL+316B1EXFrcpGqvtcZDDPKkbeR+lVGyleS/r+v8i6k/auy2X3re35/hc0W8R6deaSYWknTVvse0zQzIrruQbgsvK8Z6jOCPWvKtF0O38JzXd5b3E7q0XJukBQKuCMhPXAy3cZPeuy8E+HtIu4LrQob67eOWGO8s7pyGkUgsHQj7vBIO3uOfesmWO+g16+8La1ZRw6j5bTafcoW+z6lCOCvQ7HIz3POVOMqTUW2mk9Ah7GjPke/wDX9eRS0bxBba74T1W58R6DDYNZxMI9S0e4KrJKx2pDsJOGPUkk8DoKueEvGb+GPDksWn6RtFuhuporVC3JwMNzkZ4Pbr+FM1bwPNpfhrSNPtbBbaO5ma/1EscsGB2xKSxz8kbN8o4Jb8a67wz4Rm01LloVkeWZBPI7AoTk8LnphcZ/nWU6kpVfcVo/mbpYaOG/ePmbbtre1nb/ADf3HU6NrelXdhbrC/kPLF5rW07bZ0LDLgjqWyecdDXLT/D7S9R8VGVzLbXEcCYlZi8jx8DaQePlHGe3HBxRrPmRwtJIiz6+ZVls3gwLlmXJIwB93b07c10en3Gs3MWnGWGKG/liL3ZZPmixgbB2+Y8884B+tUmec4uj78Hv3/PzRkaG8mhX3iO5vLGeDT/mUC45MwVgkexgcYYMBzz09686+F1oNS0OfxHrbTvNpuotbx3dvcrAwXCkK+4cxrvwCCDgkc4AruvFeoWGpXc73GqR2+kaZOTclVO77VgLtCnl9o4z0GfyveBfD1hL4U06aS3X7NEzS2tvgFIzuP7wg5+Y/oOmK0jNxTt1/pmkmow9pPRu19+2nz/T8cLXbq4/sDxNrOmzX817HpF88mpRAwRRMtvIU8o8MxDYw/Xv9OL8F+OLjS/hz4e1bWrzVdQ1O/0y5jjluZBKkjR3s3VnDMZACgA54A9q9O8WTxXHw48cOv7kLpN9HFASV+UW75baeuTk59PrXGfBPT59R+Engd7SN3azW7klGEK7HupgGG7+IbCRjsSO9TG0dZK5z+0TxFnorW1+/wBPI5fX/G2s6rr9nLHaz3amURQwyZOZMAMFA/u5647+2a9g0iWYW0EN60oZgA8UTjYH4A5POMDnin+F/Dmhz2sGoQfa7hXeZklmBikO8ksDwGAyOn51cuPCqReVLp0xSaN84OT5g9GOcmjnclql8v8Ah9TorVqDfs43Vu/9aBPqMOn2sbw3ifbYy5+zoVImycNnp69eOfyrhrnxta/21LYX9xpaeTtkS2tJWlcpnB3uuV385HzEjOK7nSNBhu5LyfXLS2nfzPJitiv7qCIDGxV7g5zzS33h/Q4bCSW30izjktEZkZIgrbR1Ge4xnrmkvT+vuZnCpRjKzu33/pr7/uPMfDui3WjeItXng06Gys7qEPps6SEC2heYb0lJILEA7uS3IwCASK9N0O3a2tZikEjScnGB5kgUADOfTHArL8VacdL0AahZIbiyhCFLOYZNvHkYKuvO1TyQc/Wo/B2qwpqY0+KSWWa6TzueVOBzzyOPY0SqOcve3NJxc6LqQ1X9f1+pJ4z1i10LQYr7W9QeyglmRGkjt9zFj2UAEAgAnnPSuag1JLgG50e6W6gJElrNI3ylQxXcD0BYh89xjtXpmpwQywP9qtvOt0XDq8YkTb7qfvfhXm99pUVnfF7B4YopcBo7dwI05GdqgYBIzxgc1Mth4KaldMPiG+kzHw3ZX12VvLlWuVS0ut1x1AQKzLjbnIwcZIOORms6eC28W6StpdqtkblGtY5U5SQIcI3Prtxg4ORWnNLfSXk0mg7ZJ7SdYZLqWKBZII9oLEMf4VYsSRzxwcdaGplNFurq8gt4/wCx7q9Z7ZojuVY5fuyKM/dzhgBj8qcryjy2Oqkowsr66/07/wBNHA+HbtYLlfDwuJBDa+ZdsTMiRE7lDqin5nyqg8HIPbAJrsrHUBBBqFrdM2mz6i1vZrcX9qyLFbqXzMC2FYDKgMONzIT2rD8f6RcQeK21rSooVuCxmjVgGRndCWQ/U5607wTqs99qNjpeqxRWumebcRaQb+UA2ynO6JlY5YuSoAbqeACOm+HqKqnzfEvxt/wLfj5XWJi4a/Zevp5fJ/5nQapo+m2mra3aSyJc2EaW8crGRiZUVQ/kSN/EyuFbA7MoPpWM3heeS1TUbK2gmW0K2xVZRFJPIV8wFtwCqwXgnJK56HAFdrp3hyXX4pre2kFjDYzPbXUMMShobhQCyoejDDBgR1z61d12405Ph/YDw+XSNZC1v5ytHKZFJVyyvznOck0e1nCV0zBVE1GEdX1f+f8AX5GB4EutbTSP+EYvLkK6s5mHlEu2475FywIKnfwQOlaE92fCekahNZaJ/acYVYSgiY7snaFbdyw54HG48dwa52PXr/QdLvNSZrue7aCN55SSjvJwGQEjOxRxxgH5fc1e1vxnrcmq3mla2NlzbSRRrYabALi21GNlLSFpDhlIAwT29GIOLjSlN6NWIneLtbRkGrRi70/Ubee+F1FAiSJNHCqYbG8xMuSNykYKnnnpWVb3muTeIfs9jmK3S8iM6W5KR/NDkqYzxktht5AznjgU1Dd6lrkU2jhIpRIZBbG7R0nRsSKnmA7d+zkfdPykHmt3TLbTLvwY2vWrGO3a4eIGKAoAoJYFyQGf5lwM/SrnH2ad9n+H9fcaqS91Pc6vxobXVtG0+7SWC4jyLK6TIYyEjIUnpjgnI9eMVxVzBFZRrNbxIoR1WMIMeWqjOEPVevUdeQTUl1qN2ljLb6TEy3MBiEqz/NuI74HyhsNkngfeGQRxHrGo2Om6hZpcXXlNqDeTHJCSV3J1A9ssMnp0Oa5+Vp+732/r8CqK9nHlk9B4CtHFqD+bNewOsVxdRtukjtyeXIwQdpxnAy3GBWLpl9aaHYXxmkkkm1GCO3lCp5OJ3LKjSqxbDMMlmHyjB5J4OlcagfMt4rae0WOQhZZpD5cUS/MQ0kuDj7hAAGSeK53WbqzudHnN5awXFxYMLUWLoUN1bOHbzY5F+YlW+YZwNpPc10UoylHVaf1+v9aCqWi3bc6PR9FbS9QvtM1uwFleW4jIe2hLw3CHcFdWkDMeVIx0AAxRV2zd7e7vJdO1RdRnuTHLLqEQRROnlqIwVXCoVUbdg6df4qKwr1EptSvculGTgmW18FazJp0U8s1nqJWLy2utGuNzzIF2EFSN33QQQHwT2GTWtaeFPD+kbdd8XpbWeADb20qCMRgDGGRf9Y2MetecwaTrnhm7WxuVsbjVL/DwjTQwuFYDAYgYAByc8ds5ABroNc0rT9AsY9Q8bXX9sazKMRWBvQkMZA/5ayE5OOuAeegB60VZSnP2cHzfkvX/ACM4UmoJ1J2T7L3n6a/i9DQ1jWo/Eekf2f4f0lbXQoi0jBo4kiUA7g7RkcAMM9Rk+vSuW1nx9r1rE9vY6iRCwAeCyQIVTuE4yp6/dwKj1HxZ4rNrozQWeiW+kiIibRjCr2twAx+bPJz06NkEA962tJl8EatrsU11BJosU0ZaOK6ZBFb3GOdkgOCvQ4bv2GcUQag+WWrXb9Askn+7tFfP5vzOh1Lw4+reGbObS9cmFvCqSO10i3FzDEwB2oHBCMeDuxngc+uVILyy1bU1ivpraDT7aGe7nEjK7uoJZZzgh/kJY7cN644xvad8Nbf+0rbVdE8QTSTJGykhlmim3DneoPzLz6+lZnjDUH8KQ6fpjaJYHVNc3w/aXilubRXTlAIlUs5bccLjg9c1CvJrT+v6+Zn7WEbqMub5W+9P9PmbnhaTTfFHhSO5sbP7FPdRmUqm1WKk8O/PJbaBk880QfZtd0m+FvcQxavpl00dw0Z+4/lkJ5ikcAgghhn5hx3FUtEludYsYbS906KGGR/stpcJE0BvYz99yedm5o5CEP8ACQDjOTm+KrXXrbxDpXijwdCtpKZGg1VbhfL+0lPlTzAPvIAu3I5Xg5PWmt7S3MpKS0j3/r7/AMC34JtZrPw9d2+kq0Mkd3bxySzqFUIGwyg85Iy3X1HJJrotY067kvgluw064ht9yXbRi6hcJyoZW5JBA+Xg4JIOcYw4ri4g8U31ravZvY6jLbXXlQlka0iHzuJg3yl2OFUIc4ySMCuje5a8vpLHTbeGa92AEN8sNqD/ABuOufRepx261Hnv/wAOXUcnLmta6/RIj8NXFvp/g59Pga1udUaC4vhZJGyb5XZpCNr5ON5IBPYe1eV3Oo6jrqT6N4lgk0b+1oP3djcaYIi9yDkyxeowF6uCWIwMgVueL/iNN4X1ZdP0C0024a2mFlJPewytJKyLjaNnIJbKjr0BPBrVmvbH4laRBovjPTLzw1rDSiS18w+U0gG0nyTIAWJyFK4PIznitoRv70vw3IV6Mn7uj/4fseY+FRqXgL4np9lsJJ7N0fftGfMikGWbc3AkUjpxnGOO/wBFXmj6Rr1vcDUrSO9SeJrdmlByI2ByF/u5B6jmvOrOXSDqV9atcXV1Dp0Ml7c6fK0c0wjhTkSYPDOSMggjHGcmqknxL8Tz+KbJNFsNPn0e8hhngDQN+7ibG7zHz8u3PJ6DHvilKLleTsv1FUpObXst/wCtDNJ0/wAGfE7UNIgDRaPOYftcccsglaNUOwIVHyBFdcjPKI2OeK6bxPc6Zp+m3V3c/a2W4CDzFQznB+6yljweOMkZ3VS1nRNCm1ttRmjN1qLzPG8sjFvtTk4UhScAZHGMYA64rpbeG3uHInvbW5JvFs5lt5PO2MATsJHCsTwfQelZc/O7yX/BOppUkmm/+D/w/wChleGXkWx8Py2MD77qVSXMTKytjkEnAyUJ/XrxXc2UM81+91c71ZSUWJnyYR3wR68c1Kx1Ge+ayk0y3/szGFuPtHzZABUiMDjBz3HTIrkdS1u7t9VlWG5u/IsJDbzXcMIkS4nbHy8/3RhTzndgetLRHK3PEyfLa9vXR+n3W3+VzY1IW2kXFvPeLP8AZJZ90jy/OiOMnOSSQOc46fKOmK5X4kalYS+JtGtZtVv9NltFa/litT/rrZMszSYYCMfKVBOc7jxVfxH4v+ypFc6rKkmorFL5FtAhZYsjO5lzgtgdScL061zOn+IrrVrlLbX9FjlmeMRrG0f+kfZ2GWDMF53KPu8ZI5HNdFOlJrniaRpSi05bo7LwdqWjqr6npQEtvcyPOb1Yx5ip1EZHX+8AR6ipdOl1az8dalf319qs/hrV4keFI43cWUnChV27sE45YYzn1ziXUpNIt7YW/hFNPk1gL5FvsQOwUDO0HB2gD8B6VheGNI8VW7wzzarLPY3bMzW8ckpjXLY8wsMYx0xwDjOO9ZKKUW1K3kOSVR88l9/9fd08hfiUIhop1XTtOncaYHS1tEgUBpycJKQfmIXcWIPVtvoa6gvNoll4Y8IXWmtMtzYgXNzbzmI27RgeZJkDsSCDnk/r57428VX+k6jDZWek3k8ENykstzBEZUeRRn92w+VgG7Hkle3fZ0nWNYdblJbq51OxnDLJDchnc5TIPTIVevp79KT5rJM0dK6Wt7eb+Tv3W+/kZFzpOs6fD8S1mmuZtHj0O9MD3pMjOjQSbXiYk4PGG9R1GRxzXg288S23wk8Bf8I5a3z26w3ktxNDKYUUi8l2hn9PvZXPPHpz6t4xEt18L9Y1C6hu4p30a/QY5WRfssvzuP4R8owfdR3rzz4VeL9T8P8Awz8CWFra2dzZ3sc4KzIxw/2yfJJBwBjbyenNOknH4d9dzklN1cQtFe1vuPWPh9r13q+lwtqVu02pI0kU80IXBYFSxAyCByvT0rQTxMZPF13oqaRqXk2sAme9MJCM3BKgEc8Hg55IPGACeD8Qaj4S0fUdC1aSDUbA6lcP9pTT5XU7yoBLjP3PXbgnGecYrtdFurTT7ltEt7m6N5JG0qC6JJckkbjnnA4//XmlaVrsKtOmm5KL16bW/PYlPiBoD58WmXd1FeYkt1hOXzwDvGflBPOR+NcPrnxA8S2Ky2tl4MvtQnnLDLxsIVB6jdgg45GOK7+2vJbJls9UdI5yMRzr8sdwPQHs3P3fxFasMJSN2IKyOOWzknHShOxk5QgrOO/W/wDX5HCfC2TxPrWnT6p4vNvbWUwVbDSrdU8sRbcb36lgeMBj1BOOldfZaRYWkkhtIFibcXG0/wCrJ67f7ueOBViG8tbjVLq2Riby2VDIpQjCtnBB6HoelYFprM1t4s1m0u7K2g02JYsXizFpZZnPChMcqBgH0I7g8LR6sle0ldRutFp/W+51Qz05+lcB4yhs5Lzy7HbLekNIUgcqoIIz5m3oT05//X19xrFlbRBmuYpJchQkTg/MQcAnoucdTXN+HvCsL3d5qeppOl1cmVGg83C7GbJ3KOpz0z2AoaTLwz9jepJ2/U8g8XW9pJ4Y1IQ6gby3tkQ3sdsu2WONnACyqcYYMF9uOe2T4f3v9o6VHpWo2bx6eqrLpk8bkZVWIKlj3656d+Oleq6z4PhtZrObSLeAeSPK2SgENERypJByeOh/OuI1HRJNO1O3NjHdNcQzo8lrFtUiEuRlRjHl84wOnQnvTUrLkPUpzhVfPf8ADX5mp4mvdN0zxJo2sX+lrLZX84t7gM2RbHGCw4wVIw30J6GsO4hm0XVNV8L+KPET+ILOJvMis1KzzQxZIBmlkQiIkFPlXcep46n0vVNOtdU0lRexR3Rn/eKrxjYMdPlPQgAZH4ZrynxVpk2lXmoakljPqV5e3CSs8SlWAcnaDgYOWJ3eh24wMU4ctrLd/j2+4xg/aSi7/D/Wn9XPQvhvrmh2Vq2iaHZarFLIZLuCK6kWQzvjLKr54PGcH61h/EHxXbweIv7Kksb23LWf2lBPGI3Us5DADoQBlsg9c1xI1Kz1K6WyYbL2FWbYj7gu3qSRxkHj+XWu1tPG8p0CbTvEdidWhAASOVjHJgDjaQMlsZx3z35pfDLlmjSWGUZe1pK/kYV1ql0bu6sYRK1+swjihMafZUtdgy8hYBzIzFl29OMYqromkRWtxaXC2U+lwpmZP7PunldZgGTzkJzgsOo6EYGBjJ9K13wZZT6BbQ6LYNBfzxASeaCGaMjLrK56H7uM91HpXm1yi+E9QupJLN1v4OZEMp2ykhcYIBBcg8Af3W6c10QnpyQ0f5mcJQq3l66f10GPFYpZanFFHcPBGykwShT9pfjbuRhjPPou0LhfWvVYdCutU8AQaMba20ydURJZVTZGwQkrtC9e2e2ScZryu81keJNTspY7VZTbOgFwp8zeDIpIQeoC5JbGAWBAr2g+LdPk095bCWGSRfkA3AqvbPB5A64FKopJJyWpniOb3eRdTyu9trjQ7byrMpGqvi7u7xm/foHK/u1xyvBzzkZ75rf0JfBl9e+Td6TDFdzRLDBqOpYuHJXoAr5WIksflGP5Vf8AiB4WXV9AjvLNJ7ny4RcO7nBAjXosRxywz9OPWvOLfVY4fD/2cw6ezCAyp5c3nJHEveRQQ4bJHpuzx0pJOpG63T1/zNFy1o7/AHd1/WzOs8f+D5tKs4riG2tQ/nBIPs7CElsFvlz91iAcGsLw9bKbuWHUb+/vo41iiil1LzEkmIG4x7GOQiszADGCcmpLHVbe0ttX0DVLeTxFpN3i8sI4C8kaShCzM0efMWHJUlRkKRzjmtXwf4cTWtMs9b1q/to9KjiUTzs/MxUYYKeo6DJ6nJxVOLpw5en9fqgjU61Ht1738t7mdpUF7YzXsGkaHq+oWPm70nWEupz6ZIGMYIIJyDziirPjvxdp97qitFcXjWUYMNtFauyIiKdudoxhiQeOuAKK1guZXdK776lr2jV72Nu20bUdMtr69065L6zduvnXd3MqzvH3SMHIXOByeg4GD0xdH0bxPFcurfZLZpFl8y5u44rmTa2eUTP/AAE57EcYroPGU2vXFulx4WubVNNSJd8BkCXG85JLbuNpGMYbOD0rh/h/4l1a08UweH9avfMnvnDGB45pJYiVJOwt07HH3cc8Vzwi1TvB2tqQ6spJymk2+/Tt/wABbCXPwx8WzXOY5E1SwBaSNpJ1tyGbqAv4ewx0xVDUPCfirRpLeebwre3tvAd7rBNHPs54KqNxOP8AD616ha+LZtH18aTc2DvpV0FOm3xuCyyuVz5LHGEc4JUE4POD2qxrnxNsvDpg/trQfEFpHNJ5UcoWBkZ/QHzB/KjmlJ66sweIrRVorT8f1/I8TzYrrtzdSajb2Fo6bwELxXAYjOcdiPT24Fez+DdW1TxD8O45tRlmguUmSFLoKUZ13bSSMenXsau6rceFNbaO61nQbiW8Efy/adNYSkYzs3AYPc4JxU2oapHPb/Z1gu7GzgAMdvHEBIVUDoo7eg7VMpprzLnOVW14NWd9f07nEa9fwabPpdjqziDTLmdYIY0DNI0jZVmznKkZ5/rnFdtdRw2CuzjydRtpjPH5k7OxyCO5zgj+DtXIaf4tla3i1CHwzc3t1NLIPJEqBrdQuVZi5BRmPHH1z0B27G9h0uynjvYd00qJc2zbRLPHvOT5zc4mTdsyG2nAx3FRJcr1/M0kpTfLZ+n3X/4P/AL51COw0G+1Jry1ls0Xz3mdNg3ZO5Txjg4Az3GMV0+g2C6ZpMIkjSK4lVZLuQqFLysBksfXJx19q8U8I2Ola5o94oW7i8MaDP50VpdybRczklma4ZuDg847K3IGcUXuq6n44uLDR9Mv7i7N1eR39zch2WK0i3YKDJwwURsc9CxOK1dO23T+vvMJUXUi7uy6/d8jufGPjPSLOSc6JBYzeJgrJb3c8KjZ/CWDY3NjoMZHHsa8yk0Q30zXuta3PrniXT2WeMR3ZWZcvuVkVuRGGYHsOe1V9XbSPFPjm11ewjjht73U002wSUMsNysRRFlQADAAwMHjHvkV2XhqyfQrJfGPjpGtpzfXH2HTjGiSzPM/LPkZLMVUhc8BR24Gjgoxsnv0/roVTdOEVZX9db+Xb0NK60zSdDvtesp54R4r123j+0SQxsmNzkRhpCdp3nIYKBu25I71meAo4E0nxhZRefcm38q2kLIFby5H2sgPY4DcHpnjFcn4qvNX1LXLq2vbqW7M7xqtkAXjeZ1Bfk5EZUnAHXHXjro2um65aPKu2QPLd2d3NHcbbaRlhZiSxYgAHcTlj0x6Ch0UoXb1ZrGDjG3W9396v8ju5xI9xYJaCKO5tfniWRd4UgEK3vjI4J5IyaytL0LUfDlpbW+hXSRbpzcTyzAuZTgcEEkAZyd2a1YJNP1nUZ9X8N6kJrFJPIltVXcFmXAzGxPQgA8cHGec1au9lvBLNeXEVtZBiHuGPVj3bj1P61yWcXqtSvaJq3fdEV6+taiZ/teoXAs4oD5ttDGqmTGed6kMuQMAZJ5x71Rs9CstM0l/tmqJbQOqE27OWggQN8oQZznJOSfvNzVTxBBLHanUdEu5ZZWcKEScrHNz90Y6dQBnPTpzWx4OsZYIIdW8T3FqIbP91EkceI4pCxUBickuuccfLknFLkvqxymqdP3XZaaJf1qZel6GyeIr+XUb6wHh17RTbQKp+09AWeR2A2BvmXGdvI6EAmLwpqPh9tZl0a3ttMV5VBgEqnLJk4G7+LcBnDN0A4qPX9e8N+N9evNMsr25TVYwUjMsW2G5jj2s0Oe53YI3Ac8elct4Dj0fxH4i1BdAnvX1EDyhdTRYjhlIISZEXghAG25I/UY3UUtJ/p8v63MotOD5pavp+Jv3Xh7xNfePludRgv4vDsNyZLSewuo1S0RgAsqR9QMAZGAepOec97418Rw+D9JkFvbSSidSIWiUFEkcn7x9/mbofWvIvEMceiX+q2Wl3Go3PkFYLq4kvf3sceQWkIBAzu6A8k561q+ANK0mS4sbrxBZr9oZHkUzTl45mUjYDuJwwOQR0+XHtQqMaS5r3u/69EXVh7VRlPaK2S3/AB3NbT7y8XS59Q1LSoYyYleztomKRuAB87A/ewCBg+54BzWZbaj8QbjX4dXazXULGxgmK2dmiCJFaMgRlRhmAYKcZJPQGuz8VeMLKO90jSFSG5vNULeRdOQYoH6AZ7sxBXA6HrXPeJtQvbRZJbG6k08wRySxTGUxBGQg5kCjDLjqvfIABzxpTb5rJLXyM0+aN3HU87S/1LX9R8a6leymd/7Dv3nY7kMObSVVh2Hpg549s+9P8DW3iKX4ZeDJdGVWso7O4EoIUq2b243bgT0C8jAOSMYr03xxBNq3g/U/EiRi2W88M3r3VsQflk+yyjcpx0Oe/JGOBXmPg/VU0r4O+FJr+WZdPW3kO2JQSzm9us47hsAYyduA3fFUpyqT0S7GHMvbxa7fdq9DqbLwlr+tPZ6v4ilW1i0hx51vEhBuF8wshGMIT83OemBnrXoF3eaHp+oaz4q1ScL5Uq2aMVJdSFDbVXk7jk9Ow59awtL8V3L6VpdtqNnbaY1zcIZoJ1LjyXAIJ3dyCSSay/i7eWdsb02rLPbrd7MRShXW4MW1wrHIzhkGSO4HFYy5pyUWbuLlK0tF+mn5nRa18T/DP2y1sprd73S7gjdc/dVWIz9wjPAOS3H41N4Ph0e4uZ7Sz1a9huYJWeK2lkKkRk8bcnnvnByO9ec2HhiHW9Du7XTZLK8n0kTx3FrK3lXNvNGGK8nh0ycMc9RxxWP4Kv8AVdX8WeG7O7QQTfbI72WZSJGKx4O0nPylh/6FTlSVrp7b+g1CmoONNv8AP7+mvyO98TeNNX8IeK9WlvPOu7YGNhaygDzrYHHmIV5VgD6c4JPau/8AD11pXiCwTWolESyArJ5xG6Nhycg/dbn8sZrifjXAtx4i0eXTra7udXsbeWaSOzB8wROdqkgDoNrc9sjjFcjZahEfDvmJPcwpK0blpFzIiLu80lRyx4UZA6HPSs7XSFGgq1NTjo7dPuNHxxZQX/w7vrrw+kjSy6wFMTpsZgsLZG0dCW+bHTI7dK7z4Ua/LqHhCCHV5Nuo2AW2maRss2FABbjhs5HfpXCW1/8AbNNn0aWRUvNRnttR0rzFMX2sYIYJuxiTbgYOMnp1BrA8CS6h4dlJgkE2o3rSQJAwOyM7sFyM8t8oxxxnmqs4xcZdDSpQVeLSev8Aw3/DH0dNGkqYlHy8cZwK5/xf4dOuR2qWsrWtzC25btDh0XI+UY6/Q14LafF3xhdWspF3blrV1mEsi7dw+6Y8Lw3XPPpXpHw3+Iuu+KTLbzWNr9rilVCI42USBiclSTgKg6nnqBjvRy9UziVCrRtOL/P9UdZpL3bLc2mralZX2qaZhZWt8xs0LDKO6dm9ccUvg+eJ4761ksydRji+zyRPuCuiDoXwQoJbt78cVkatocWiazYa7daqbe8t3dbqZuFvIJCSYnzycdF6nAHcDC3MsthqFjrugzR3VhcxH5lDGJ1zkqcd+M5PIII9ay5m3dm3s1OPLDZ7dFddP1PJ9Z8Kal4f8Rams0R8mGQX0sdltRGXeWiDTEAqgOPkLAsV9dtaOoSvNess24zyOHaSTqScZb6ZPQdMY4xWl4m0x77WZtWudbVdKu7gXVxaXMrxIyJtbyZwoJ5AITGR8vBBIqlo+p2Wo211PounTT26rc3kJmk2NbWyswTaTkHG0kbj6/WuqUFOEWtTqpVPZyd93r/Vzcg8d6l4f0iGyu9tyzSSsb2RmZVA+ba/yscnkLx3A7Vnan42XWLH+0L7Q7O1hu8tJcRK/m7F4ByRhyOc8duorBufEc0ki6jaTzo8oaGJW2ohbgJGq/eZ933sZGDWnp+sahFo76fr/wBmlge0ee4int/Ke12ttILYCurZOGGeQVOcVXsnGF5RTFy01O6VmY72959o1a4li2QaWI3vl8sQvEx6BYh1zkEuRggcHAr0Pw/rEXh3ToJtctEEMjPK0gKswTZuVSM8fKOOBnjFefX+nx6hZpNDdyXCvarGtyYMultEwZWLL1IHyh2zkYBIxmmX+onTILuW6kmmCQRspjAV/vgFgwP3slRvzn0pz5ZxSV/S39IHByjapb+vxPR7D4oRzWl7NFIdjsGsm+V/LXtEwB5c4+71xyTXIXmnyQmeaO2svsktw98bq3tgtwqqQwCEjcrZ3IcnG0n5c4NM0W5YT2i6Fb2kloYZoJ0mQSxOkh2SFmH3slOGBO4VK2n2trpAt4XhsIt/7sIMgMW3YVWzkexJOM8iobjTd47vpv8A1946dGK2X9dDOvJVuLzStTt7+LTbm6UOslvcmbyUwSGcpgJ7qDndweM10Mvnf8ILoWhWjie0snuBMqsIUuj5p8iTLZO3HJXOTnr0qDTLO1s9YzBbWNlclGBisLdkiC7txZtzNubjAJ4HYU/V74W6STS+dIIsG4IjLCFWbaryHtk9/aqnVuowprzCNO7TqblCCO102ygtfs9ndCMENLLFvBkzhwBj5eR+PFFWNNGraijz6dpl7cQ8KZQjqNwGCnzdSO5HHPtRWLs3ee/9eRq5Jaf5HW6pp+sI7wadfafo7peSQySXNn525JWyuwkgeh//AFYrWvg1il1HqV0JJMKrzW6gs38LYHWPjB4Nc3Z/2vLpthp2s6rdahFAqlbkna1y/mbRt3fMX2uuQcj5W6DmrH9rw6D4ifw5F53iC/u4iFSFFZLIk8+a3bPPP0rNXey0RxtPRy3fT/g9P67G3aTafcwR2tnqMEiRlYpWZsPDMfuOoPY89M5I471jwP8A8JBpDweJbSKfQiiNb2c5PntMsjKZFb+EbckdyCB0NaWi6LK9sVja3v3gMcZAbYsW1sHaw4DhSTkZ6dea5+6mnvbuWdbSK3mN4bKC3kn2ny1YDJJwMnbng4Hy80KVkUoKbcU7/wBfr3NPxXqM9h4faxMP2LSmAmE6SFikYAG3/d5HT1xipND0zVJvtl7Lb6dZ6asYNuZjJJIYyOrgnaMdgvJ9R3bq2rTaJo2rXmh2ZupLaBEi0t1NxDAA6oCz7sgEbzgDHGTzybXjNJ9Q0eJNZkm0eFGy0tlLteYryI0Gc847YJGOQM0KL6iU2rQird3/AMDq/vMTwpc3uoWJlsNEuraGHzFN9qJSN5No5YpwVGMAZOPXNV9b8W+H9Lk/4RrQtVu9Q1W6Rh9qsmRobYFSN5YHGVXrjoMnNcrrfjbUvEGl3emXMH9kaHfiFLO3ihWS6lAlH7xwPvbihG0AAY74y1+XR9O8MaAPtdg9hDd42z3xVJ52BDHK53FTjnIUc9jiuhU1FrTVijzT1k7Lz3f5GLpdvpGmrpFj4o1S21vToZHmg03TbVpIbiUKW3TXDbSSS+cAMMdeOKvWWpSa79vtLWzjvjev5DGAG2tXfaipbRhcF440RVAzjli2Qa6qw8O6R4qsJ7vR9Us9RlEcUdzYwW6W0iQImAqZYkMf7xbaeORisKa7u9I06/v4tL/4R7ToNLa2sFjjcTW8kjhWfc4DPL8xXcoAyTg8ZrRe9rHfTf8Ay/pd7hFwW2r/AC8h3hTwpLZNZweIbi126Rdy3UVra3KvLczLln3iPIiRdq554xjil8Qa+/iLxbpf9vrDcraTbbVLXIjErYYH/aIUevGPwrH8EsdI8Pvd+baxXHzWdvYXk5MsZY7pP3SAFztIbJwqhhkkg11+pQaXqBt7i0tNJhv2TMzLE0UCxmLC/MMncc5GeMdemaJe7dT63/r/AD7lRs5J72/Ax0soCqQH7Mz2sUVvai0k2ecUyxeVcZMnz7mxyASc1rfFqe3u7aPT7idv7I1GJXa4EolYSlhjHqAdvBxkdO1SmF9PtbaDT9RMU3lyrp5ch1SWUMWkXglmOeSSTgEAdai8E+FNKnvZLXUbt4tRlgWVYspJCrKQgdi4zJKzNuJwMblA6A1LkpPnbvYUmo6vbXzMT4bazpXhG6mtmtteur26uEW5vbm3KxQJGCANpOXxzyQPQdOfXgEubC5lNva3EsTeXbywKVSckdcngAk9s/jXlmo382kT3Nnqwc34kY/ZQS4kKknfxxtwQfxx9O1sfEOsz+GNMitbO2huEkjjleQeZGtuFyrcEDe+ANueM59K5ptyvJoVWjs6f5ljUkbTZILOQRi5SASSeUhYD+6ccAHIHOOKyPiXcT2Hwzs9DsLu1tNd1J4wFkcBkLMZGbJPyEkYDngc8g81oavrFp4e0XVvEd4/n3Msnkwh08wNcEcLsBGVVcYGeg655rybXYrfxIbTVLjWpr+aS23yRy24ilmaHLN5Y3bRhTg9wvPODV0aab5pbC5HUST6b+v/AALnUW3hWxtrmLWTrejyaoIFF0Yr8yfOFHmOqqpG5mGTz15rW+G2j6TpM93eaVDDY3Wsu0cfluzGFeR90kjcQSwHbJ6jgefaZfz6no+o32kWkQS1AaNYwWA74PTJ4J/Xmuy+HPiFtIs9UutRt7loVSG4gW4wPKOP37kjkjGCO5+6vJolTk27/mb1Yfu9NX/X9PujB1L4d+KdJvdeKR/aNEvZcq4lV5Cu8FWYEjbgfeboAM1lW2pCfXrbQrqyn2RXBQ2UEW5p416RncwLFuSGz1bPtXT2fxOnvb2WzeSa30xxNcTXkm1pBAD1CDjB+VAMnr9ahv8AxiLLwgmv+D7SW11C4kWzZ5AkuRs3B2IHJAAGM8buemK6IqotZImM5pOMt/Idf+Hbq+gs9MvrqwXR7dfLLPeq9zYSiTcVTbzJLswgwMEoSccg3Ib7UILbNuYpr3ctuPt64iutpBJcA55BYA9c1yXg6wiurUSzEC7M4SAoQzx9NxJwBnJPbAr1jxxF4S0jZD4os5WTUA4hjg3FnMajjPAXO7HJA6+mayqO8uXsN8tNpNX5uiMLxF478PQ/DLVtF1LVI7fWbvw9cyW6TIY0nDQyoI42JILKw8vBO4lenNeefCHUtBi0zwFLNrNr/aVlbXG+xEJnaNUurmZncDAUBPm+ZhjhgDU3x48O6Nqfw40zUPDkrSmwjN/CshzK1rJJskz67XCY64Ac+prjfgdp2m6dps2q69IkB1qRtKsDOn7qQLteXc2RsBLRKH6D5geM4hT5W3E8q0o17Lr+R679njvdXk8Tx3Nzq2kavC0umW8hzLCxcecjE9NmCMZI5rzqW7ifw5ZXup3Zvo59V1BporNwXnjaKEKADyiFkPzEZGMgZrvrrUZre2udCm8MPq2nQMYbnTI4/IEBd922B9wZm9dpI6detXfGnh7ULH4iabNoWl2p0KWOKF51AUWgBwYtucIQFTGRyTkc5q6dbXU9GUbOMJf1/S3OYuXtBoMT2unX9jbahGJ7a68zzDAPNH2uaUqQ0jLyg3DJUN71teANJ0XTvHN1b6dKZtNglW9S+WU+XIkUYMxPQFMuAvJweQSDmn3scOn39ravfG2kuZY0toZrgiCZ5C6+YFVWO0MHyc4B5OM8vtdU03QdHn1GOYXeq3GnizjtJV8yNY2k3XbAAbCGYqFZ+DtGMrW3M5RSUdGOaVmou72OV1PxFc+LVj1a1txa6tLMonVZDLG6uT5eW+XY8aKeBxjnjvtak93ceVBp17DbXt2/lLPMN8ssZX5yq4JBPBzjgZPfJyb670864Y7xdNS7YxIk8AMo2yAHblNqNtwBuABzkdBitS9tFuNT1hPCFjq+o6pNbwXouYpkjYQr/reuHGThRGBk5OMjApSheSi9EvzNIyVOnr/SMrVfDt0z6VZTSyLqcUsRhMEXyspyrCPOBn5VIXuW9qb4kvZV8d2SWsU0bzXLQzxMuPLnd/mz7nj074rV8AtLdXtnOIp7+SNnmmtp+JWfftBbP3Cuep/ujvW/8WtNlh8feFteSGOD7SFWfzWB2SxnIB2n5shgCRnoKylVTdpPReXkUm1OMYrV/wBfl1Od8P31rFZ3M8thBeNZRu6rK3lYieTYWJ6DnGevBOeOa6LT5tJaTT9SsRew6pfxvDbQJI0xd1b51jABwihW+fgAHpVO/wBOudK1P7VYCxi8N3IndywEtxvZSDGj8qq9AAcbjkHsAkqS2Gu+HtXG+BdPRJpradFRniVcN5BHUspJw33vpiuOg4wjyzdn3OnEXrSc6a06fr1t6nT6h4Vs9Xjsjq6KJL2YGCK/vGZ0VQ5yAG5yMfLnvzyKbH4x0K50w2Trb6aLLfbC2hUnYejKAB0xznjJBrhPGGv23ji7stVsNZh0TWbCaQ6fPPuW3uI+piY87Z1GOMAHcB3GE0TR9PudYl1CyHmWLae0l19mlw326LJGwOMgyAgDd0O70rS0VtuzihzVF+9Tsn06XT9fQ71r6G60uw8L6lFA8s1ysFtLLETDNEck5III3puXOerD1Fa9l4X8MX99Jp11psLS6dbQwrFHM0beUFG1ZArfNgBTls9jXk99EdY0+/tdUuUNteRILaxe5jE2n3hkUIsKg5KuApB4U47Cun0nT9S1rxJpWo6bcBvEOgWsNpfSPPsNyMMHinIJ3OeCp5AOQ2eCKjZWZlWhJX5Xb52s7/k/68+wn+HME1mbV/EWsSWe/wAxILjy5hGRjYFcqJAqgAcPzivMfHHw/wBck1NtIVLrUFuIWuI7qAkxtsBCoQ33WByduT97I6kD2jRfEcN3FMl8VtLuFtslvI6l1+uOD9R61u8OI2I5U7lPpx1/Kq9pKzV9zlVapSbjNXX9dj5uS7aCSytkQWlzplqLZreaMYLEBTvBAIIJ3cAkAEg45ILe2nkwJ4ZBC8toJgCYpADgnB7kLuHqO9fQWpaJpep3EVxfWFvNcx/dm24cj0JHLLz905FcpY/Crwzbai15J/aN0TnbFLcAKnJOAUAYjtgnpirdW621Ounj6e8rry3/AMjzeDVoWuxbzFY5NqGRwfM2h+AMd2x2B/EVm3Op3V/5Fzp9vb39vcXM+hi28lZvNk8tW3jPK5zkEdNuCcGvXI/hfocRuBDea1GjqFhCXmGtCDkNE+M8dMMSKjsPhN4Vs7f/AFV/c3odpftsl46TbickjYVVT05A7VUJ04NNRJqY2Mno/wADgLXStOvfDcskXim1hvEHk/ZLyZIlmIwWCPwxJUYPHDCpPB3gPWfEt1JeavLLpugSxqBAWYTXUQbhNuQFU4J3cnDYGQc16GPhtoiawl8sabIowsMDxKyRMMZYcc7sZbPUk10mr61p2hWyNq11FE+zKxRqSzhRztQZIUfkPWk60l8LM54hz92nq3+H+Zb060i0+2Ftar5cKklUB4GetFfOXif4weKtZvll8Jh7DT0XAjSMM7HP3nJB5PoOB79aKysYPDTbu+vk3+KVjvj4a0KbWZLbUrmWxvdgkRY7x4Y1HTIVSB836du9Xbzw99luNMWXWLtbFLkGW3tpzsuFH3VfGGYZIzknOOeppum/DR7DSrEL4hvl1eFmklugvmRNkk7VjfJwOnBGcknsBTvtG1XRZVRPJnju7iOJZVUqoZ+nUErk5yASOnSpcnZP+kd0JQqysp/1/XqTXl9qRu7+28R6FdtpKqzW0mmXsaRTsP4XT5XOTgY59171zelaheWOt/214kt7LSLdWwttd3a3EjJg5Ee3B4HqOOtLr+vR2HiKDT9B2TXNuzx3sjzBpJ3wQSpwSAmScDjIGelc0NAFsXuksbrW744KqiySeQh4eXYCSckZZvU4AFb+zirOe/br+OiNIJpOz0f3fd/Xmdh4x8Srpqad4qtrKG+bUoHtreVJ3W0tYkO4K5AG92J5B67SBxxXHTaz4j8S6/by3c9zcy7FjstKgUkITn5mB+6e+4nOMZOBivQvhv4S1C9t11LxGk1jbiQG306PdEsgXo8iHkD0X8a9BtLzRLK3vpbNrK3jtXKXSxIodGGeCo5JPb1zxUyk7OKXqzCVaFKVorma28vI4DxbBd+D4NC1LTLO2k16Kx+wveeUJGiU5cmOPIBOcjJxw3fmvPVi1PxHJIdbey1HXJHDfaZmCRwA9Q54AXGDt5xjgGuw8XeJJtbu7u9gjn/s6yKW8UAVXkBdlXcYsjLMzBeoA4rkraa0n8hRGUnGVaKV1BiOQeCCeAfxz3q1eMbvTz67HRQhpqvee/5mnBq1khuPCPhLSJpp57Z7CbWoFVJ53HzOE3dI8rjGfu8jpzs6Xo8z+AYrG/vptXsbxmtzM7iUWG102xEkA5LbxjkcgCuasLtvFl+NAvLNylrKssVzbOceWONxb+Hg8ds5GMivU9BtbA+F7rwlLqGm2+t3P2idoYJVlMWXLpKFBBAC7CM4PHarnUslGO617/iYVXGnZvv8/NnnVtoGi294sNjaq2pyXa2we+lLCN8bQSBjOQcbCTnOPStGYuLjWrTWbqwWONFWeO2fEKrkhmYNwjhlORn+7nrRqH2TUoprfQFj1XTpSVinudyQXMow5jxlVLDYTvHIGAMYyWfbLSyN9beKLcJcXdjHdXM0cj3GCnIj3uxaRQFweT6c5Galrvdv8V/X5+hcW27rbsXNU8Pm28lbBUnE1sFjuGdSYdrAko2Mg/T3x1rE0zxSh8T6NLptpDd2MN/lQyB9sUhG7Yq/N5hBL4Y4QqPXjd+Hdlr/AIynvPEF8zaV4fm5tLQQ4kn2jCsg/gTGOeS2OuBWRd63pWh38ECrcRx3dwwRBD5akbgrMcEEsMj5QCSPSso1Oa6+LtqKnKM4tX9fmaUtil7q8n/Cc288o+1SCGS1lAcjIKxybThRtYHaOcHODXXypMmmXE6mW4geWWSGJYxErrtwqIvHyjAVScZPPeuch8D/AGS21OOS+n04X99HdlUJkYqqupLZwdzlsqM57npgdPdwH7L9t1qZoLWzjxDvOGjG0rnao5JBAx1NYSd3ZDk46O/9eX/A/wAjzzxXcaxefDi0Or6BLD/Z+sQzR2/ltuaHYxkYHq4XcAX9fbFQnSo9T8JvqmmO0smi3y6lZyxLnfaEbZUUjHRwWIPKj/ertvGmo3lvpEeq6ZbXtzqmkSedBa2QVjKsymMkDDcKhLDAPOD7iprrReEvEXh3V9IgeNbuO5e8soRsjmcRAjcB8qtlhkgda0bTs9iITk/cS1ev3a/ijlrqym1O1hsXb+yLS8mF3508JhUYBOUI7qDyO2axdfl1HS7+za1lmv5bho8XwjxEijcF8tcY285JYYPpjrsfFjxpf6z4J8Mapa2/l2V9JPa3qocmC4DLtUuORuAJx6CoLFLptRns1uYngjTyZk3DLxlNuGyPl24OOvHHFaQlyL3vuOmnN1bt6PqWLHVLfStRt9RtbewS5ktsXN4ttvVhnJYqcBQvynIA4I61txanba7pTXPkloXZdrXEZTeGBYMBwVU4PIxwc4rM8D6JpiMbc6xd6hc3wkis4LiAG3iwSwQuTlieQGGMEnA5rnddv9Qi0q0WOBIIZ7kxSSTTvsQ4A+ZifmGB90nvUpQm+WIWu79v6+47fVLQ6fYI1laW1k6o0jRWRDCPHQ7/ALpz6HP86i8W+JPC93o2iat46kumuIYz5Wmwj5biQ43s2Dtb5RtHOMOeuazjYLfareyS3Eg8NpbrbwWCM7Bw4CF2x90BlZww+bpkjFdb4A8AaBLbHUprCC5t5XP2WCfE8cUYAA5Yc9O/v1qbRtzXuYV5KMfe0a2f9f5mvElr438K6TqOj21rbQ6lCtnPBdRBS1nlhLAoA4IAbaRxg56VV0Lwho/h7wlZ2tzrtjd+GrGNFhW6t7c2fmAEPI5bOXaQuchhjdjnFch8Q/GWqajqj2WiC2tdJs/mgvMFHWQDGQOPkwSvHZs+1eY2GkXtvpV/awyBo0k3W67hIgjOS7BOeTwOfeuadWOti6OXVZWk3b5Xa69fz+XU9dibx4/jJfs+mWb6IGE0V1BIHhZHIIkVj13ADhAMD0HNd5rVmp064udQs5pbVUMlzbWjbjJgZ4DAEnjjB614FfeNfEHhhdP0PwzqMsNpBbxu0KouJXbG7azA7B7DABJPvRaeMr+5k/4SrU59UsoLKBNPlZFF7Ffhj80TfdCvgsxz2x3wDfOpdCKtGUZLmaVuqT/F20/Q9RtoLaa70m6TUdGvfC00Uk7W85jxEij5nUOMooUEMFIII5HWn2/wxivpYNSn1aDU4S6zWssUIEbRAfuvuna2F4yOMHpXmfipZb2eaG3RL22t2dp9Ot7ZYktY2Jfyyi4JO0BifvAgk85p8FjL4XsLSHwvNq2k6teW4uTG5aO3O7gMyljzgY6cEe1Sq61jqdMsJWVpU5rW/r/Xnod7qvw407TLe71HUktLqyt2acxxQeXJ8xxt3A8KM59uvFebSfatU8mbRZr68n+QA283lGG8klCRgSg5YjPBboCc8c17R8LtTvPEHhy+0vXlMlxbf6LJKzlmnSRThySOp598YzXkXhOwvtIn1azjh+1aHDNLsDK8dxeSbOFUqQE2FFOcZB6A5OOnD1baJ/11Oa9RuUKmrTt8nsdGJtZ8O384uEuLDWJP31wZnSRrgMeWDgYYZGDxwRxkcmh8T/EWn+I9N0W11GHUI7+yuBNsjlEZu424YQvyPOXCnawXPOOSBTLOH+2ruSHTtTutWmtbXz5pLiCRWtwCP3GZGZmxuZjjB46HtHqXhmXxFYX2pXjQlNJijWOFeWuZmI2kg4OAoGT/ABbRjpSklGev9fmXKEZ003ZSWmit5FOHW9Q8M31q012L/TJLj/QFktQJS5Ubty4I8za+COckfQ11Nj4hh1O0hi0l/wC0LuN3nuI5rUo0yiQfK6FmGwKSBtOeOgFYkV/Y/ZJ7S/tdN1mGaUb4gMzQygZ3xSL8ynt1PI/CqdrcaJq2rvHBstdeX54J4pzDvfGQsiuMEnufqDWE6Uklyq3f+v6udilFtuevZ/59fuNfR7XSp7rXZdR8Ly6tpFxMA66XCZTHOmR5qDdkLtJ+bHOe3Sucvbvw6IriLTpLi0khu0KTXY/eyQleUdPusM5w+QwBHXnFdfFF/wCHbUrYzQafcxy+VK0sklwYCGJcKhfMS5AVl2nPrg4rsbzx/wCJ73To01DwvoevaddQiS3nMYTzYySobG44YsCNoAIx361NXDuOilt3X/D28vuJjiuWo3y722l0723fnt1Mg+DLefUGu/EsNzY3N7Z79OurJw0bynBQoy5+Yemc9Tg8Gr3h15dI1fR7DU0kulmJE00cgD3MyqFEUm7b82SCCeu0detZIvZJ9Phs2sbmxtw/7oFGW1imDfKqRk7lU/dLscsTk85qxdXt1p3ii11TVbSaxit5InkhAzHIgUEIsnIYEjkHuo71dOLhJRk7r+v6/wCGHUSmpTStJ/L+r9/yujsrGWG+11riGWKWBbWWOay4+1wTo3L7W5IK9geM9xV5PEZ0ux1KRJdXvdTs4962z7XgO7hBvAAjXI5J6YPfrhTWi6545ttQ8PR/YNLmiM9pfwQjeLjbhlPfjjIPUc9zW9baDpUGrTafqs1jt1CEC7t5JBE0jYO54+Q2CMHaOAVB4NJX6HHUULe92vbqXvCfxFtdT0uafWbWXT5bXC3LorSwhj6MoPHvXQ2Pizw9qFtJcWGt6fcQxHDukw+XHr6V5t4OstV0671JbBri206CErZtJIA0pLZj2nrgqTncB1GOOnH65qMfhCX+wtEsLma4uY3uFsxZhfs55yEYjcwwGyw5wAAcdNkuZ2W9jCphKSk3eyPek8V+HXkWKPXdNeRgWCrMDkDqf0qK+8WaXbNPHE091PCqM0VvGWbDnAOPTkcmvnjxFaNqFnaajpen6dbW8ccdylnLctLJCVTdMW2neAdhAHdQTgGu18E3iapZOI7yafw2LkNdNaQ4vYWZDtjlUDcVJwFKghhx1GKnldm30B4OkmtXr/VvXyO71TxTqMdle3DW8ek2sVnLeCSZg04jjHLFDwuThRnJyenevGbbxFqPjDw/rNleWtp9r1R0eDUHlKGSNX8xlmYZ2oFXHGAMY4FVvEk2mNpf2jR7vX1h1nUpN97JKhMjptCQyocBcb2IAbpgkHAC3bLwjrWrrZWFjamPSTI9rcXRi2wx4+bdxwRweCMEkdzwotaS7/1/kbQoqPMtEl+P9dv+GL/gnwL4g1Pw9bzW6Wv2ZstDK7eUrKSQFQH5ioxkFhzu4zRXtmseINA8HWmnWmr6lFZp5IitxM3zukYC5P6frRRKMZNtoxWZVorlp7dDX4IyOfp3pwJXkE571Q8PXsupaLaXtzaSWUs6lzBIclOcD6Z64PIzzWgOtJO+p5souEnF7o8G/aGt107WNKudOtza3l0sjNNbMIvNwQCWIGS3IHXv3rCv4Rpz28V7qb2OqQqy/aLiZ0mYkYB8xcEbT0GQG/n7/wCKvD1n4n0aXTr+OIk8wyvGHML4wGGf6V88eJrSz0HUGsbOa7lSxkW3vLm9w5lZCx3CI5woPCqcgkqxPcdlOakorqj1cJU5oOK36nc+EvE9/oerRW9zq93PpzWzF5L2TznM6ggMWbLDJxkjjk8Vwfg/TDp/jVlvGin1e7DLBJE5Mc7shdsSBhiRlwFxgZ44NdHZeH9R1GZLCWYyXWIXumfYYIFMe6USZO3KMQCMnpx6VofDvw7Y61rcEl9Z2EC28MdxCtsXjlmkV90UoHGzaODtxu6t2xKtCm7ve23+f5mk+SLc4LVf8Hoch4P0hfGPiLy9EnnsrFlaS4u5iqCO3Xb5i4P3mLEDnI5BPINer3/jvwt4MvI9J0uwhuYnhEkUulCORS/IxJt6HjqM/QVH4v8ADuj6bpGtR+HtPgi1GeJhqZR3BW2+9IQu7HO0cL78V57GuNJGj2kM1hqNpAt3CZmG6SF13L8y5AB3BsfeBz60+aNX3pf15v8ArsZqKr2cnp22+fp2O8k+J+oXdybeGGy0uNgCZ7iX7h6EsxAAGcLnHGaw7nQ3XxPLqcf2iDU2WaRFJ/cJfPGVRpB/CS+0HnByM96w08P3/iWCQX8mmQRF0Z7u4uTbwSxgHERfBZicj5gOcV1Wm6/a22nx6TqVzJLcMhs5L8xtNbXZbALiSPd8uTglsMOCRzWfLKMbwd+5TjCHuwjb8zKOn38UtjcapYSXV8BFG0aWfktI7cSNHtwikttJIxwpzVzV9QsfCbWEcmm2+teKdSYTWsN1J+6sYsHaxz1JOSFAycZyMDNBNIjtdauptN1O7vDFdR21vGWe2ecTuqkmTqQuQoxgEKSB82awNRs7jxPq1xK8kP2uS4Gm6exgKPP5TBF8yQfOSUyGbn7oweMVo4RspTYWcvdi7Lr0+R32p/EHV2sYLKNLe0uZYhD9okfzJ5mIwGWNR8gYgjODjpxiszw9Y6hoNnPrOu2lxfalHMJLG2l2uLOXYFJSPO4yuT8q4wvBJzkVo2Gj2Xgu4Js7ZLzVVbbfeI7xPLt7Mf3YwxIYqPTgcck5FHhC4t9fjF9YT3otvNMf9oXIKG7bdlnQE5VMEAE49Oua5ea11HVFWpqO1k9fX/gev3WNXw5bambK8v8AXrpo9cvoZGhdVMsNk4zjK55ZSeee2B61BpNtqK6PdaZrVm+rRwF7q01Cxdg13ksXVlLFkfkjqQQ3GMV1lvbzpE0BgWI8kqR0X1z2PesHxdGZrO4iE9+JrRXv47GzumtmuljH3HkXohLDgH09BRzu92c1+Z+6WIVDy2d0oYMgBiEyCIQR7RwY+CCO4PI7VVinfxLa3ltc6PNALG6wkl7beT58vK74sMR93ueDuHpWV4f1fWddsILy51CSz1mxkK32kWlhE7qBk7i0mWJK4JZQQcgKM81e1XW7HRtOF1run/Y1kd7m3i88yPO2ASEC52/eA5IHU1DlCMb30NlCo5JJa/j92j+45IQ6l4d8QWllocE91a6lerbahYy7pBPGcJ82eFwp+924rkIfDwsvFWp/2dqYmt7aWWGMbj500XPLY46d+45xW9ql7r0ni+617QU1e5lvriGORYoi629u6Y8shc4Y7Rk+o5xkZXXNEj8K3L6mQWZJTIoDHMajGIsbSBvYBc5JIXHAJNdVOzjy826Oi7U7yVn2/UxLNb22mdtNeUpZ3aWsNlsLSXLYDMyheemSSQAFHBziug0Nf+EtuLzw3G4WG0u11WWR4yfNTy/KlRVHO471IPHc+lbXhDSnl1+fxlqdzDa6Vokbw2se5cTXO0q7s3dQx46545wMHqZNe8NWVnBrlncxXOq24EL/AGUhZ7twozGc4LKMgk9OB7Upy5baapGM6zk3GKv/AJnA6f45i8MeDdQ1vSbJru6uZ3hsRNGRGlrC0cfmbc525faMkZIOemKvjxprmu2V5ZzaZfaXFbRw3U9xcBYiiMuNqrtX77E9j8ue5GJdR0zUiNU1+21BrKHW7cQRxG3DNFG7eYpUcBGA3jcCcM4bHORh3mu6VfaVZ6TFqbXL6arTXEUwaQzMGxG28EtLtByVBHc464wlUVrxWptSoc1RSlZ6r7/6Vv8Ah2Y+v6bZjw8bxri0h1G2cp9qeFmC2zZxEygEEgsFDYzjg4ABqloOsX1leyDXFtNMgigzvlYFJ3wdkGORsbgE4IXr7VtQa+LvwtHa38unW+t3DF7S+0y0RxIyMWlVgML/AKsqCPUdCSao3M+mazpV2NIsUstSAacyXY82G5G47kcEfKSdrL1xgA9iObzO1NzTcLr7nur/AKr/AIIySyubmd5dT022silmjRyW9yhtpCVJXy2Hyt1yTuPPpVXRNL8QXUkDW15Dp8GoByWS6cRJtwxyFODn3zj2rddtHs7vSrK4a5n1zTYRDdW8EoSyhJUFkkA5MikkEIcfKAT2qnp8lve6lLNp7K9rbBrYLZwBIUVQfmI7KxYngcsaLcrNKc3Vik3t+O2qRY8R3ht/HGuo1vaRtdTvNZ/ZJdhvTjDdM7ZCOr4ALA9eKreGZbwWxh1Eov2WCSVRfzCRlPIRdwwScMMDPvjik0+WQapptrDZ/bLy4mKiRwu6NS2WIz0QLnJHuK1PDuk29zqk+p3uoaTE1wxitXaYo7kElcbuN2VU7jxyKlatMGlSi432Vv6/4HzPSPhzeNbpdy3kgFjbkpNdXE5klxGgJaV8AZGCd2B17Vw2i3MniSO91zUorOeBbhmhLvt81SxZSgXG7AODnupzyDjbuPAutajc21lBJdaXb3Ng1pqHlOpjfn55MhssSNuABjk5OOKxPGsXh3wfrS2upw2t7YaVZpHa2CTtC6tIc5Yc7uAxP1/2q7aKvbmvc8iUqcaknTa1X5fP9TdEP2q+tWttWsoA14b6FvJH2gSMu3YH3cR5AONp4GORXPXXiaK7W60yC7srh7keTIsR/eoyA/vEHT5STg5+nFVPCGn2uv8Ahtb+71KJ47O6NzctBGYxKxbKKyBQVUZXaidcce2hbWvhcXUh0yW2sNdSR1kZ1KyEkZbCgfKCDwR746GtZLybt+A6bRe0m70PWNT0ceKRpekR6Vb+XDBFEBDeZJyrhgdoAxhTzliQTXS6x4N8M+IdIgurG1s4bmwUPZX4XJRM52SBT84xkDOSPrnPlvi64Oga5Boy2v8AauoSGMiK2QShVJ5UluAzdzjPQ5Fbmg+bo3iCWCT7Q97EwBtoYwscaOu/YxXhuMt65IqHefvsmVNN2py26dO/z/Q1dW+FMepf8TNHg1HUJ1VLlGJhJY4y4bPOPfHHrXnfjzw9r3hKyZLzTYbTSYbpo7SWNDJEiEgq4kGdhJzkMRnIwOOPV7n4iwae1wkljdx3UgHlIUG5mHG0g/Ng8Y44rqfDnjTQvElrIkVzDCz5iktbxkG/IwyjJw47d/1qI3T5kZ1KuIgruOne2v4dP6Z4o9pc6v4EutWdHuTpksJN3ncwjkVhKM8hgGKnr8uc1yGs/wBrX+rWujG8vZgpZrGCWQtHIpyd6NnBJ55r6H1DwrBpWvJqNrptpceHghLadbwbTBLtILRomFdXHBDZ5xjivL9YsPDOp3GpQ+GtWuksrpHB03aYJrKbeCwUMATGRkFOmfpRG7v2/rsdMa8atlFef/A/4P5mB4em1OztpbGXUbjTtRtrlHtf3vlgkghjk+gH+OakivPt2pyarq0899rLuNpO0D5VADlie2OgAHvk4qjc2bafrcen3MFpZeHoY1hWCSYGebJJE2fvCYtkg4Cj7uNpIafwtJc28sr2ca3N4cQxRmIurkn5gf7px0J4zx61zV6anOFuv6dTvwdb3JOcbNff9+9rnYeMra+1JbCe8tItN0i1YXFtqOm3ojljnQglH3Ha7OASmBwSDkDdWDrWsare6jp8cMEEup6l5dulyYGkmeUsHYrtwCqqQhIAyQSO5rotI8WQQ6be6VqEs6PHKzJbvBtaY88MSPlAOR9BReY0nUdHudL1EJaJMJpFiQkP8uGyw+7x8uOBkDrmtY4haKyaRz/VXHmaupPZ67b27/i/wK/jjR/E/wDZi+MZbFLW6QRxrZQygtADhB90Yyzc4U5G89ecYdt4WfVbLT7uVYLTQZ4fMnntIgDvUhikgBDBhtXg8emM16bfR/8ACaeGrmwsLz7LLaTxXyTMxILK5ZdwBB55z+BHSud1zxaIdES2iWS5udbtyjvNGVMwUbS4I4DAgjDcn5e9dEa7S5lb+rnNFTbcJry/r7yDWtW0rWRe6dfWFzLpOoTC+R7VkR98aEOSSPlc/uznJUgY6nm74A13VNT8QwroGmyaLpcEcjyWUl2twt0/99mwGAJOQehIGMVBo+rzajqJeSOI2Ie0eW3kT925RPKlPcSfKVJPBGCCMDNO8OaRrujeLtaufh9qWmeJre3lSG4sC3lmC3YllQTMNrHAYZUnBUZHUVMpRi0kulvn3/rsKorJ81/nt8/082O+IFlpmv8Aiu4u77RtOlnSKKFjeNIj8LnPyuo/i9OworT+I/w31nU9fe+0JLS8t7j52ivbh43t2Cqu0EH5lOPw57YorLna6f19w6awzgndbeR2nh3ULhbd7O6SRJF+45O7APT+ea6UEhiCe3WvHtB8Q2t5HLcQ3ZsRbyP5sdyQIUCnG3zOmeGIXrgegr1PRL1L/TYZopYplIGHifcCOxzVuMotqR5+Kpcr5l1ND6V558UfhjaeNo/tFvObW+RMBI1ULK2SdxP97BI54OB0616Fn1oHXPpQm1sc0ZOJ8oaRDLprNpGoSyXF7Zs0WyQbXjAP3QCc8dec4p/iS61CJIJ9LaWGaBjI88GRJ0GDkY/HmvUvjj8PbnXFHifw7JLHrFnFie3iUlrqMD7yY5MgHGP4gB3GD5lpF/Z39g8lvI9wjQlHkVdsm7jJ28jt/wDX9KUVFqXQ9zDYiNaHs1pbz/p/eew6P4lsrT4fabda5E82oS2yrKJlCucj5XYnGUbAweQfzrkJLSxttMmTSVks5ZIxNAmUlTdIuFkB6lSuRtbgDIAwaz7+W5k8KWUwWS5hiXaolciaME4ISPklOvA6AEio9Q1R/s+m6ba2TQtLbI0cLxbWcykgBcgZzt4bkHpx0rWEHy+7/VjONNQd2/68jp9A8IXra/BFb6hLNLC/2yK/W0RDasTjDISUOQWIJGRjkZxWnd63p2hXrQeFtMW/VG/fXkp8z7VI/Uq3RsY+Yn6AYFed6tqt7pHiXTtK0XW4Dp3lwQ3VrJCxiebkvGeSc5HOCBk9hWp4qt9K02W51rQ7trjTXj2T2MU4a5s93ykeWSCYuR83v6c0580pa67ERim/fem3/D/ojS13xLLYalqFy8GlC2s4pbnTNsKlGuPlDLxyThmbHTcOOKl+HFrqza9ea0hhbRfsiNbPcSh44ZCFwFXqZQS+Wzgg/Subeaw1ltPFr/pUN3PHZQRSxtG0M74B3BTztGTkHnA5616V4qe4s7rSfD/hRbS20ux+a4dlaVmK/Kke0c84+9nr9KylOKVrarcqcNoRWj/T/hzmdV8LXet3EX9qPdT7ZzJLcSPsigTsgUggMeu3knjOK29dOkz2EWhamJZ459kaW8TlT8vzAls4AAHf246VpxPci2jj1OX7Tdo2G2glAxJPyj2HHPPFY1z4cmvr6C4ivrWC9uH8pHl+ZYwF3ZC5xIQO3A5A7ZrNcs/j7W/r7xuo49bWd9PzR0dlfaZpkun+HbDU4pb+GAmO3eUyusQ5+c9yARgccdOKZcwRXIzdTCe9iYPHPbnDp0OFI6A7Rnn0qr4y03wrpei39ra+GrHUb2ZliazCkSzZIPzuAWzj5h1Jxx0rzXw3o3imH7Q15p6aF4VghkmaxuBtEasMhdrZkfcRg5Ix+lUoXjoc9Ncz5tr9Xv8A8MeheLpBqM73Cf2C2smNIobe9jKll3Df57qNwjHLbATnpnmuT1i9bT41svPtdZ1Ha8s91d4tDchmDpGqliYo+EBwAWVFAKjBHNWviTQNTufsFtqNv4TS4Kh7m3s/NZ2LZ/eOzbyM87icLjkd66CTw5HmWbQSt5ZSFo4NQkmEnnkfL5hYDa2WBPGR3pTp8r1X3qx1UuWL5bu9tr6fpr9/5DvCXjDxZbm4tnXSLvxHrNxGun2lqA0VjEMq8knl8KmPLVQWJ+Uk5xzr/DuyGq3niPX9bCHw3atJp0EF3ykwRsFznA2joM5yzN0wKxvC11a6V4ojOl2uqSXccUqQWsx3m+ukzyzDhUzwCvB25wBmrum2zDQQfEd6NP1OzuTeXETxK0IfqiTR55JDHgc9D1reUeXRnO6bSai/8/6/zNfxm3h2+0TT4I1l/sWESzQ29uVjh4B4IHDBW+bb6jniuZ0fwzY6ppml38d5HLfeYYdjBYwG5PmSHqB7dxgYzVu2ikM8uoQpJeWiXCTuWiVEWMsFVVTnC4GO5znPWsPxOpv/ABXNp1rq955NsDdM9rEIkuFOAmHyQdhIQ5HbisJzeqi7o7KVPkSit/6/ro2dL9pfS2v7DTnOp39wqxRpfZS1j2KBu2Eh93GM8YGOtYPhbQN2v2+LTQ41titxfz2hkBtY48HYEJJyxBBBPzbhx1rRiubvUJXvbadTdTpNb27XFrvCvCoDuFPMhxwCxIz1BxzYtrzSvEfhTWX0pLG01+5eK41VrJsNetEjOzRr0WTcWboNx7mufozolzRkrdd3fbpe3X8PuOXd1tJZDeWGmzadcXs7KpgFsbeBxsWMGLaRI/G8gdF5JyRVbwx4cnt5zfT6Rc22h29/BceX5gmSJkxks46qSwHqR781Xn0jVHvoUudbe9sp0LQzsY2MzA52HBJEgHUkHB4rRstN1K11uS/sZLxf7ORbYXqTArKXUtIpCnB2nIYZPTGB2htvVmsadNJcq1emv3Pv/wAON01L+21RbjVdRL6hG0k0oMIPmuWzuO8ew4wM4GeldI+h+Fbqx1exm16bR9R1i5junvrSApaiRCSsOGPTLbiPlHC4PFZF61/e20V7aT6JezJaRLNLNdLFclVfClk/iB3fKQcYAyelZElpDFHdra+b9qm3GR5WLLJLyd47AYOMD0yc1PM4u6LnRjiI8t7W7W/Vf1c7Dxx4CbT9V02w0e2v7katALe4vUUkQMCpaZmH3FJCttyM4IqDxjoNnoelL9rkkvZ7VfIN1NGqBZVB3ymMjGGBAQEsCOT77/hPX9X0jwfqt9apcahpOnlYLe28oLL5ruo6DJKqH3n8h3xxVzrWqePNQ0+xuJILu1YDzWuf3RGWGU+XBBxgDjvVytbTdnLR9sqj55JqO72v11/4fqewWOhWOu6LpepXFzcSX09tBM15bzPEXbYM4VSAFIzlcAdeM1k3fwk8Oanqk9/rb3moTSdN0hTacYzkcngAYJxWR448Q+LYpdMvfCN5Z6doIAi33kKCCRyB8jMwJ4OVyMcgjrjLdX+JXivStPsZbnwjbXE0mTLJbyyGFgBzg4yhz0B3Z7E10208jx3Gu7qO3bT7vl2KEPwk8R6E+q/8Ix4gsHsZeUt7+Nh5kfdJSowMdmHcZG2uYufGlvYapBpnifWLm41KwQJHLbW0UlpHgHaAyndLgMfmPI54zXf29hrfxIiUeIb6107SWAH9nWDu/nDqd5bAL9MZzjH3e9dp4b8HaB4Tij/sTRbWzkQbftTR7pj65kPIz6DA9qtVHawTqypW5neXpt/XkfP3he+1XV727s4tKjaebDRhLgw3MkvZmc9wCccYHpXa+F9TvPCyXjeJtDn01LZ/OuJZJDdSyEoV3kxhsncwJZj3H4d38QNf0vTbPyJn8zU5ziP7Lt82Pjlmcfc44z16V5tJdRX0+nJpV3qKFC0zFHaA7wQXlLYIlyAVKjp1z1qoXlo9EdSn7aN2v69dDJGp6b4l1Se+gubfU7fytl2vMM5ARlVw5jLDLMMhRyduSeapW9pYazp0Gk20XmXCMplBQxRh1GCzDI+XgnGc49MVp+IfEkmu+ItQk0kR297ciNJW3bQ0OTiORQMyk/L8w5GAKhl8W6hpBGlQLMoOIXkV1jumTHzCKRkZF6dfvccAdRq4uSiluaQlKnG7X+Q+L+0PCupWNrYajNJDp7xSymO5ZI0UtukUxgkBGH8JHTmtvxhPo0mqaBOdCt7fUdTgM0+srceWsUaEghkGQ2UA+Y4JDDGTxXOadG2iW9tqUl3ssgkrw3V5bR+Zh1DMhUE+azHABY8fMcej/Edhd+N7231OHUrm1t4rXyY4Zoo4y8CsWzhSFXq3GP4fbNKvGaXMrMVouSdrW7f8Gy/Ez9I0TXPFOo+do2mWmp2EQESLLJGrWp7ZQnci9TuAIPfngenP4HuJNEuxPPb6Con+03FwyiRpfLUgyZQ8JgseT1545rj9Ah8PnRdU1aOxVb21jMC30ZePfC/LRPHnaGBOC3PBGfSrXiTVLqF4NHuknt5NNU2jwrcl4Zl2jHGARkHIDDkciuZ0Zxhaa23+f49fkae0nOranK2umnRfh+B0Ou6toOo6Hi0hnviJRATIB55A+44PBVeCcd+M1yMesWt1q6f2ejwi2kWKZWhWWMx52hQG6EsevXca5jxHJfQXF7Fc3EX9iXUTQQ3GwJ5DnBUbh82cjac9RurovCOmXTaTcJqWnFtQ2BZ5E4kQA7gxx948LzUzptq7/r+v1NaMo024K/z/AK/r5F7w34jfwpJ4s09VU3kN7GlrPcZLCNt7BW7EEAlcdyc9BWbH4W1TQfDOiXNnHNcXYv5JJ4ixyscyFAyjPorMVHcir/i7S7fxTpFvNp7xW2q2CJBISoQXSEj5y3U7WB7dzW98OdNvNQ0Zk1iYefDqa3QyAY0+UDbzyQepHvxWvtIOHu7/AOX9amMoODc579X/AF8jnvB1jevq/iC60GFr7VlVJBYyyeUqHaVLDccHfuORxjpnpXM65q0/h7VvJF7qui6eYRMILaVojHOSAVcLjcQNo56AHjk16T4AiurPxFqVprO2SewnaSO7eTyzGrMcK2cHyyCMZyKs2v8AYfibX4PFkun3Q07T7yVVeWMGC6liVtsg54w2cMRjIweTxFrJX6dfL+n95FSraUoxW6uuut7/AD6/f8yX4f8Aj3R9L0e503xbr89trlpdyR3MepzmZw3H3GGfl/2SSQdworySx1DUtR+1aysUKrqN1LM2y3Z42kLEsRjHzYZc9+lFbwhT5VzNp+jMXgHUfO5LXXSx0es6dPZ+BLizu57aC4uGaX7JuWb5nZduSvQgAknP1z0rqvhnqieEdCgsNTt7m208x+cl1MymNixxgMP4u4HPHSovD2gD+zBqurabaSXbTrbLI6FPNAPynb0JG0AHHIP1rT8U6Jca7e2kUeqy2mnWqgXVpIA0dznnkZ6dgeo6is25czjUen69/wCtDapKlUhypa31f3aLV/jqekWV1BfW0dxZzJPbvyskZyDU4znpXmfg+xPhfU72aC4u10R/mWKZgyYPcnqCOme+R1r0WOdbuEPYzxHBBbI3cehAPH1qXa+h5Vai6b8iwpIIIJBHcGvH/jz4HuNVtrXXtFXy3s9326GFQpaPqJlAxll/i6nGP7teuIz9JowjZwNp3A/jUsTMNrAEMDTjJxd0Zwm4O6PmTR919Haz297cTW2wJuPXcvc8cNnnPv713nw08RP4m1JvDHjPTrK4u7GFn0+6MA37F4OG6Zxt5XB+U5ql8UfBS+HNNvtS8NqsUGo3CxTBmK/YS0isGjxwEJBUg9A2OlUPCV9qgvIPEOleHL26traVoYSrgLIzAqxyPTnkD271covl5uh7M3DEU7x36epmW1tp9r4qvYxtfVUYRyRyHCyAYAfnjOOd3Wtnwl8PrjxBc3erXdxb3OnG8KG2ZTG8+xv4nx91QcbQSpK10svwzsjrL6xrWqSrZSJFNMHRY5A6AgK7D6846kVR13XZtIudOSy1620TRimYdCto1mvboFuGkb/lnuBJ4ORjoWzik+kG9V8zOpX51anvf+vmeg3d3onhHT47VRbWkgTEFtBGGkZscEKOfxOKwUuBZ+fvtmklAcAYAMsm3JBPTPDD0xz3rlbHw1dPeR32v2o0yy3l2t7a5a4vbh8gqrHACDueST0AGc1uXupWtmIVWOKCKNCyWskgAVR/E5PAGc9a5ru+oQoQStFtt7sktnnvXsLaNRBcySDz41cMYmKkuMjgsOme1VPiRFp8zWWiQQwXctiGvLhEfbIZAm2ONcHJzkkqOgwTV74Y6TNF5t/JcwXMBBIeNsur8cDtggcnPX1zWH4g8V+EtM8U3V1r5S4tkVhaQ2cALRN/HJ5gYAsc44/HpVcl3a1w57VW19ldO7/r+uvm3iKS316CG5a6FlfJOss1/ebkWJQpLdAc/wAOEUZPYVu2GsfDWW50/TNam8ReMdQ81YkuCkqxK7NwBHvVsZbGMN6c16DHd+B/Avg63sbuR9Ssb+EagkFzAJ5LlGAKsy4C56AZAxj61zmoeJry/wBEmj03TtN8P6OsZaKONEjbJ5QscDHOD8vp6VcW1FJoKl8TO9PRd9ro2/Fni+M6tJ4a8LeB7fW5Il8j7VdWqx2MBzgj7vzIuMHBA4wM1z2s6nZ6VqVtBHHcJq1tcGLUbkS5jkgXICQgN5UYwVwm0bcYzuBJo+EbrUrxVu7C5i1OG6uTZiSWIQRW90+MFpQPnAUdFHOVAwcVcFtDqHjHUbCDQNFvtcilnit9S1CVoI5GhRRIywZdHKlzjPPyknBHHRGnZvsYxjCl1uRlbLTrYz3VtfXGuXUJj0lPtIiZFYbjKuDvUoSQV6HnaMGql5pjXOtvBqG97Sws5byC2BURrcBAxMp+9I0hDYb+E8AYrp/D+k6RoS2F1puntOl1brJcalevuupGYY2nJwqnAwFzn+dMGfVNM12+j1O2WISW1rCdxRQVctJEpAyGbCgkdhnPHEe096z/AK/yN0rq9uq/MyEgtxrN5rtqWM8crQwtNErx2oC4MffccnnjA7DOTWvHLpNmX+16PpL3E1uq3UlsJIXZCcoqBT+7+XDcLgkdKg0GCxttKgs3voojBEUaN8gSSkEthjkZDEEbuDkA9a1bHwrdazq0QkhkjtmQwyXr7RIUVhuicA8HjI9M46dOKpzSl36HfelCPv6Lft+PUZ4mt4tAFpeWQNr4Ut4Y7pbwEvLKZD+8UE8lnAXIAwBzxzXF2Oqz2UgmdYALh2uEu4LZI9gZeN3GXfGOWyTzXs3icafqVpe2c1tJJawQgKsCqzqAM5UNxzgDPfmuEFhDqcL6bp1klvOpMenyzNuNwwySsjY+8TgjKhV28HmpmrPQnB1lKF6i/wCG7vu+/wA2c1GtpJ4SaG0aZb+Uu0FxEFVAuPmIz3LBf++ay4Y7TRJrW3S+SbUJtoulvU3RXMDk7nzkDfnpyGIJHPNdXZ2+nvb2enprmnX96crLJYp/odsoyXIkJ+Y9zgc54xUuoaPFaaZLPqghvrZii2ssEscqhxn52XOQABjpn5qzs0dfPCdmnq9t/wAF/X3HOeIbLR2uJHaF4jbRbo5I2ImfYPl6dVB6egCg9KgnkUT6fM5eeBoDKiEYYs2CxAz8pxjv7VeOpR292jXenpdxeXvt2DPDERuwAzA5Y9eOV56dqh8UJbnXbyOxvmWx81vKkt414VhlRtPRl6YwOQSKiXc6Kas0kun328zpvgtc6lpviiLSp3vLuC+gmlkkTHlJIAMM4PK8fLkdcip7h/CfgoP9gtDrOqmaOa67Fm6RRr2RSxzk8YGTnitP4faHpun6fd+L795b7UrCKb93b4PlxopOFUcGRl+gyfxrF0e3ufHl/da7qzyWGgefumtZwIXuZc5SB3Xl0RAvBwCSM5IrppxVlc8WvUTrTcb20T6Xe3q9/n+Jr+JtQuNEuItEv7k/abiNtRu7SyUL50kkmCkbEEptxjcSNxOQQennT2E12ltd6Kuoz3+yVL23069e8mtZASI90crnzUwRkYBBBOa7TxZqcF1rF9ca5fzW9jeBYJIoGxvWJj5WDjPDSMeoB3c5AqBb8vb6VqMMVldizk2QvBYmC5ll24UOQcKG/wC+eCSccV2U4pwWn9djnlTfKrrXyMHUvCUujiSfXra2fUrnzP8ASUsvMiMhUFP3YcBT9/cwGQcYB602zt9c1EGNk1VIIoBsh05pLoXEuD1M7kQjIHOwjHTtXX6zdW16pttea5sbyJ0EkSOs5jZkD4+U4ZQD6g+1cxqmj+dYR6zF4quDaJlUWwu/sLIwI4bIJZ8cgAdsDtQ5StZxuWneN76/d+JqeEPDMbzfZdYXULOZ1RAotJIwzEYZix+UAHgDO456AV21n8PNP01Y2Oq63eyQvm2FxdZEZOchQBjnJ/M1zmn+PNRsNJtrJp7tZAFSN75Rc3ExJ9QRnIx94A1NrXxAvo9KGoeXGIUYrstPveh3M+Np7Dr+NZuE07JWIqe3nK6en9eRvw+CtIt7W5urzSdl1MSmFmboSMsCDweO1ZM3wrY2pjsdaJ3HkXdsJAv0wR7flXJ+HJ9Y03xFGmsH7MLqNb6NQzPIyM/G7GeuQDkY4z61Pr+ra22q3K3eqeIYLK4kby7y2k+ywptbYBuCchWYAkFs8k8Cr9i+blWv9egv3y1jP+vxLOv6Xc+CAb3ULq31COJAYoRHIgwTtAGdw9ep6dKx9FvIb3Xodb3NDsdQY2QOjyKpUA5wcAMchR9ail3X0MWmeLNQ1VreVyLbWfLd3nwWCxuoBEpBHX5XA9RVPS9GtreeCbw/46tW1Rgdokglt1JAI4ZgcnthgO/pzzVJ1oTvytxa8kd9KNOVLlm/f79PvV0hVvpLTXZprC3jZLraoildjJMsgbYVhzhojkckdD2yK0NT0j/hHLaa41nSW1eRR5wt7e/eJkgVfvZ7FWDALjO3OBgVh2Gpa/4V1K5upJG06VJ0gunFojeUXJKoMD92rkMflKg/lWu4jutHu9Ujso9RvGuCoDmRYZpgpZo2XcMyAcgdSOldNOs5xsoNJq2u5lWpcr0mvky14QsvCfiHS7rTtL129v1mjLjRdVgUzo+Pm2zKAOi8HkDAJ71U8V+Hrzwkvh200+/m+xxWUhmuJvkfO4kIwXOGClFHUHaKzbea81Q3c/h35XtrfzlSw09rcRTYOIguTk9xzzzmu2uJfEWofDXTL3WoWtNdWGdJDeQCN3YMNrgY4faBg44pVJSpSb7fMxp0lGcE5Xvf+v6uZdlGJLdPtLeddyw7nkjwrTFcliR0P5dvWu00i+sbzS4Y0t3uSLcuI4CFlk8ttrDBIJZQd3uBxXiHh4yC9bbLJHcQRvLCPM25PUr/AF//AF12PhPVGttetLjUI1jcFmicnam4rhuSPl7EA/Lkc4zz58a/P71rXPWxGDfK1f4fx/r/ADLWoTeJZTfCxiN7qV48MqJM4naSLeQPujCrsCng/kciu/8A7U0Pw7AvhmS/gjdZxawWwiO1fNO4K7EYAO7HUdeK84FmfDNjrDJa2eoLqZKwJbyMgQsMSOFX7rMuR8pAU9OtVNc0HT7Pw3YSeIZL6HRBkaLHGRCbPIL+Vclx8xLFcYJ+4SNoOK7qT9rpI8rEU2mrbfr/AF6Fu/8ADmmaK39mXm2G1hd2t0nkfEe5vmjBBGcEA5PO1lz0oru/GnhWPxAthcXRtIZ1RgXc7TIOMH3+v/6qKz9rJaGtOdJxXNKzLPxT1+DRNIhW6mgRywkjiIJZiOARjtk9cdTWV4e1hNUs1vYSnlGIeeu4Ft5GCAe+M/ypvj+90+x1hfEeoxSTXNrbrbWkBVWjDFix5PHIHJ7DOOarQ2sWoX2n6xYLDp0MscnnwQKHQMQDh9vAYEDkdsZrapGPIrLXv/wP1OXDxSgkzC1a61XxjealpdvbJHHZ3DQXc+0KVZU/dqV3ENk4DEf3ewq/o2h6lpV5qN14b1dbe6ureEC0u0LKXQfOwb8OCAepHoataRoh1DxNealbIxu5pZJXgDFS+7nfwNp+6FBJzw2RnmtW8+yGGC4urYrKrStAS+WIUEMcDJ4G72I/CodV7LY35fsM2fDOv6qujibxLHZwMu0GaOXCOzdFGf4vYZq43jC0OpPpsFleS3wjDhDsiRieih3YAnvgZ4H4Vi32n2cj2tzczzzi0kSSAW0AkSMtyCQRwCByTzzgEZrlNY8Iaf4t1OebVDrdrE06LFpcd9EsKt0ZimCwztYliQcA+wpJXu2cc6VNu6X6L+vQ9LZ9QvIJE1a1gtUXkQK4kVuoG9uh+g6cc1R0i1i0z7Q+nqLW6nAmuFC7oWYEjJA4DYI6Y4x6VavJ7b7JLbyzRrHGuJY5eQoGOePvAgdemayxq9u0s8DzrFZQIAZlBbcGAI6deP5Vm/McISlFqK07dP1uT+I3hvIo7a/jj1OVh56wEbIYsEHe2CfTqcn864/VdQ0HQvECapbwW8F7dI0AttMgEjuTgu7N8qqMFQcYJ6ZPIqt4t8S6fqlhb6boc8dtYTAi6u7k+SX5IA6EheD2JOR+POeKLuzVreLRY4ra2ji+y2rBWG9mOXmAfLluVAPUdu2MZ11FNo9XCYCUkozur3+X6K/pe2p2g8T3Oqpc/wBmwq88Y2JFEfllkOfl3YGFGMlj0APtmhrvh6ZPB91YRXUc2o6vPGuo30qknZn52jU/wLwAv9a0NOso7S2gtdMtzawBVhMjJukZmxkYz/rHOfYDHSsTT477xd4nvtH0md7nSrd0j1DUMYQMgwY4znkDkZAAJJIGMV00nJRu9/6/r+tOeq6SnaGkfM9U+G+nx6ZoUMcUaxQvMzRKOqxDCpk9yQoJPqTXzRdaqQv2O906BkhlkiQzYZd4JBfHZdwHP3eua+p9RubXQdAurlmWC1s4DhvTjCj65IGK+cXsfD3iDxRCItWvJY4IydRvEQOSFPEcKkYXJbO5s88+x0hFPc5cJUlzTmurPWbXwPo2t6FpV9J5RSOxjEFyyHeItuSd5PAyXbGO47CsLW5/Cdrq6WctjF4jOnICyzIWKyv2fPBHy8DB61saLq1tcahZ+G9J0zUJdFaPymkubniNFU5ZlHIUnrkjPoBWBP4m0Z9futL8IeFGu7NX2S3yOYIg394ADOB0DZBOOO1TBX17DSnzOM7u/wCvcu6l4nvtQkgsJrCxg0Z4xBHZu6LFjsMHADDGACMDH41R1TSbrUI44NG8NaRMMjhJEfI9c5GwcDO3g9TSx6bP9vRFutLiWe3MUkE0TXYEQO5iF3DJIBBJPSut8Lal4X06zlttLnmvXty09zKQEKFn5LIAAqKTjCjCgfnS0XMv1Km/ZaQiQXXhK4aO1hnmWbU/J3qPMcQRlRgqrA7lXBI3DnB/CuD1m9vD4dkso9HtXubOZbn7MF2KjqWX5cY+YZc4PJzk5xzbU69qlwPFp1y71nT4Wk8u0ig8mNIvMK/NGMM0fHPBzty1dDry3en+Trd9GEsVLTSEDzGiXON7YyOM/Wh3irLW46TbfvtX/U43QHu3u57U6fJZ6Ozu9xPepwrMANqMRktnn0Hfiuy0md/D3hXUJo5IRfX4Eqxs4/cwDK+YemdzKQPUAH1qT/hIF8Q6BZ6jpdrZxl5TbLDqQDNIAFJ/dgbdxDKcgg4YVj6teWOoeINSvtUETWypHbOudpMAwpUBfuruA79+nphUa5jpp81SNmtN38nt/Xa3csXvh/8AtnxTB4wsNRlic6XJam2VHIeSSJox0+4oL7hnI+UdOtc3HFq8OoKul6mkF7E/lRTyKjmdSu1gyN6jr9fUV6No2uSR6j/Z5s47bTQvlgRkqIyeNpB+97nPQiuKg8F3rarcQapJDZW0Li5RnByecFs8jr6ms5pu1i8K40+dVLJNL7tuhlHTodOsE+yabJozpcPFJZuxeM4wRPExG5o3BGM5wQRkgVZ0S+sdNsNTN5Zvfz3cnmCeaYhIFC84x82cDHXoo9K3PHttBf6xqV/YX0+ba3i+0CSLcoziIFHHBbgEg47nPFcnp9kbkQwyXCxz3xaF7hkA2ovG4qMggZznvurOS952O2g4zoR5n+at18v+CiO7mW+tj+822srIY0eXehUZ27ST1Oe39KjJRUeWWYJHApaQ7gFdQORjHOMAj6e1aXiTS7XSRpeilYr6O3tm8+a0kAKTZJQKOp6KCo6ZbvijwlejR4IvEesWcwEjsltHPGfKBxtaRyeMYyoA6nPpUKDbsbOsvZ86Xp5/15nokV9Y/Dz4Ww3sWnn7bdBZI7MfNJd3s3Qc8n1I7Kp44xXHeF9N1K20OwW/lkvr1nltvIkuVUPK3zHywxy7bmyzrnIB9AKs65qGow67aTa9q0TzTxE2YZFKJhFydrDC7uuVK5wV6njD8eRw+L/Bl9oZtSNZkUXMDLwi3EKswjUd2IMiccguM9K9ONOSina582+ampVIu7evl/mdBFDbpaOby0cyJMbV15l3PvK7Vx98Ejjj+tYt9aFgsyWUUmhTmRWgkvZIXWVQMtiNSfkwSc/LyoO3HPh/g74peMraS00hbhtct5JUSGzvS0jbycKEkBDqecABsex6V9F2FotzGLDXJE0rUY7aW9u9NmvRcG0j6vcSSR4MmccoTkZHOMZcLX0RMMYqitLQTRNAtPFFvZ2KXTW8WnRi2ZpI1BllByzIgIGRznryec03xL4c0vwrpa2unrbXM0jeZK+oMGAB5DKOuRjO1QfpVbxX4TaeKKbSdRstVuLiMRRwW9sSQmd6vBtzsx8p3Zx1HNR+L9Tv7KbTH8QW8Ueo3FnHZsk8PnR/fBxt7qxIVwc5wOVxmtF7zVn8jVOV7xlp935lCXw/5UFqy2E2nx3r/LLPeosVzkBhHJIrERucHg4Jwa7XQPAd6tmwvrmwVXJIigYybVOejdOOPXPtXC/2ZpHh+KW6llghuQkkoAc4kYDkJvyMkYHrjgnvVsN4r0SKY2dvNDrNukTvBC0cqmByOUdQRjJAxg8jjIBNRK9TSC0NZqaWkkn6EFt4fuPDmp6nH9mENlZOpvrqK4UMyuCUXy2YbjkjBUZzwB2qIW9tr1w+oaRE6XrksF8kvKBxuIGOCcYbAz9RjPT+KdQn1Wx0q48R2Npp0ro9vJqX2aSQHlf3ezPHVnG/j5Oxak8M+Ire3mlaax02SWyvikmpaVamN5l2gByp5UkNyASME4qqj93me+xMJzfS7ON0O1cQNbXDXy28SvJJDIdsdtKoOBGNxIwpPJwfyxT72byTaXM1oqXkkkH+k6jlYolkGEllYDhcDnOcZGe1ezazN4f1yTT0vdU08M5ZgoukSQjb0A6nnGR7VDpvg7QdKtrt3sYJrKeIRtFPmZBGCCPvE8ZAOBgDj0rN1eZtz8iPrcVHRWf9eh45FC1xrM9ys0EEqvJbyzWcyXUJOAyqGIKSgkhgCAVx6iujEs+jWXiLXPEltDq1neCMX8EcS2wkUHCugXrKpYndnJBPTArv9VfS9O0KcnTPsWiWiNI0cUCBZVAzuUDkFeo6GuY1LTPDvifSbW9sWv8ASLcx/aMBd6sh45QkgEHPTg/TFTKtJ6IuEozXvL5/8N19L2OR8R65b2ev6FJol3dxaTeRxXFhcW8si+aFYho5CTjergjAB4K561M/9uC0+3Wep/2iZbuW6uVv7pIADgAKsbH5iRxuXHIqXxHoovPDOm6PYWNuL/T7kMl+YXWCMuMOXHJUDbuJxtBXn35nw5IfEY1HTbdxOtkjyxX8kjRR3BU/MX3DIDD5gpx0PQ1LV25I3hJK0ZdPLp5/mb994UtpvC8fiHUpTYwXLxoSCN8Y8zDAcYJ+U+mRUmqWEoSaexhkmt4QIEulRfvH7jSRfeCkdwT045rdk8T+GobDQvC1zJdam1hZrcz4PlxSOoLbJEkXcSTjAIGQ3NR+HxLFc/2vp9m/9lTOIIYreQvMCQWeIAjlU28E9iOSRWMotpRextSry96bWt393Rd727/Mz2isryWS1ieSSeCGK5u44SELoMBiAMkAnGQemR25roPENnYeJYpYr/zrrT8xNcWdx+7+4W2tuX5lZcnJyAQcc9uN1K5XS9Xt7tbq4eGSVn850EVzCWz8oCABlI4JAK54IBxXbaBYX2sTaneaXcXemJcwkQNdQDe+VHzMCcbQ3p1yamE1zNR3FiaV4KdR6W/pM2M2t7dTSi6DQ8LHEMSLEB2X0+lFO03TbjR9Nih8VXvhuK/Zi3mqggEy4HPOATnOcADpRXQpSsea5wvozJ1+xsLu7tLfUDPMkTsUtg4VJCP4ivf0yfXtV3wyyWkN1JFBttU3GRY2GxMt90dsfrik8PR6T4hl1C5srW4iitLuS0Mso2vK6AB2IPIGTjt0qG/SZYbSWHW5IYN21LXyRHHz1Rz3zjGD0qJLld7amyqe0h7JvT5/oZOu+DodZ1v7TbXd1ZNgBhbz7Gx0YZ7ZHFZcdjr+ia9Y2tnpthd6IJkguXJ/05EJG5m3HGAO65BA6jNd7qhl0/wzf6jKhuLpFBZozszjG4d+hz+VcJp95rup65barHes+iyWnltpksQkWd1bBx/cPzA7lyeOmMitk5ON3qkRzSlFpPTbT+tTr9VsoBO32aSzhsBF5bkzFPLjBDFIwOAGO0k57HrnjHvpfDzSSXE+rQCV8SukO1Y225UHeBk+hA5/SrT+GND1S5uFj0h5Jok3yQbB8hbpgkZGcHGB0rFPw7WLU11gaLqSwAbpLO28ncxUcMsZOMkgAjI65rKMU/U2jUit52t6f8H8Dc0vU9Im8O6jq2jSWz2NiXDqVO+YAfMNpOcckcj/ABrh45dS1XS01HxC8+nabdTt9jRFCFFB/UYyRzjA610eo6lcaf4U1e4m8JjQ7u3T9yslxFKVZiADgAfjnPXFch4T0jUL/RLiK+OuanaO3miKLMrSM3GxCeEB53OeAO3TMzlFRdNrV/PQ3w0Zfxr6LvvsV9Pv9KTVJ0gvrm5gtV3I1qmZbh2+VIlJHDtktkA4Ve/FdR4F8J3Ta7/a/iCxktPJiEtvbyKSxyTguW7gKT+IzjpXS+BfDmn+BrF9R1aKM+Ibkt5NrF+8MA6LFF1yT/E/4ZwMmh4y1+ay1CSxe4t4NTdRPqEzSZh0+AjJ3N0LngKO/XHTOVOgpO9rJa2/z/yLq4+c+aEHvpfv3su3d/kaV8LgeHLu4Tc+pTsdhBwITIQgx/tYIGe2Sa7Lw3olj4U8OpZQmG3t7dTLczsQilsfM7HsPr2rlrNJLHR/7Z1namh2ka3FrblcSTOPmV5PTswX6elcTdXOv/Fh7DRpIfL09ljvr+UF44IYS42RgLw8pU7ueB+HHTGLfvdDy66c4tJ6J6/ov67i/E74k6dq9mtjaBptDlcplF3S3TKeWXn5UGRg9Sc9MYrmtKso7m/C+W1j4dsoDe3KLHhpwgJG8/eJI6AnjvXf63oOl6fbxaZpQtYrXTkLnU54RPcgZLeWhwNqrkdDyT065i8K+D7C/wDCl5PZajdz6lduUvmuHxsKuMwyRg4UAc9T1B5GBWsZJLRG8Jwp07bJ/wBXZU+GUzN4okknjtrW1CGKYFF3TrIgJjceoAjzgkfN65FR3NnDp032eKR7WOdx5jhi7tGmVQMRwirkAOxANb7fDvUJboPJqEGnaXa3H2lZInDiRM52svAAwcdSOOlS/E/S/L0x59LjvbiW+hNncNb3GEuEyMROAOnLHIwcbh/Fiqlyylo9GZxrR5/d1bOMu9dfRb/zNDTTRZyS5v72dSSoz82MkBgOPlU4yfetXwtrnhB7TfLp9il3dBobmI3jCCKMsCTFvIMe7hsDkHA9KveHtPs7SxJvrUzNBEbeBLyTzvKtwc7ACSqqDnpnIxnpiqM+h6Tr93Pam1MC2shEi+V9meLIGHTcvI4XBHGTmmnCzj+K/U0lZvXQr638MksL+z8S/DnUrm/voJMtaXV4u0QsDnbJwdo6FSSSD1yObmiaNrc+jQHxBbxyWmoyhZ4Fm3KQCMblVu7Yx16c46VxN/fWc+sQ2HhHw/8AadVsZXhJvJXmMzIeZcAqQc54PGAOOa7mK88S6fb2DyaPayajcbjNbvfRpHCFP3gSSFLdQuSRjFTOErL/AIZk006aaT311/4f8Tqtfv8AT4/DlxBeTQm7jYmJY1JxJ0+UKMg8jIFcTp+qWEfiowyWF1b38kPnQ3YYBVbYvBjI2AFs9zgn16dHb+HrDxDfXX21p7S8CiZ5BIJI2U8EY6Ee4x+tYMt1FaeN5fCWj6HNcW1tCGv9WEZlnjldAySANxsx1ReoOevFcsk2a0Z06acNW3+F7fh9/miK50ifV9I0/U31SSCGwnmubm8KjLxO4OPU7NpGSMc57U+xvLfWbuPSpdTgt7WVAhgeVhJt5bzFL43ZJJJOAR2wKksLOKXxdY2c2oXkMNsruqWcBkjvVdgMuvIWM4AwcjqOOa7DUZ/AdjMz3UGmx3kVtJYRxCEibySCGSNRyE5ZQRgdQDUqzV2a1a0qcuWMW+1lt+H/AA22hxWi6hbG9voFt737HbQ3Md5FdqifaYlBKbRnGSwUA54JFcBba1GtzLDqdtNpkwhR5PO3NFGHIC7tqkqPm64NdrfsLDw7NP4Z1aK9tlgS3iklgWUwZcMv2m3YE9Y2CMRwDkDpmf4WW+veIvF13eS3tu+j2AjXzLVD5dyzfNsGScqFG1lyccdKlQUtzaeIdG81t38/Nbp6/kuxylzJKXjg03TZIrrT9sUcEjKsl9GvmPJJ5ZJIXgHeM8E49K0tQ8Ppr2pW+n+I9ait2tka8m+zTiSNwgGVAznKjgEn6LjJr024+GvgXTFmuNV0u3LXUqgz31y2Q+flVDkbfTAx6VtxeG9H0Rrq/wBL0i1iuRE2CIt+3AJwq849MD2rop8sFotTzqmP9pprbp5/18zzy8stM1Cyu7uwuTBYSTCPyJUDTyKgGGDHlVPbr2NYWkajpMPi2VoYFlu4ZPOMcJZAnHGZ+QxzjK4HIxniul1C3iN+usa1cSR/ckcIu+U9o0UZC7myvXPt7VLWx0LxN4xezhutbtJFlbMFyqJbzOuPMgZV5UgqOuRlcjtneE7R956bf8At6p2T7vrp6/qcTf8Awy8LC31o3y7JNeuDe6bPasHbTY1GcbR94eY8iFe6xAg5xT/B2rRReIG8M/EXSrG68WLGiaXqk8pWDUo/upvcD5yR90n7+ArYYc9fq/hG8vtQvdNsrKU28Uiu7O4MZKnJAZhuwRx8pyM+vNYs+j6P470Gbw9rCS2t3DM8lnNgvJZM5J4Y/MyEqdwbH1yAaXL7vNE5HQ5PeovU2NHt5Vulv7eadZMMcIrQzY6bXPBAHpgdBnpV6xtruUu93ZZjjk3R3G8uB6lm5wcdea5Pwp4mv7bUZPAfxFka18QRps0/VEwwv06INxwGY4wrEjd91sMOdfwzqMWl6lPZRS3zz7lQ284khSUPwpfLFfvcAqDtx1x0Sg6ib7G9PEKavHcrpdW+va3bG2ktZGZvsU1vNAjSRq4JBUtndkFs4wO3PBq34n8Pf2dPpNvpckNnY3rFg0kuy2do1J2yMo3B+4Xp16VDqlqYria1sNPtZXe6jUzxRrFNvmcMkTXJOEfK/fAztxwCc1oXsjXNlaaZdTwyXdxI0D2l1GJFMyNtbLZKLjJIY5yB2rV/Zcdi+Z3tcNP8dNJ4eGktFo3kxREStd3TAzgMQUTghn3DrnHIPPWtGNtP1SWDTbK8+xa4IwRYyNsinXA3Kn918Hp656gEjodPns/B/hu3j1iytzKjMIk0+2V/ObPCqo534/PGfp5x4ku5VknuRJY2unXF8TLp17EzXcU0YDnCjquDu46B+PSojCNTZWM4O7fIrfqUTZX11DrVk1jcR6XcSrd6hLJY+XdQFHBIEjDoNmcDIGTg+vT+F/iPFqWproeoRXFjGLgW3mRGOeFdxxHmQdATgEY4PtnFOPxF4q06R73S7yy1rwrevteC8YM1iSfmVCSCyjsp5xxgdTwXi2xmtNTgv5bptL0C8cw/a9PhI8mVcMqT4wGz95STnBPpionLmsn0Lls3Ndf03/r5n0PrGmy2lu15JdmQwqftEcq/I6gYAC9B1/GsHxVDd/8ACGan/Y9qX1CExyxrFF87KGGQoA5AXsPSsbwD4y1DTrGK18X3QvLMF1XUArSOBwR5o5JHXkZx39u68TXSTeF21rS2a6a3jNxbS20ozjozDPDYGSV9j3rBmVqtGcYzXXfp6GN4mebVDJZ2BjeXyxPfWkJKy3MYQgquenzfL+Nc34M8Ax6dFFqmoXslqGHm2emw2ZX7JM3CtIGLGR1J6HPIHbiptO1HRfGN7oVxrDtZeKtNmZ7aW1JjW5JBIyRwR3wffsxFT/ErVfEDalHpNjM+m6fhFu7yKYRTurH78OCXHIIzjnp0zTg+bVGso1KbVFKz/r5O5z3irwP4b0Lxjbahea5qMeoTSJdSQy2zTKC7bRJLKo+XL5+91PA4pnxJ8Ya9D401Hw5a3T6Xo0YSKG4svlaWVkzkkDPXOQCAMda465g8UReHF0jTdbvUnhlmuJpGlaM30ZxhVfPzldrkJnnca15tL1rxePDVzHaSNqVnmOaZz5X2sBAN53YywBHPOeaqTvFJFUqUlJOqtF6W1tf7vvL1l4l8dXGkRWVx4liupmU7z9liaTZ6ZIBIIIJ/irmxCml31xKZls4n+SUJKwaeUk5Zdx6jqAPQ1t3ulX2keKRp16bKx1NY2nTz7gQweSQSGMh+9ggjAHBLZ4FW9P8AA9/450nRhezCy0+ci8imjjMkg4IIJ4GCOhzyMEelVNS5U+jOiMqNGL5Laf1v6Hn3iWWTw61mDcGCS4iLvEq/aE4YgOpkJYBhgkeufoCuw8a+FvCOia2LXxR4p1Sa6hgit1it7AMIQq5xuJwc7wcDpzmiri6M1zVJJP0f6HFOdbm/dStHpo/80etT6mdJ0x57gXVzZRAr5EMO5xnuemcY7ev5YtrqVj4h0hl0+7NxcxNvSJgEdSuSNykZ3Zxn1qDQvEeheInWS6RmaI7DCWdSDn0zt+9kbvp610McU6GK8haS1t0cNNGoDLOhB2jd14yM/SsZXWnUpKMVdrX8C9A0dlEsNxKzQID5kkmAiDGWbJ6Z7kms2wFtp2mXdzDaXeqhHeKKCyTc7qzY9gODknr1pTLLqf2a1iDRm5do9gIKrHtGXP5nA+ldlbpa6VYqu5LextI9zM7YCRqMszMfYEkmhK5z1Z+yWu7PMPiD44vNJj0/TfA89gGjVGlkuEL7VBwI8fwn+9nkdOKLX4z6Zb2BOv6Zdw3sbLHItjtmjcn+JMkHHHQ9OnNeWSzyalrOtalFKLmHUbyW5ilmQnyFZyVYL944XAxgYzwKrz6CdR0mLUGMkl5OZAf3QgkjKDOCM7WBXDALz82CTito0m9Xsdf1Wi4JOL5n5/5H0DBfeH/iPotzHpsq3sSFVkSVCmOcjORkdDyPSuKsPEmg+H7O7hiv2g+zXTxTWrna5ZQRgLySvGSeM+vas/4MeK9E0SQ+H5Vukvbu5UfaHZRGo2gIvGD1J7dWz612fxFtbTRLmHXLBIINVu5Ps8hZEO8BD84BHUDjPuM0pQjCXvpmVJuE3Q6PbtcoaZqkWrxx3xvPs15qGEhmuv3ZEZHBhVvXIwSOT+FUPGNrH4J8L2dpYeHLLVL+5uGmLXyif7JISM3EpOS0hJPzcYxxgDFebatp/iRb621Hw5c3mo3k0y2yII1IicAbeDkY+oAGK7747y3+m6n4UWK1lvY4pZLi7kXOJGJVVQ45x97A9/anya+7qmVUVpxpy/Il8P6vrHinxlaW/jSXTf7KFu8SWdsrLHPIwIw2SSWKgkc44471q+Kl1Xw7bi91/wAStcT3l81vYafEwjghtgcoFjABklA2gsc/ex6EuuLS50TwTHqEUEJ1KG+Ms8iNkxNnapXjB2ggEdByOea4/wAaP/wmXiHwdqK6qlv9n0g3t/cyqDb2caylWkUHgys2V246quOxCjee6IqRSlGUPhTt/X9di9Y3F1qEk9pdvNLbylYpArKWTJ5LEcKDjgHnitDTp7e01C+0mxs9T2K8MdxK8pLzeaQgfjhlA78AAHHSsCNn1bVba38AKslsqrdWls10VO9Wzumzy2VQABsqN5/G74tv9S0jVID4117SNKYlJksdNtBNOU3KVDsEyq7sk/Mc7QAO9bcqatfTt/wDSU7NIwPiVZITcadG1smn6W7+fA88wAKttD7VzuJ9gPXjk10vg7xBoVxp09zA8c93aRI/lKhKIGGBldxCng8Hn8+a0d3Z3dxZS6bM9x4fe5Md1eWcMssyd2yqjeWbOM4ON2cHPHR/DK08Rwa9eDV9Oubfw5MGW2M9vDbJlWyjmMAMHPOSRk5GegqJR/dq46tRRu7/AKX/AK7GJbahf3tqzwWUyZO0xG3Mm9GGCxRSWA5Hvg8VhL4osdFvdU8/VJ9Qv3kjinjZ0DyMoG1Q+PuDBznGO/NeieMYPDXg+1ENhptvHqN9ODIkbSGaRXbBA2nczZPyp064rI1qwk0rwtp8viabQtC1S/lWCOFtME9uZCPuzMg4LcBmLYHJGcZpRSStbRkPERkubYXQbOz1Kztk1TTLSDT9VV5pba3k8po1ByHmb7zMTg9ccg9sVz2j+EdMi1z7R4c0y/drad1ezu50cEopKvuxgKw4AwScVVXUdJudU/sXTY4rG8gSSK6ktYJHtnuFYM728rMWL5XaAw2kdM8Z1PGukXfh+wtNZ8QSNHp29mvp5dQkCIvBWIQKys8jdgDjPXAyapWg7X3KlUUVzt2/rscb4q+L2k6Tb3WmwSXWsXGdjLDF9jijx96NnYF2GewRen3uat/Bnx54m8R6rNqOpzywaDYL9jtNN09SsbTSK5CnJLSBUV+GZsEoR2rnfEOia18WjN4m1GKTS7R4JIPD9qIDJJdtGpcB3x/EFKhjwWICjCnHrfwo8N6X4Q8M+H9F1a5hOs3FnLqsmmcb3kYBiz/3QFVEGcZKt1Gawd90efCpKpNe0em/qXfh/wCM4L3wvqVzBILPdqBs4JHiBeFnBcjaewwSAeM9a85Lf2XqW7UWmtNW1J1dxfNkv7rjopGOB64zwBXb6FrF/wCIPBmsu3hqy0rU7HUUlj06CHZ5yoclgeCzgE8jrjjqaNdj1W10m4jt47DU72OSOC2sr2NWSN5G4QNkEZXOCCF6ZI6Vz8jnaJ7dCtGnzVbat/PZfPW/3nEaL9qlXVNVg0mcxQXO7ULidwI2Uchi3TnP3FyeQa7WIXGqaFEtjHdaD4K0+wlZ7EQtLNeysDl2I5EYzkc5OOBgjD9Y0q7k1Cw8QXFtdR22mEXLaTBILi2sGhTLqsafLvJ3Hc2fvcEVQ1f4j6brOo22paNY6hGZrExm6mUvG6KzM0UiDjK54PP3vStIRcdtSKlV13GLVtbqz/NbX9P1OV8E6TJoeuR3bQ6fJo0jhpZ7zewuVB4O0H5MHHXvgHODXuVt44sL60u59PJE0IfatxmPLjsM9QDjJGa5nS9U0LxDFBdJoX20SouJYyTDEqn5tycBGB7EfjVH4rXtp4cgt/sFjBB9ol8qGSeZgJ5MAlFj7J93LDAzgE1q2pb7nLUjCc0pqy9Vb8+v4nI3WoXOr217BqzHzY5niuLeeyRwkLKoDLKDgSGQFUUZIHORgk6vw7tY2uILiZbIpaR4jt2j3spJOGQI+N2QQSTnvjnJ1fClvqer+G0W/wBJtrdYJRJdTRTqxUqylGUKT8w2qevb3xWJq+nf2frdokbtYQC5LRiA5MsmRiQkcs5PUNnJJro9opL2drfl/mbW5k0n/makmo66s0dzZWqJoD3ckNzNKTJ5e08uUDZC8n1J2k4x1yPJkvfE8FxYrNHp7nyGuo5WDZSbcZI8Ha4ZcqM8Y6577VxBoUV/My6YLKCa7FpcyJqTxzTS7gu/yumAT1HIBz3raGkw2F6JPD+iieVyWnvWcyEE8lQAcBcY6DmjmjBXStdGXP8A1/TOO8feG9N1uyuLTxLq8ZsfKuLqyuhHmSzkVgVRAOSWDYMXIbZkYODWT4I8U3UOrR+FPHSW7a+qqdP1Nm+TVIsEIvmf3j0Vv4sbWww56iKF5J5WuNeOkaoH3vZyabJIhyGKgMVy4JAAMbE8+uBTfGvguXxN4SEXifT3tAiefFdL872LkfMQe4zjchwCOhDAGsp3Vv0MKlPXnpv3vzNbXn0TxFaRwyTWllrsioqQSFoZJBk5XcCN5PzLkZIycVU09bjw87R/2Y1s0b5SJVbbH8oDbCw78nr3NcVoWv6rb37eBfH8dqniCOMx2N7eQeal/C3QK5wVkPBV/wCIjawD9dvUPENxqNx5hTxEzabthkmVMvEpC/LKQCpPQj+LrnFaKLnHlg3YvD1FNXsWhZu2l3q7GmkZjPbqy7CJAdwckHO4YPIxS6Dpd8LW6vIfC8Go2SArFJqMWyQShi0U0XmEcszYcZy5C47ir+ox63Jp9pqt1cxy2Xk5le3kiiYS7cqx6Arg84PNYviZ7TxTpFnNJqxUQ58xoB5iq2AwIXPysNnGOTk+tKMmtGzoac1Zf1+QwXWovealeLaXlnBey+S9teQ75I5NueQQAN2c4HY98ca+ma9oehWNzofieGaNLmLyQiYa1vA5IJB7AE9wNvY5p2iajJrtpNHfmWdNVZpI7y7eAC5kSMHbtRsxEIvBfHIwSCRXnuueEL/+3bxdbeedrWEXBl+1LIxhUDBOSAQPmHHPB46U5XlPlaFaM48t1951/wAQdHi8OnwwbSG6i0g2pMj23zSJIAvzAk4Y7QMgjoWIGem/8ItQW30XVrG9+zxSI4urnypAJEeQbcBc8dF59TWz4N0uaPwja6Zq0NjqVus5u4w3zRpEx3IU6EEZI5+lcjoXwzkh+Isuq3B+w2E80rJEbnc8sfUrx0XHHzHNc3NdKLJlUThKE3/S6rzsdr4cfSbWOJNHeG/t7WVkiEJWR4mbgqzDocE15d8br7T4PHl5Y6hbXElld28Mc1zbHEse0jAAYEEDHbGee/Nennw3qWgPqupaTqAhjuLlp5oGgSSOJTjMqBcNkDnBJ+lc14ptvCfj+zsr27ubqK2iRkGpxwMojnycxyjGQDkEY469O82dkyYvmk5Qd76X389dPXbU4+3gvodMhEaarrVnA+XvLO5iiuYTkbTtkzv4GCuMcDkV3WuWvi3UI4JzbLJ9jijuIbp0W2aNXTLS7VY/vB8ylQcHr6V5rqLaBYRTaYup2pvwFCyTNN5coBySrMvysw+XP6969W+GV1EmgSaXJqFkkt3M0tlZeb5gWFlw0YA52Bg5Hsa2cbwc33Na0+SXNF3t07fr/Xkct4W8UaXL4J0+LxfpF1r0LTySK8sa3TROuPkVXwV7HAJGOPXGhrHxbub3V7LT/C9o1pFGFlmu5mRwqlTsQqoKjPGcHjoOc1SsdH1jwV4Z8UR6xLbX19fIwsLSRBPbjbwHA7DBwAQO2eOnmFiZNF0sS3tv9lub25jLtaq2YVAPyyKchcnJAHv9KmL59GQ6dOdTm5brv0/rX8zotY0tZBFJczWktzIzySBGDcsc5PB5Jzn6UVBplvq+oarqP2LT11Cyj8vyWVZVTaQfmGMEk4Gc+nFFaQw1Wa5lJLy/pHf7WPVf195e8i28LeLBPcafdlbxDDKm8GPLMCRzg5PBz2PIr1C1vS2kgvOJrO5ty1vNDuPlZGMOvZs4Ge/PTmvKbW+vfE9vPfW2h3FzPaYhZQxZJG++CCAMkAZK44wOa6X4ZawxE2j3LumvJMbmKzVdsf2diCUIOMNuBbGAQCPUgFaErc7Wuz/r8Dkm4tJ/1/wDuvh1cLrF9Pqa+YbWKBYbXdgZyx3MQOOQF49K6rxPbrd+GdVgZioa2YkqcZ2/Nj6HGD9a5b4W2kektrGlRFyluyuoY9Axc7fwOa7qRElRo5UWSJwVZGGQwPUEelYxaTutrnn4qTjX9Lfkj5P05YIjIm2OSS7wuyQlJEcltohlwQHycnjnbiu18PwWdhFE92IxME2yFxyrE84H64H5VY+IWl6HbXMq22i2d2sRkzE00iCI9wNpAGeBXB/b79Y4LiFI7eGSVo9it5zseCFGckjtuzn3rqneuvd3X9fM9aDVr20Z2stvo11fPNs/ehldXA2ncv8AEMjjnuOan1DV73WLFNKeKTWNTt5SLNXk+aZZCAyO3T6MegHNckupzC7t57dpZdNEii5l2ZKx/wAZDDgYXkevP0rv73xHpPw/l1GXSNHl1PWUYQI2GVkjZchySD8pyvAHORzzXM4TUlFjqyjFXim30/4c0vBviVtLj8QaQdMUXnh+KVvtCsTHeSFyvOQCAGwCQenpXm6HXRr8V1HcnUrvVJgLu9uZmFtEOhJUYAK/w46ADArV8PazaRHX57v7bBNdxx3d1FOxdbOJ2YvF0y27CkDGemeetjSYdPi8BWmtwzSwJcz3Fx/pLhnMJOzdg8A5Vwvt71o9G7LT+v6+ZzwjBN33l/X5/caVrqhs/EF74W0q8l1hGtGiW4nJEcM0hUNtHZSD19c9e9DxTq2k+Grybwstk15p2m24tYooDvN1OxUtGFIPzkyE5OQMYAJqh8M/GC3OuaRZyWItHeUyPdvJ8gizgqQR0OAAe7HFSaparLq2s6n4WiuYNQvb5il/Kp3rG2QXh4GwkcZ6/MSCCOLslL31bb/h/wCvzFytu1Pt/X9ebOw02zPhL4fXI0OzisfFuog+XAji5uIwONuTwCq9uAD2zXJ2Vle2ei2dx4jmZhcvI0UlxJG+ogt91iWyS5KkAZO0NzxVzQvDdtpWlalp1ppET315KHi1N3UGzjCgB4+N+/7xwMDJzn15a2trrxhaau+laY17Fpxkmhh8li8ob5QoK4Ct8wbbnkKfSrg0mtb67kwhbmlLc9osvDcklrHqiXCWhMImjjgCpFHIVyxABwBnJP41xnie10O40WxvvFesXcdirySNEXd3ug39wE554A6cZPA5rO0DwpqdnYf2RdaRDp08rF0t0uCqBQCPNfLMAQ2ec9uKm0r/AIRTw8JoE0Ox1sWt3Ckt7etulvrpm2t9nDAhgpJHGffGQaxhF8z8iXeKve76bf1/X3WrHxLo0Fvol74b06x0iF1b7PdT2/nzyBW2MqE5IG7ILZ5zxitm98RjxBZE6lFY3mmQzK7wBSBvB+UseeATnj6Zqx4w0fT0ngudW1m7trqbcLaCNFLTRqQ27y+MMpAYkdOOD0rH17UtO0vwsX2poWj2rJJdPu877UuMBRnlnbHyqO+ScAZEJR0dw5oOPNbbr/wXr9x0CeLdN8P+FdRuNXii0y309vNVxDhAJMlEVCcs+BjaD+Q5ryRRf/FXVP8AhL/G8bWfg3TwZLDTC2FdM482Tp8pIwW4LEbVwqsy0tM025+IlyniHxBaCy8JWQJ0nRmfAnOCFlmbI+QlMM5xu27VwASvoF/Nea94euNP1OCAWkUqCO4iiUBiRhUSMcNECAPQAD6i1BN32Rxwp+2lzPY6DwheTyteDWw0GmBIpGsblg3kOkfyvFt4VSyoybOBgYxXnngPxVb6R4zubr4gaTBpmosdrO9mYtqsvzMScu7NnPzE/e444rpdIt4ru8eGwuDJpllbrBIzwu7zTqu3aHbhlUKMlcqOFHWqPiLwjaa5qVwZv7Lg1MOsl68Eu6VVVdqxlQSEY8cDn19aJSjzNPY7VSi3o7aWNCTwzq+lXQuU1htbS1jWaOeM+UyxliM+WCeFwVBHTJyB3YmmXWn3mj3OpoUtdPMs1ncXcmVhBUgLIR6YGFPIGcVZ07QfHUvi7Tzb2em6FoVpavb28ufOkEIGApGchm4OCAPqRWxdWHhXTZ4/D2tWct+bmVfNmuWc+ZM3Q5B+XPY/WsXF3vE0jirrllr6LX13t/W3U4DxNL/aoi1fQU1JL6zlSS3ttNlZVmJfDKB053Nlsc++cU/x94omttdns5EszFp21ns3cCeYttQiIgADYRjb35PTmuz07wjHY6hDeaTrWl3en6fO5tIZ3BEJIxtZs8sOoPriuf1DwwD4p3X2kWWtfa5TIb6SUbVjCDaUB+XHLdc/MfXFTFuOkka3pylzUn09Nv1t69jjvFd9p+k+J73Ul0/UbHRphIRpyxyQR3M+GCNKQQGj9gcnDcdz6HZ6UvivRNN1PxDE95fR26zSNcKA9uccqidEBwCAB7nJrndYvL3TI21G4vrmb+zropHFbwK7m3lYlkyRjzBkkyAZ5H4dD4CuGtvF11FeaXqMel3ixtY3V18+/KBnWTsrKScnt79a0esU/wCv61Mqi5W3H/P8fRfedpbeFtNUIy/ao5nTzJEWUhWHoQODj1qWbQNMZY5Fskk8tCyuXbOePmyTkH3rzfxVqs3h3xU2q2fiOWOeROLSa2LwyQr13c5CZxyOetbN/wCJZr+4EELwiT/nkLkRFo8qWZc5G3rgnsM8U1TbSaOdwq3vzfmOvNMs47yTUpo/KvI4zGbrZ+9EYHPIGenGetc7fstrLHDpepWtpf2zMI43kdM4OGVm68ZGcHp6cmt6w1/w7b2aWk02oSzyyHC+SzNHG52qGL/eUkE7unXoKzY/D+nMv2e1uni0ATuwimgUvDPuHGcgjPQZ7dc450guXSbaNVO+6NDQtevYLVLeXUbvyDAxngNwMgjA3QumWGTzt5GG9a5pp73SL6WC3ufGs0hQs8V/cg78uM8YIKgHaTzgjBHNFwml6dcRpbTmSwZohPbHDfZwx2rsQ/vCM8kqflyB14rqxoNr4ejv7yW+F08MTMiW6syrEqDOegB+UcjBPfOK0vGHvNb7aaCtFSOC1nRLPxXYyaNrv2yJFkP2GeRjMbEYADoxOQp43RZ24HBBxizoGn+JLvSdS0/xzINLvNK2Wya/JPst9TgfGEkPHmkLyG644bDddKx1jVBeQW+pWT2HmRF4mKho5g2PmikXKupU84Pem6rHfxy6dGt6LKQO0kF1e/Pbwugzjbtb5m7dMDnnFQuZzSejFOhFyVWm7fqI2uodCudCOq6XDbA77ZY0AKCNtwKh+GX5QR6g1o77eLUtS1G51WNNQuLYM9jFbLCsqgfMwZSwYkkndnIzxWboeraKdJEviOxtLqxnmWdwiLPHbXDLuLDyySN2DuxgA44Gas3Xh/wtrQEWgi80C6AE8Em4SWzAj5sEfOqkcE5wO46CqbUXKDLdk7tWX9f1sV4tc8AeKxNZ31ld6PqZAkWV7RTMzAcsGwRIuByGHvjIBG9YeFL6TRLSTQpNP1C2sY3+yy6nFv8AMOMgjBPy8Dg9wOKj0fwpIHSyl1LQ9VSQOnkxSgTAhfnEecHJHOR061i+ENbOiNcaXD4iaTS5JXhxd4DR++eoPqcd/wAawlNrRMIxbv7N3fn2/Mo6rb+JrbwzYRa5d3N7qV7ctenzRiOJAVLIOwADE7RgD+fRfEm91DV9E02TTNUjtrKe1/efaAPLd+RJE5xnkYx1zj8a63Uwl/4VtYtINtrASVTtDBo3TlXQn6Z49hXlPxayk2nWrxtb2sELmNSCCTgbVAOPlUYXI6EtWFar7OPNa5vhIKvKMNrX/rv28yT4SP4k0z4irb6fck6TPMPP024lCskRABby26FdwwR97HGapeHUubDVfEOn6fdiW3lmmmtYnDMbdxIA7MvA4XODnnC+4rtPCMWoWuoWNz4htrP7S0cXm3d3KvnRwBeVPHXoeeeeTmtzWdB/tPQLyGexhsLHUrzE0ltL5ouYQ25HDLyoY8+o+hq41NtNv61IlGFOo33639b+v3HneqnS9SkmiEC6jaoXhzdttMXIEUhl58vc2cqAOMZAqp4RsNMtPiNpVxL9tTUpQ0YiEZEW9o9oX1IBPDAkMGUnHNaHiq2uvBFg1hZfZbFbgF7Z1gEhOBtkUgnB6qdx+lXtKkv7HSLfXdHtLrWZorQrZJaw8LdSfI7Mi52kAk49hW/tqcny21/Ec4P2fNuunmz0bxVo9xfwacsU/wBkjtDGZJkUODtBDx8cgHoap+JJrldPafTtHW+vJHEdxFbny5jE/wB4oQcnBVePTNYvgiLVNK0S10fU4zY38jyTiZX86JXck+U4J64Bz7n61348q2ufNYeZcGIBvJTkDGQw9uv51h6nJKXs2orVK9un9feeC3fijVPDk0+i6T4jg0ya0ncXO+Pc7scYBbbzjB/76NFW9e8c2ekapOur+GF1QSsWjmWYw7Dn5k+6d2Mg5z3orRU421evqjplKDd5Qu/T/gnReK7mPTL2S804zDSr2N72FYg2xG2ASMpT7yFT24wa891S+k1yKO68PwpdakXAllUeXLHnGw5GBg8j2wK9F1nXbzUdTisPCWp6ZbQ6PcL5UaBg/lopUxquMbMcEdwPSt6ybw5dEWtx4c07TLeQh5LmCNEjEnZeFHXnFa8/s0r79v6+8zjNxjrH/P8Ar9TnfB/i1x4otZ5tMubeCWAW17LMpB3kAmQseDhgenZq9iidZEV0YMrDKkHII9a8r8f6ImvrZ6Hpt1NDHZ/LCjXBKO20sM4yc8/kK7vwfqianoNtuQw3dsgtrmBsBo5EG08DscZHsRWUlFW5TkxS54qovT/IreJ/DEetBUhkS18zJkfYGyegJXuPyrxSfwN48sL6R20z7UgXyXkjdJUcbsgohPHHHAAGK+jQf/r0qnjg804zaTXciljKlNW3R86yfDrxtqVskIhjtAOIzvWNo424ZGx1yP5VueMfAPjy+1ue60kaF/pTYNx5x3QKAAowwAxgAcAmvbsnv0pDz/8AWpSlzdC546pLbT7/APM8eu/BqeCvA/inUNddvEWp6qYUEMYKRs4+4oAG4KrEk8jIUcCtiz0jTfiN8JbK2gsk029trZraOBWYfZJlxhGzklCQrYOThvWp/jZo11eeDp77Tb+8i1KymilghSYrG+XCkEdOAc59sd6PhZomrae97q2sxvZJcnatuXy0ijo5UcDPOB1xVXaSsNS5qbqczv8Ag31X3fmecr4n1bwv4BGl3GjQ3Wqfavs1rBLF5hg5zuYj73zD5R0z1yBg9DouoX8zsup3NlJM1tEJZJMJghRuwF4+9kcfyqr4m0bxX4m8d6hcaE0Nno5Cob6WYwxpgYyxHLNuzwPbPFdJNc+G/DA+zXVqdXXDzC6iEUpkGBtBXOVKg4wRgnkd8Oor7W1/r+kdcZRTdk3J9O3U3dC8KfbPCNpDq87pqEqmRprV8FQSSqZ74BAPvV/4daQdM8NxlrNbKWd2mkgUACLnAB+gHX61ma14zm0Xw3pd/b6Rc3Ud/EBbwquJFOOrZ4xgjHfivK/FOralq3iDbf65qOl212RHa6dBM554BDBflOT354PfmohTvuc6p1aylFuybOq8Q3ktx4l1K5OJLaWdIoQTu82MLyykfdAPP6dazQlop1DV/t+kWOsWJK26XUPlvKuzLsH+8GO4qoVSc+ueEuhq2jXOh2erFoJtSmeXyZfm8pI+mexZiWxwOB7CtnX7/RLOe81a+1mP7NpcKySsihpIgW+Xbjqzk4Azz+BIuyh00/M6JTiopX2/Q5zxFf21zYS32uvJaWNluea7uHbzYyzDase0gtIdpATocnPALDi3n/4S+4s/E/jOwvLfwZavt0jQ7ZCzXPIHmPjHy8Dc3BbG1eAcbeiaTefFLUR4q8WW7Wng6xLSaZovmhWu+eXckgkHHzP1ONq8Dj2C+0mebUC2l2otWJWRBjKhFULgYIwMdAOBgccVPMno9jicvbu8tI/mcxA+j3FvfQ3OlXlxqF4uRaXc3kZQR4CLEv8AzzX+Efd6DBrDOs6bpOsaf4fsbFJp5Iv9Glt3AhgdgwXzEPLLuAJywO05Ga23XQjrcE8mszW13ciPlrJgbgRyE5S5YYiVnGW2nBxn3LNDf4fpqlzF4h8XWGq6pd5RosNb2sY/uoBxwOMls1co8urv8zqdWMVrf5XOWTxmw32YvrzxTq6Ax+TptqYoYyOMK4HQdQwB5xXVfD610mHTYb7SQq2UG+4aKPdsgcqCxLPyxGMFj+FHi/4oaRo0R0fRtFkXTVKPDdQReXGzAggBCFyOME5PriuesdUvvGelT6fYwRwWBuGuJ7eRhbw3BZshGZATsByQO59OycU43/4YqHtJJ8yt/l+LPSk+IFncaXvktI5Lu4YpDCtwqxsCcIWkbCqWJ4Gc1w/iWLxS+u3cWqadeyS7Asl9bR7Y48qM+UcZ+UNwfXJ60+21LxXpuky6VqXh/wAKTWIViIZF3LN6ZzxjOMkj0rA0Dx9q3hmS90u0t7K4e6dTAkOoyNb2gxjYjSEgAEZIHAyfalGnfZipxdN3pR/r9PzNO6+Gn2rTNGCyTNFaOJ206AiQXC7wdwYYO8IGOD6YHv1mgXN1ptqX1ZntYxNKLZFiZGEI6lUZVILE9wOeelcn4j0LUJrmHVdL12PSLjUp/Oi003LInmKdzPGcZ2A7n6Y5OOoqh4WTxhd+LYLrxVqjjR9jS3M5dJ450jJzGoQngkYPPGPwqnG8enr1HJ31l1/r+v8AgnbeKr2ysNHe71e9urWVWEvmwruiG4/cIXnpwSODz64rc1fTjfwaNrOhXsg02BXmkCEhbiEqMNtP3jgEg9wfpXjfjSSw1DU9S8R3N/b6v4e842lvAgdPKDfdVAduGUAA5yCOnbHbal4z8Rafomj6do0GmabdSWscsKyMJN0Q4AT+BThcYORg8YrPksrilGb5eX7vU4nxfeTXfjhrC4tzLbywE28K3f2YTYU/L5jg4O7PHHU+or0bRNVkVYNO1220myWW2SJ4nj58kjadjg5OOmc4PUVi6zpQ1HS7m7s7Uw6rO4mnsZ5C9uz7XwY3x8uS+446lQOBzSx6Tey6BZPq73cVzcWxtLyGONXXylckorknaDvAwM4wDkEZrZcrgueWxU1fSwatp815cTaToEkl7qIiSMTXMqxzW0Sk7QjEcgHknnt05NT+MrC6j0OeGy1EC6haOKKTaB5spwGOTwueoJPBJHequsaTPqMunauLY/aDcJme2MgdUJ5DIDgx9MsOcDnk0mpatqsdq5a0EFoXa3cyW7kSMWdepOB8gWQjHQnntVe9PlcQV1oWbLRkTw1ZS+IWRdRDfNcmMu0cmThg3YEg+ozzjFZd3dpdW8enyXuyfPn7LhC0ZwSjK5U525PrkHBB4qe00jW7u/tpbawX7DIAqJbTyP0HzMyvwwPQdOME811epanoXgzTNLlvdCe61a8yVt2Rcw4bkAkEKMgsB3OalxvO61fkDqOC5d79DktF8Pa1dS6j/Z+j2jwW9550mnwSvFFbTbRzGr85YfNn7pBAHSnp4t0PSr6Wwv7qaxuY5BHNpuoxPgkHqkmCABzjPB+nNXvFvjO51S7ilsZZYzbiKWMWtwkXDOcrcMWDMAB8sacHOee1zV/EEt3GP7Tg0TV4ok3/AOlWayPEm3cVz7hT75FTUTlZsUPaNWsl/X9aneWNlpOoWRjt7W2+zhdvleUBkMOpGB1FcX4m+FkQjh1DwVdPpmrWwO62mkMkFyO6PnJUn16e3euF1TVvFFlrFncN/acNi/zWkhcy7oyowhZGPyAEbTtzngk11UHjuOJpoop5IryYbp2kHUouXUHpuUHnHTmplSlGzaMlSqr+HLQzL/TdS0S8j1DWrBkmh2z2widT8w+bYW5xg98jOKw9ffT9clfxZqVzaWc6osd7HDZvGLiZnIjChiW3eXlmdeMAAjPFemJ48tNRurO0tkjnd5UiaeUkwEuPuhxkZOOB0PSm6l4M0R9Zn+XL3UbxyRhAkdvux8yKBwcd/epUnFWaN+dNp1FaS7a/8McX4L1/T9Qs7nw1rKarpzsu6O+T5ZI4sghWGM7SBjOO9djb+HLPxBevqOoanY6ncRQmJ3KAL5GS4yg6MDkZ6/jWb8Sru20LTFs9OiVr1bWKIX8ijPlcYVyBltwGPauNs764hvpNRkuY7NZI457aSAmNE4+ZG3cnkEZ5BIPSp9nzptLRGivL34vlb/r5X/pHrH/CManLqcUk13Zf2DHbMs/mDLOWU5GeyjI5JB/SuOutK1/4cXyPoeuTSaFdnyobe4wyrIACCARjaRnJGM/rXn1gL6aeaC51Fb+1trk3CRXpNzA+RjLITjOeOnGTWv8AD7XJ9Qsp/A2tbLWQMosJZCf9HuQflB5J2tnaSvZunWhwSV09SeWaklUs4+n4+v5nT+H/ABhY+PNQbwv8TNFtbLVHb/QLmFWiEnIzGrkkqxx1Bww464z1vidrfwH4Snt/DcUNreyKsNu7rz87EZHHzFSdxBycHPNeD+Kv7RsdQe6+0z2l9p8vkJbOgkWO4U5G3JwCSMhh7dQa958Ut/wnvwc+3aeyLfXVnFfWhjOCl0uMoh7MW3Rj3bFRpJcyRzVo/V6ihK7he9uh5l4G8f6pfXNvpnim0S+ure92xmHcly7AYYqVIV8ZHB6/qOm8S3usaZr2l6f4UW9u4lbzhKjeYoiK4YP/AHuRye2QOted/CZtV1PxzoUl3G/260+0SxS3e7ldjIVcnn5HwfxPtXq2iT6lDpWk2clvK9+hmgdlcZds4OPVflznNafDZs0p2a028/v1X4ee5z/gzxpJqllO0lmsd/G+25hNtwrc4YZBxnnjPUfSir2p6lo2m30um3X797UhSYuzEAkEgjODxnnpRVqDkrqL/r5GzjF62ueaWHhfUdO1vSNRtorn+zxKC7kfPFhsNv8AQcE5rtH126XULsjUFubSRDGIfK3AHIIJXjA4PP511HiHxPp1zYx7IZ21i8TyjCnyw5+bDMT14QnAPODXnyJLHHqVxaxm6uYIgZ4lcHy1bkfKOf5Y4z2rWbdV3tqKkk17ytqanws08wJrmt/Z549Ta3k8i3llDkDJIxwMMSDgY4H1rq9C1O9a2+03ELWt8hVWmcbRdrnBBX+Fxxgngn07M8FRSW2j2NwIApuTL8zAjfuAwQD27/8A661tKNtqNpKv7xlklkjTcgRZdpwS2exOfwrCU+a911InFJ66o7LT9Us9Q2fZ5R5hGfKbh19QR61dK4ry5rTQ9RurvQrfxPLFc2gWaVtOkw8QB5XeAR94gY68D3rqtO1jUbXMV3ZXNxbxqgS5baJJTjuAcdccnHWptZanBPDrem7nT9M0uOf1xXJeDPGh8Q6lqdjd6Vc6Xc2khRFnO4Sr6gjv1/Cut5DE54x09KbTTsznnBwdpIoy3VvNfx2OY3nYMzRsRu2DqwXqRnAzXk3xr120bxFYeFtXvr+3gn2XI/syMNKWbKxZJIwAwJwM9B7V6brMWm2morqswhg1CONY2uOkkkWf9UD6E/yrgfGUth4mgl1/w5YW2pXunBbdmPyuqE5JDfxDBJGOvOKqne+h10IJtNbdb/19x5vfNf8AkxI+rTRaPbtIgW5DblmaMIJCFPO7bjk/Lkkcnn274Y+HLfTfCukNc2QGpCLLyPJvZgSdpJ912nHb614RdSP4ru9K0exureze8uliaORWWRWzgnngj079s19E+Kddt/CeixRQtC+pNH5On2ksgVpiuBn6Ac/pV1ebRSOnFvalT3bPF/Gw07xB8QrqS41qW+a1fyreytLVhEqxYLqJc7VBY9gSfbIz13w/S9jg8QeIfEGky6dHaqIdNM8GXBJO5lQjJ5KYYjufevENHXW7uK51DTVe18ptjzQOUYt13Bs9gB+JHevX5neT4J6ZY31/P9u1D91E0rlpG/eb5Pc/Kdv0+taTjayb8vTuNpuKhHZspS3er6/47ivrrUEfRLVIxPLNKm0QEBXDRDksxLciuh0LwRptvc3Mmn3+l3GmSErLaSQeX5iODmN2bIZCSOMcbV9M1wWi6Pp2m2FzAl1NPPGGMsjDYMqCdintjnj3/AXbSa41iWCztbyzug80cMYsmaN/JZN7MCemMbTkdT2o9+S93RW9NDSdPS17I2/ESwRyf2dc2y61ZLNJLBJIphWKcEbGBQYxGoKqnQggYAHPUQ6vcQ6DEbW5iUttS2t7tALi4UewOSqj1GSARzXJ2ltZ3OnJZjxHqWg6lLOwEcK71KEfKHYrkcZHXk/hVWw8I6A/iUyeI7rVtQmjJQuZ+BsUFZGPDBQAfbI/Coav8T2M5Qjslt/WhkeKEuNbuNO8J6cL5bi5cXEMUjskUCEsWk2jJCEDIGAcd8YB7jXV0/w9qX9kaTolvaxQzITdSRCT7S3lkETK330YO3zZ45PasrxF4kOvXOzwbq+m6RHPcSw/aIFP2m5VFRd7EDK8scKxUHjk9Kh1jU9YbS5bp3nu5xN/Yj6pK0ayyzlh8kaKoyOT06YPXBrT35WkTFXld6IZJZW2m2X9nskLxyfOLSNCEjJO75QxYg+2fXtW5Y6NqLJar4b8PvEgO43E0ojj46DHJYZH4V57oVk2k2etSDV47fUVVZIo7uYbn+b5wXIID4BHHdga6nxdql74cu9Kj1C/u7TzlDLBE++R1Yj5cr8pwCAzDHOcA9aynTm3du50udkorR+dztpvA95rOoW1xr8ltFFG4JtLOUsuOo3EgE89ulbthpXhrwxo/mW9rZWGmt18wgLIxGAMnqTjHevMX8XXXhe41GXTorWMNGslzcXrHcdoYoqLkkk5POMc8muUh8aPq1o5uZvOmikjMFtcSMYjK5O4qEH3cngdeuTUKnU5bnPKjOcuWU9F2/r9TevtP0TTvt+rGK5k8SX87PBcpAJmhXncEQkBQAcZPbn2qjcaPK2jNpuveKJWt7y2NzbmSPLNtz+4ViepKr8ueRyM81s+MtC8S2nhm3u7qTRrTyt5u7oSFPIHUCNXYKwPC4Y5LYx1rGf4k+Gtmk3E2iXWoLEI4Zb5pxA6uq4BWFdyk4zjkYBIBraEuWKvr939f1oVKcdeTb5GlYaV4U0eDTtCl0e4U6pEollkdpptxUncy4wFQ98DGPaifTLXUNQ0mzg1BEhsLf7Rd20UXmv5ahdrJ3YD0zWtpWueH/FDgwXrW9ls+ywrOXhllfhmTAwCoHUk8DGTzWLo3iPRtc8US6jYwfY9Ttmt7IJOuIo43+QvKBtJCYwQCBnbzikves/+G8gjPl0X9en9dCHTtR1rSvBUP2yK7E80j3NtcTr5fnwSOiRnfk+WPm5z0ymflJNegeHLs3vgppr2FmkS8khjTglWRijHK5VvX5SVJziuL0jxNpeimOxvcXqXMctrYbneayuIvN+4ASdpHXYcEDA7jPSajrLDSoob+BdOt7TKLBaRN5CIvHmKoGVAzjnocUVI6csY9SGnKyMu60rRfF4khtNa0f7bbRhBbXTOrW7AkrJGysCCcgMCD0610Wq2muWujRQrd2txJbWvlJP5xdWbcT8wPzdCF3de9eZatpFhPrcV+s8qSs5I1GxwuSxJy5zndxgZA3c9a9Dh06+uZrZiLiRkhOFjACsMcMRjuetTJy5UmXKHK7t6GTpa67aMJLG9mjLYEtu7gscgcsVOD82enOMe9O8aR3eoytba5pT30jWyhJIcebCpPzKOMMVbacnGetZA8N+JZplFrEmq3cKM7RpcIsTIeArA8gkjPynGecCsrRbK81DVLuEQaloPiiNeYJl3xzdgVY9huwU64IOTjirK+6+RVo81zT0zVJtFvlvXshOtvay4t5BtjWPhsITyo4G3PfI4FRXNrqPh/wAUWdlrUMSks9zYSwun7yQpny3kYqvyKzDOMMeKuW17cLbXemah9ju9RYSJbmYkrvAz5LMQMn/ex1AzWFoNpo9na3V3dWMUnlbQRJb/AL1ZWYARgHrzz04x3rdSvdv006+g+XXTQ6Ke5061tLfUI9LtrS4eEGG5VXYxRuAC3kZwSq8bR0H05zfEmopqFpa+J4yYLmJXRrzTY1CsF+VJpIGJy2xmHXcMD2xV0LU5tb1e4S9hkjuoGSSCeFmDgk/LkEbSSD24IJr0htKsPDvh7TrfVRKbiWdpTtK7sEAbXBHKgYUgDjtWTm6T97dd+3YU+WLS6s4Dw74da81i4iSS1LW6q0c0TeWkbs/mKyqmQfTaDgbj616o+rWd1Zi91i5hsSpEcshwMccD65/wrzWK4s9FurJBd6bPbX0c1wI9I34tynzsDnBxsIIJ5ypGMVj3pubbX7zSo7+3muGm+0rHcx4bcUbhs8cq27P6c0qkXKavoglTVXVM9N1PSNG8WWIt9M1aC6v7Vd0bAkKQemMehwCR071h+IPCWq+IPDWoWmu6XHYXkMfmwajbuhMzA8RyKn3h3zx05rkktNT0LWdAbTbqXT4JLVzNJaHCCVWJYKWz8vKZB7V6N4Y8V311az3El3bXxVdpyuMMuP7vTKkHpg4rnlHlldMJRqRhZWa89/O1unqePeLfC0/h+w0a+06WWfVYlf7Wg6oMgg7ccrgsCOuOabrF7Fb2djPq1hLaHUSIRJJEVZFAGSG74O3Hcj0rufGV+dcfUG+zRiztztu3MhHnM7bEWPn/AFhAwOCD0rF0KGw0y01WGF4PE/h22HFjexHzFkzgLuwQpHzYbHPIq5pyXNPr+RrCc435fi7eZH4nv18U6HYWfiW3Ntr9tLcWE15bLuaSe2YYDZ6kqRjnOd2OuK2dM1KS98F6F4btLyytbi51hLiOPft3Wsbl3A4++JVGBxnr0rJ1/wCzeJYv+Et8NRS2F9Ffss1ndLmJpHC4yxO1ZAwJycZBGDkYrB8O+FtVbx34W0nWLa50u8mmkeNzJgPGr+ZIoxyrbc4PfIHvUJcslf8ApmU7eySfS34f8Oz0Lz4z8ZPE0NvFvFnfQGIRkglposy/qGz6816P4W0ybT4Lia4aB3kmLRLEpwkfYD6nJ/KvHPGOvWep/FvxFp9hCbSdpEiNyGZWlnhj2A47YOQCPQHvXR/8Jfq+ofDXQJI7mWy1O9huILqUEeaskLqhcMeRnOSACeevFKMb7Iwlz1acFe97r7uny2JvHGn2d7rsr2ywyEAeaoXIV+5z78flRXIx2Q1OJXs9Ph0raWEqlstNJuOZC247sgL3xnOKKqVOMXbmPTpNqCX52DxBewxiSaC3Vru2gExBfgEnCjI6KN24+2a2PC2k2On3PiHxzJdRXNnocVxbW7pH5aX04UBpVOdpUt8oAzkjNUL6fww+sHUNRub/AEm4u4zvtRALmFVUhQ5fghcgHGOM+ldfeaCT4LtNDvL5JLG0ujc3RiT928m4sluh7opPzEdT0xyBs5KOj2dvuXT7/kcVW8rQvbo1/X3GHo2kwT39nfa1J5WtxokQmWTLuBEp27CeAA5ztxk9c1Nq2rpqHhOa8KXFlZrGTEvklLiVN23dsJ+Xkdc9DmpNZg0yU2tvau8WvFfO81lDEOoIC56En09AAegqK71jW7i/Ng2nfbo9QjEUk+Avl8YkVwcgDIJ49utc9NuUve6fkdTirKUf8te/5mR4c8ReHbzw5e6fqnh62tba52wiK2G57hAQVds8g5A+YnqM960PEtnf3NtBJ4eGuXOmxfZjDbQ38KtY+V8oJQgs+4Ekkk89egrERJvD2nz20t9DAk6hRbm1WbeoGPlkzwjc9OeOgIrKs5NSn1GOfw/a3AhhIIKyF2QD72eMlQT3zWX1yUajur+Xr83+Njq/syM4c8Xbze36fK1z0zSLl5NV0+8miks7ogh7cybsKDgfNjnIya9OhfzUV9pUHsRyK4TwTp9xc6jb3upMxmtUYbQMKW+7+Q6/Wu+JwM56Vou58/jpLnUV0OA8T21/9s1K4uILdTMNiSg5RYh93Of48E9PetbxHqvh/wCHnhKNpLdFsG2ww20OGafI5PJyRjqTWl4vuPsvh26mazN6igboExucZHT3rwe48OXsvjXWNWn0mZ9NuHA04tmVMYBULjsBnjt+FaxStd7GlKP1hRUtEn+h2vizX9Bg/s3xN4f0i0n1y+uPJE0sR3qfKViMdA2Coz65964Q2174t8e6Xe28l7fXstwkdzN1S0VCPnB7KDlgOAT9a7v4ffDe4vrKG98ZOZjueS3sod0RRicb2IwclRjHp1rubx/DngWylmdLew8znyo1zJLj0A5P1NNTa+6xo6tOm3Tppyl0/r+kcHrnw0uLm8uVgvHgs0cOigfwtk4GOuOetdP4Y8N3GmaE017A1zfWMrz2Ku2SSI8ADuAe4H1rlX+IfiHxFqn2TSLW303RwGluZ5FMk6W6j94cg4BxkfKPTn15OfVPEOvW2qXduZ9K0aytftEJuLktcRq3+rbe2WMsm1gFG0AEc5xmo0pzsN+1ceWq7F3xnoWraZFZPc6TfvZXkUpuPssAmKTMvHGeA2Sueo6jkVJZ+CvEemX1ra2MMWnaSIVuL+4lwy7sfPl+ScdgCPoKu+BNb8RaXqCWM95M+ltOQskoeUPx/qIi3U54z6ZrpviXq9wNL0d7Tz4hNcMtzCc/NgjapTuM859qUqrS5N/1NL1VUUXbX8P69Wctcvp8d9cw2VzdSW6RR3F6zeUGeNXCZ5O7G4jhe3Q54q3rd/ZX2s/8IVYXMsWrarD9muLmCLmGNjuIyecFQc+x7cViCTTI7q3u9RWwlW0uIxFZMW+0OGZcsmB8wUngOcdcbetaEI0zwr8Sp71baafTtJtZbjUNR3Z/fuW+RST8xyyRKvHO5j0q+RNJq+39f1/w4qkmrrf+upiWfhCXT/F19f2+j6jHoGisfs8Dhg1+y/KAGxyHI3sccdBxgV1PgmYR3t/rviO0hs9ammYWUTktbWnyhW8tS20SseCQO3Xk1PovxBs/FmqWba3NNo1hao1ybYbpElYnCl5B2BzwRgk+3Gf4wvNNu9fgfRB58srEQiVC9uS2My7CRg8deP55HO75amhKpyn7somb4h+KMt9qsemG1sYYbQuz38qIzDCnDYwVXnA79RWR4c0XxBJpKarpytNd3crsl9qUWyKNOoMYfk7iT82P4e+c12MN3caNqcGm2Vhp832xhJfvcxLK10xzklSBtAIPGMcgDpWjcah4jGu3smo3SHRpIzhScI3yD5UjPAwR9ep7nC9oto7FqDhblSPLPEtpfxtbRz3dh4k1PUpSqWtk8jSIAOMlQDsO7GD6cdOPQfCOjala+ZZD4eaNZX9onnRzyTSNFI6gZwxyc5PGD65qlL4q8WaZEJvDlnoZjaBvOvZrUbxINx8tSpG4hVzyDnNbdj4w8Ual4EsZrE2d9qpnUzTPGYPOi352qgwBkYGc44PenOUpRTtoZz9o5tW/G3+TJtF8R38esXbfELTreCVcyQFWFwgIOAIkGQu0E7mPI7mr+s6dYeKNKP8AwjP9k2hgb7TLLcWEcsUiHd6jg55z71DLp1r4ovpbbzYLe+ZjK9oZg7Qlh8zqqnIztGSeDz61zHizRx4Wa6t9LuokhvNkc7RJ+9aNwVJWPOMgsMBSOeoORUxabSjo/wAPzFGCvo7S7dCzr3hq01m4gY6paXVmC0gis2VIo3kGJASvIyPfHXPSsNvBGojxBK9sojtrjiS7BRZU3H5j642gH0OcdeauaXM+kaLqd/qMV3I1mI4pHMJh8wAcFwR1BzuLdevfFT+EdKvtY8S+RctaF5CuopdW0xkcwhwGh3Kdo+Ur7YPAyatc/va3SN3LkWpy2v3zW9jF4fubiGSW2ffcQPZonmAj5ZY2CkK4HfjPf0rsNHs9Jl8NKs/izxE8jqAskoWU2znlyW/iiOPmQkg4yOea2vF+j6RqE0EF7plnqiQhgSrsJ4jnhC8ZBCHDDvz271zmu2lppT29tpml3jQ3ci2lrFYvkW83UCWM53dOv+yamLcrWerIcoz6W+4ihlurG7S3k8NwasBIsk8ulaiBHPySv7t1zgZBx7fjXTah8S7nQxBPqPhfUbhpIvJZ9OkWSISBjhXONyMBjr6964nUrbWfDsFrqvhAStYIxSaxlgzMnOCckbslgwPcEdwa6LwXvtdCnsLWK7XVEjkuZbe4LNI7eXxHkjPQKuPypVEn7z/r/IVSkprU2pvFkPjXT7/w/aXUmgX95bBUluosMXyCyHa3AxkHByM+3MPhjwBe+Fo7NkK6lIWeW6WNyFiZiCojV+SgwRyc965iK5lk0IfZWtdTnvoW2W1uGgNvMz4CMXPyq3PJGSQPUVq+Ho9ZsNRe3kZ7KayijN5bpMJRH5ib1UtgbSOcjpgAgkGiVOUItMj2cYv927eT/pGz4tOmPqqXeqWn2WaVhl0UkxsBgOx45Ocd+gqTxfY6SdKhleKS50gyLFeNbRNJNGSVIJ289cHd2pbXxlFezDTry3h1aIlYjK2Aqt33HHPsQMVzPi/xR4q8M+I54vD1jp9tbSDzWeG2LibBA+fPJIAwcEdT3rFKbkki4xlZRWjXno/1RZ1fxJrPhK7g0zw34Vhiso5d9wrzi6muHYDBZicg9MZOTx06VwusfEK+uJ11b7DJPcFz58UoKLBgg7MAHII7g56111xrdjqk0GqeI9Nm0/UpEVvt1pcOkEhHyktEeQegxzwB6Vyseo61e+PbnTre6ddPvHby0MauijbkEdBkY9RWyhz6u/ncuEeTW1n9/wDmaPgLwk+r+IkkuNNhtoYJTfsPMLyyo5yiMeVKDJAZQCQORmtXx1pOkDU2kuYWm1JZMRXqkgpgDCnBG8DIHcjpWlH42mtZLR9NtZ7+XToltrpUi3FFYkKS3BIJGcc4zVPxTqtn4sW0FnOtlf27NIyxNj7RGw3bgO/Ayfz7VU5Sk1zaIUFLnvbT1ucrplvfaprLaY94LbUZQ6RFnAjLKMEJ6FgCRnr07Vulr+11aza+jisZr60RTKm1UYZOMnoBndnoQTjpg0WGnRiGaaKV/JhuGvdgiCKkpXl/Xp2BwM5A5NbOveMdMjhtLCSziubSymh80AsXiWQ4wzd+pBz6jNLn1tFXRpPmutDhtR1JbdZ7zUIhezWkhVZ40T5wxDAqwyFOMAkdCDiobCbSbm6h1rRxNaMzHzl8wI6nHzZUHDA5+h9jxXa2/iV/E93e6T/wjNj5FuzQNbomcKCQcMANh+oIP61kaR4IiM0tjZQRxzCUSfZZblHdl/ug4yOMY+tZz5o3jt28jSnNXTnZK3dGFrd5qng3XbtreRRFdb9Pv4xhkaRc+VLj1GQwPUEe9ew+DPEGna1o2iazq0VpLqtuhia8eMK8cgwrY9yAD6YNeQahY3niS7upNZdLK60+4mW7tow3zOgXYQD22jGT6Z716n4YsLW50HTJNNtbK5sHO8+UvzQXHfg98VlaSa1/roZV4wlC8tG7a/LUi1H4YaJfa3d63o93cW+uyTveQtM4MDyNyQRjdtJzzk4z0I4rzjXLzUfDF7BB4j0y8sbTzjHJcmISwRs3IYEevOdp5AzgkYrS+InxD1jRtatxZiOCwViDIse9o2GRkZ4/ziu98OfE6xsdK0+LxXevBLc20Vx9uMRMEiyEhc4Hy9O4wPWqUnFqRz3qUoSjGz6+a0381Y4bW7JWvVxCsmyNUMKzKoiIJPcHOQRyPQUV6B4/8M6fqFzZ39rbSvJLGUdrJQyMq42njgcH8QPaitoV3Bct/wAEbRxFKa5m/wAzzTwz4OtdX0e88XeIJTqEFhp6NHp+CgeRVGHZ8nJ6k8DJPpwfRrzUJNWutQUAW8NuoSCNDkRgL1HTnrzRRWVZ+/byX5EU0uZvqv8AgGTqEVsltcXZt1a4jZYw+cHD/I3P+6x/HmsG+8UTeF7PTvsVrC8k128Idi3yRK2AvXnjjJ9BRRU0vfqKMtrf5ncop0nfv+hS+M94buDSJbLzLG5knmRpI2GCEk2k4ABy271xjjBzmuF1RpLm8ikdlSQsOUXbtOeox0oorixzvThft+p35VTjySfy+SbPa/hZrF3HYRWsshnXyw4eUksMnpmvUU5QZ59c0UV1Q2sfN5jFKrddSnrNyLPTJ5zEJBGpbbnGcCqejwAosoYrHcyFvKHRMgDA/wA96KKtnNHSndHDfHC81O1uPDdrpmrX1hHdtJHMsEpUPgpgnHJ4Yjr/ACrhrW4Mnju10eFdqzQyu0shMhBKnGBx0/X2oordwi4KVtbP80enhm4UE49X+ovjXW5fCV3/AMI3oKtDZWuZJmkbe94UUsfNOASDjoMAdhXXxRWOi+B4fF2p6dbatqP2cPAki7EhyoPHUnlj3+mKKKbiuRS6kzk0oRXW1/uLfwh1W48Y3x17VRGt1awGOGKEbYowxxlV5wcZ596muLh/GPxW1nQJ3ktLTR7RI42hILSO+GZ2JGehAwD2754KKzSTcl/W5yVpunVbjpZK33FfVNHsLW+hsjE07WcRuTNNtZyV6Bfl+T681hCD+0EETyOiOS7hT94ZLEfj0zRRWUdz1KLcqfM97HBeHtammvG2RxwWQtnmNnCoWPJcqo6Z465JJP04q9Bql43i6GKKdoYVuordUTsGKgsP9rBOM5A9KKK7VFOtZroOPwW/rqdZFbtbyanNFPM0dvctKhmIeYnGMNJgEgDAAxxz68QS2tjqFwNXu7QSakdsJnMr7io4x1xj2GPxoormqzfOOnFOCbJ/FerQWlla6Yml2ktm88e2OYFgrHI38YO75T0I6+lSahqdxAtrb2BS0iMIlAjQEBmfb3Hbk/lRRW0Ipwg31uZtKN7FCGWe21LSdOS5uIkjvDZ+fbvsmAkjG7a5DYUsu4rzzXV6tdahFez6fe38k+p6RIv2XVIkWKQxSl8JIuCrFfLHzADPoOclFXV1Sk97HO4pzSfb9TVm8cXVnDYyvZ20q3CFbhSMGUg4zn6HnINc7488Q2XhKy0+y0DRbXTbTWFn+2mx2wzMqJkKr7SF5brtPGcYJzRRXPQ1mk9gq0IRSaXf8DL8ZxnTPDnghYRA0Vzbs06NEMzZ2sdzD5s8IAQQeDnIOBquv/Ht57yyOsKB5A5R2YLjdkdCcn160UVvX0pwa8/zNqKUoXfd/mdVpuhadfRadqEMctqbe3WTy0k3Bju8znPvnn3NZ/jTxIfD+i2PiDRbG3hvdW1SHTLgyEv+72yHcvQBsjrjoT9aKK4uZvfscL+Oz7pfI4DxJqQbxEbdbaN4p0jM8dwTIkpaNSQRwcdhg568811Ggadb2tldaJDFGIRaNI3HyuCCQpHUgBgOWzhRzRRXfV0pwitmrnXU0WhxHh0WNjLo1xb2svkzwecLd7gsqEOoGOOeWJ59B9a1I9MGreD9F1e9vtRkurnUms5ka4zE+JZSH2EYBARQAOOOc0UVc5O3P11/UmTs4+pN4hsLdU03SXDvbSB0U7sFHTJDjHGeenA/Diuo+HuiQeJfBZkuZJYjeRjfsxwcFQwOOoAoorCWtJN7/wDDk4ipKFNuL7DLrwdBo9rJPYahfW1wkSiWS2lMXnBsqQwHHqfbPGK5PUbEQzx21uUjTyHfATjCgYXrnGT680UVFNuc1zGlCpJwk3uaOi391oHhe5mgeN7hDNMTswpZMgfL2HHTPeq2qRSP4q1izmkS5t3itjP9oiBaUSR8gFdoX7gPA64OKKK0k2ud9dfzHZc6Xe52sOos3gXWb6CJLW8sYWUS23yFwqZGevNeV6DmO9WSLCO/kal5mWMgYAttznGMk9AKKKyotrm9GXTik5rzL+tO1x8SNYu5XkMqy7sBsKyOVjKEY5xuUg/7PvxrW3iG48P+MtJ8M2cMB068t5L7cQRJDMqS4ZG6DIQAggjmiiufD+8lfu1+I8f7lNcvaH6HE+O/E+q31vczxXk1viMGRUKgOxUHPyqPce4p/ivUn1r4ZaJrcUMNnPpxOlyxRxr5dyoUNkgAYByfl5AJyMZOSiuiorJr+7f53Zy1m07rpH/M6Lwn8VoPDGnx6d/wjdvMphinDQ3Hkj5wTgrsYZ9xgH0ooorWlCMo3fd/mcteKdRtn//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low-power photomicrograph of an atypical pulmonary carcinoid tumor shows focal necrosis (arrows) within a nest of tumor cells.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey Myers, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_11_11448=[""].join("\n");
var outline_f11_11_11448=null;
var title_f11_11_11449="Postmenopausal hormone therapy and the risk of breast cancer";
var content_f11_11_11449=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Postmenopausal hormone therapy and the risk of breast cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/11/11449/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/11/11449/contributors\">",
"     Wendy Y Chen, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/11/11449/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/11/11449/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/11/11449/contributors\">",
"     William F Crowley, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/11/11449/contributors\">",
"     Suzanne W Fletcher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/11/11449/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/11/11449/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/11/11449/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the greatest concerns of women who are considering postmenopausal hormone therapy is the relationship between hormone use and breast cancer. The results of the Women's Health Initiative (WHI) trial of combined estrogen-progestin, a large randomized, controlled trial, are consistent with the increased risk of breast cancer seen in many observational studies of postmenopausal hormone therapy. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Women's Health Initiative'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Observational studies of postmenopausal hormone therapy and breast cancer and the results from the WHI will be reviewed here. The relationship between endogenous hormones and breast cancer and a general discussion of the risks and benefits of hormone therapy (HT) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28954?source=see_link\">",
"     \"Factors that modify breast cancer risk in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ENDOGENOUS HORMONES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Support for the role of HT in breast cancer is derived from studies that suggest that prolonged exposure to and higher concentrations of endogenous estrogen increase the risk of breast cancer. These risk factors include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reproductive factors, including age at menarche, age at first live birth, age at menopause, and possibly parity and breast-feeding.",
"     </li>",
"     <li>",
"      Higher serum estrogen concentrations in postmenopausal women. The association is less clear in premenopausal women.",
"     </li>",
"     <li>",
"      Surrogate markers for estrogen exposure, such as bone density and the density of breast tissue on mammography. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41754?source=see_link&amp;anchor=H6#H6\">",
"       \"Screening for breast cancer\", section on 'Estrogen exposure'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28954?source=see_link&amp;anchor=H1067591470#H1067591470\">",
"       \"Factors that modify breast cancer risk in women\", section on 'Reproductive factors'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28954?source=see_link\">",
"       \"Factors that modify breast cancer risk in women\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Obesity and weight gain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Higher",
"    <span class=\"nowrap\">",
"     weight/BMI",
"    </span>",
"    and postmenopausal weight gain have been associated with a higher risk of postmenopausal breast cancer in multiple studies. In premenopausal obese women, the majority of prospective cohort studies have found either no strong association or an inverse association between obesity and premenopausal breast cancer. This topic is reviewed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28954?source=see_link\">",
"     \"Factors that modify breast cancer risk in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28954?source=see_link&amp;anchor=H9303004#H9303004\">",
"     \"Factors that modify breast cancer risk in women\", section on 'Weight'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EXOGENOUS HORMONE THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H150019706\">",
"    <span class=\"h2\">",
"     Epidemiologic data",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple observational studies have shown an increased risk of breast cancer with postmenopausal hormone therapy (HT), which includes unopposed estrogen therapy (ET) and combined estrogen-progestin therapy (EPT) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Furthermore, a reanalysis of original data from 51 epidemiologic studies comprising 52,705 women with and 108,411 women without breast cancer found that for each year a woman uses postmenopausal hormones, her risk of breast cancer increases by 2.3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of potential biases in epidemiologic studies may cause either underestimation or overestimation of the risk of breast cancer associated with HT. Biases that may lead to an underestimation of risk include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women with menopausal symptoms appear to have a lower serum estrogen concentration at menopause than those without symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/3\">",
"       3",
"      </a>",
"      ]. In addition, women who choose to take HT tend to have a lower bone density than women who choose not to take it [",
"      <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/4\">",
"       4",
"      </a>",
"      ]. Thus, women who take HT are likely to be at lower risk of breast cancer at the time of menopause than women who do not take hormones.",
"     </li>",
"     <li>",
"      Women who have taken HT for longer durations in epidemiologic studies tend to have had earlier menopause (and therefore a lower risk of breast cancer) than those taking hormones for shorter durations [",
"      <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Biases that may lead to an overestimation of risk include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women who take HT tend to be of higher socioeconomic status and consume more alcohol, factors that are associated with an increased risk of breast cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Women who take HT may have higher rates of mammography and therefore a higher reported incidence of breast cancer.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The last factors are more easily controlled for in epidemiologic studies, suggesting that, on balance, the adverse effects of HT on breast cancer risk are likely to be underestimated in studies that compare users with nonusers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Women's Health Initiative",
"    </span>",
"    &nbsp;&mdash;&nbsp;The limitations of epidemiologic studies were overcome in the randomized, placebo-controlled Women's Health Initiative trial (WHI) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/7\">",
"     7",
"    </a>",
"    ]. The overall results of this trial, which was stopped early because of excess breast cancer risk, adverse cardiovascular effects, and no evidence of overall health benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/7\">",
"     7",
"    </a>",
"    ], are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\"",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the WHI combination estrogen-progestin (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/23/35184?source=see_link\">",
"     conjugated equine estrogens",
"    </a>",
"    0.625 mg and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    2.5 mg) arm, the risk of invasive breast cancer was significantly increased with combined hormone therapy at an average follow-up of 5.6 years (HR 1.2) compared with placebo (",
"    <a class=\"graphic graphic_figure graphicRef69819 \" href=\"UTD.htm?17/26/17838\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/8\">",
"     8",
"    </a>",
"    ]. The increase in risk was first seen in year three in women who had previously used menopausal hormones, but not until year four in women with no previous use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H150019616\">",
"    <span class=\"h4\">",
"     Post-WHI rates",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a subsequent report of health risks and benefits after stopping combination therapy, a nonsignificant increase in breast cancer risk was still observed after a mean follow-up of 2.4 years (mean HR over the follow-up period = 1.27, 95% CI 0.91-1.78) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/9\">",
"     9",
"    </a>",
"    ]. The clinical significance of this observation is unclear, as multiple epidemiologic studies reported no excess breast cancer risk for past use of postmenopausal hormone therapy (HT), although most of these studies did not separately evaluate unopposed estrogen (ET) and combined estrogen and progestin (EPT) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a more detailed analysis of breast cancer risk in the post-intervention phase of the WHI EPT versus placebo trial and the observational cohort (postmenopausal HT users versus nonusers), there was a rapid decline in breast cancer incidence after discontinuation of HT [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/10\">",
"     10",
"    </a>",
"    ]. As noted above, the average HR for the postintervention period was 1.27 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/9\">",
"     9",
"    </a>",
"    ], but the HR was close to 1.7 in the final year of treatment, followed by a decline to nearly 1.0 in the postintervention phase. With postintervention follow-up of only about 2.5 years, the true time course of cancer risk after stopping postmenopausal hormone therapy remains unclear.",
"   </p>",
"   <p>",
"    Changes in mammography utilization were unlikely to have contributed to the decrease in breast cancer incidence in either the clinical trial or observational study, since post-intervention mammography rates were similar in both the postmenopausal hormone therapy and control arms of the randomized trial, and mammography rates did not fluctuate over time in the observational cohort.",
"   </p>",
"   <p>",
"    The decline in population breast cancer rates is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28954?source=see_link\">",
"     \"Factors that modify breast cancer risk in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Unopposed estrogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;After a mean follow-up of 7.1 years, the risk of breast cancer was slightly decreased in the unopposed estrogen group when compared with the placebo group (0.80, 95% CI 0.62-1.04) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Abnormal mammograms were more common in women taking ET. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Abnormal mammography'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The original trial was followed by a postintervention study that included 78 percent of the participants followed for a median of 4.7 years after discontinuation of the intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/13\">",
"     13",
"    </a>",
"    ]",
"    <em>",
"     .",
"    </em>",
"    Use of unopposed estrogen for a median of 5.9 years (total median follow-up 11.8 years) was associated with a significant reduction in the incidence of invasive breast cancer when compared with placebo (151 cases, 0.27 percent per year versus 199 cases, 0.35 percent per year; HR 0.77, 95% CI 0.62-0.95). There was no difference between the intervention and postintervention phase. In addition, there were fewer breast cancer-related deaths in the unopposed estrogen group (six deaths [0.009 percent per year]) compared with placebo (16 deaths [0.024 percent per year]). These data do not suggest that estrogen should be used for breast cancer risk reduction, but they provide reassurance for postmenopausal women post-hysterectomy who take estrogen for symptoms.",
"   </p>",
"   <p>",
"    The WHI results differ from most [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/1,2\">",
"     1,2",
"    </a>",
"    ] but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/14\">",
"     14",
"    </a>",
"    ] observational studies. The reasons for the difference between the WHI trial and most epidemiologic data are unclear and require further study. Some have hypothesized that this may partially be explained by differential breast cancer risk according to time since menopause, but this has not been definitively proven yet (see",
"    <a class=\"local\" href=\"#H150021291\">",
"     'Timing of hormone therapy'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H150020278\">",
"    <span class=\"h3\">",
"     Absolute risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;From the woman's perspective, the critical issue is the",
"    <strong>",
"     absolute or attributable risk",
"    </strong>",
"    of developing breast cancer. As noted above in the WHI, there were eight excess cases per 10,000 person-years at an average of 5.2 years [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H150019838\">",
"    <span class=\"h3\">",
"     Mammographic density",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from a subset of the Women's Health Initiative (WHI) trial showed that mammographic density increased with both EPT and ET. For EPT, breast density increased 6 percent at year one in women compared with a 0.91 percent decrease in the placebo group [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/15\">",
"     15",
"    </a>",
"    ]. At two years, the mean changes persisted, but were slightly attenuated, with an absolute increase of 4.9 percent in the EPT group and a decrease of 0.8 percent in the placebo group.",
"   </p>",
"   <p>",
"    In the unopposed estrogen arm, estrogen use was associated with a smaller but still significant increase in breast density compared with placebo (absolute difference 2.9 percent at two years) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41754?source=see_link\">",
"     \"Screening for breast cancer\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H4\">",
"     'Exogenous hormone therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Abnormal mammography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both EPT and ET affect the likelihood of an abnormal mammogram, but the effects were stronger with EPT. After the first year, more women in the EPT group had an abnormal mammogram (defined as recommendations for short-term follow-up [the majority of cases], suspicious abnormality, or highly suggestive of malignancy) than women in the placebo group (9.4 versus 5.4 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/8\">",
"     8",
"    </a>",
"    ]. By the end of the follow-up period, EPT, when compared with placebo, significantly increased both the cumulative frequency of abnormal mammograms (35 versus 23 percent, respectively) and the need for breast biopsies (10 versus 6.1 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, the use of unopposed estrogen (ET), did not increase the rate of abnormal mammograms, but increased the number of mammograms requiring short-interval follow-up (cumulative rate by the end of the trial 39.2 versus 29.6 percent for ET versus placebo) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/18\">",
"     18",
"    </a>",
"    ]. Similar to combination therapy, breast biopsies were more frequent in the unopposed estrogen group (12.5 versus 10.7 percent).",
"   </p>",
"   <p>",
"    Stopping hormone therapy (HT, either EPT or ET) short-term does not reduce the rate of abnormal mammograms. In a randomized trial of 1704 postmenopausal women taking HT who were due for an annual mammogram, suspending HT for one to two months reduced breast density slightly, but did not significantly reduce mammography recall rates [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Duration of use",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most studies, the risk of breast cancer does not appear to be increased in women who receive combined estrogen-progestin therapy (EPT) for less than four or five years, but then increases with longer duration of use [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/1,14\">",
"     1,14",
"    </a>",
"    ]. The analysis of epidemiologic studies cited above found that the relative risk of developing cancer was 1.35 for women who were current hormone users and had taken hormones for five years or longer compared with never users (",
"    <a class=\"graphic graphic_figure graphicRef63013 \" href=\"UTD.htm?13/27/13759\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/1\">",
"     1",
"    </a>",
"    ]. A similar time frame was noted in the WHI (",
"    <a class=\"graphic graphic_figure graphicRef69819 \" href=\"UTD.htm?17/26/17838\">",
"     figure 1",
"    </a>",
"    ), although the increase in risk was seen after only three years in women who had previously used menopausal hormones [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For unopposed estrogen (ET), there did not appear to be increased risk of breast cancer in the WHI. However, in an updated report from the Nurses' Health Study of 28,835 women who had undergone hysterectomy, long-term, but not shorter-term, use of unopposed estrogen was associated with a statistically significant increase in breast cancer risk (RR for current use &gt;20 years = 1.42, 95% CI 1.13-1.77) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/20\">",
"     20",
"    </a>",
"    ]. The risk of",
"    <span class=\"nowrap\">",
"     ER+/PR+",
"    </span>",
"    cancers became statistically significant after 15 years of unopposed use (RR 1.48, 95% CI 1.05-2.07). Similar results were noted in another prospective cohort study [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/21\">",
"     21",
"    </a>",
"    ]. Updated results from the Million Women Study (MWS) also reported an increased breast cancer risk with longer duration of ET as well, although it should be noted that the MWS reported an increased risk of breast cancer with ET use less than five years, which is in contrast to the WHI and many other studies.",
"   </p>",
"   <p>",
"    For past users, duration of use does not appear to be strongly related to breast cancer risk. In the combined analysis of epidemiologic studies, women who had stopped postmenopausal hormone therapy more than five years previously were not at increased risk compared with never users, regardless of the duration of previous use [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/1\">",
"     1",
"    </a>",
"    ]. However, there have not been enough data on long-term past users; there may still be a risk associated with past use if the duration was long enough.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H150020558\">",
"    <span class=\"h2\">",
"     Effect of progestins",
"    </span>",
"    &nbsp;&mdash;&nbsp;The randomized WHI study showed that progestins added to breast cancer risk compared with estrogen alone. Many of the earlier epidemiologic studies have grouped together estrogen therapy only (ET) and combined estrogen-progestin (EPT) users. The majority of studies that have distinguished between these groups have reported a greater risk of breast cancer in those receiving EPT compared with ET [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/2,14,22-26\">",
"     2,14,22-26",
"    </a>",
"    ]. In the combined epidemiologic analysis, treatment with EPT was associated with a higher risk of breast cancer than ET (relative risk 1.53 and 1.34, respectively), although this difference was not statistically significant [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the Million Women Study of over one million women ages 50 to 64 years in the UK [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/2\">",
"     2",
"    </a>",
"    ], current use of postmenopausal hormone therapy was associated with an increased risk of breast cancer (RR 1.30, 95% CI 1.2-1.4; and RR 2.0, 95% CI 1.88-2.12 for ET and EPT, respectively). There has also been a suggestion that progestin given continuously with estrogen may be associated with higher risk than regimens in which the progestin is given in a cyclic fashion [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/27,28\">",
"     27,28",
"    </a>",
"    ], but this has not been reported in all studies [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/2,23\">",
"     2,23",
"    </a>",
"    ]. The WHI used the continuous schedule.",
"   </p>",
"   <p>",
"    Progestins may cause an increase in cell division in mammary tissue, thereby leading to an accumulation of DNA errors that eventually result in breast cancer or in a greater proliferation of malignant cells [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/5\">",
"     5",
"    </a>",
"    ]. Support for this hypothesis is derived from the observation that the proliferative activity of the breast in premenopausal women is highest during the luteal phase of the menstrual cycle, a time of increasing progesterone secretion (",
"    <a class=\"graphic graphic_figure graphicRef72415 \" href=\"UTD.htm?34/26/35246\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/29\">",
"     29",
"    </a>",
"    ]. In addition, women treated with EPT have greater increases in mammographic density than those taking ET [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/30\">",
"     30",
"    </a>",
"    ] and more cell proliferation in benign breast biopsies [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/31\">",
"     31",
"    </a>",
"    ]. In the latter study, breast proliferation was localized to the terminal duct-lobular unit, an area where most breast cancers develop. However, in vivo [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/32\">",
"     32",
"    </a>",
"    ] and in vitro studies [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/33\">",
"     33",
"    </a>",
"    ] have found differing effects of progesterone on breast cell proliferation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H150020565\">",
"    <span class=\"h3\">",
"     Type of progestin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The type of progestin may also affect breast cancer risk. In a prospective cohort study of approximately 80,000 women, postmenopausal hormone regimens containing estrogen plus a synthetic progestin were associated with an excess breast cancer risk, while regimens containing estrogen plus natural progesterone were not [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/34\">",
"     34",
"    </a>",
"    ]. A synthetic progestin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    , was used in the WHI trial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16218?source=see_link&amp;anchor=H17#H17\">",
"     \"Preparations for postmenopausal hormone therapy\", section on 'Progestin preparations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H150020086\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The impact of hormone therapy on breast cancer prognosis and mortality is unclear. Data from the Women&rsquo;s Health Initiative (WHI) suggest that breast cancer in women taking estrogen-progestin therapy (EPT) is more likely to be diagnosed at an advanced stage and associated with greater mortality than in women not taking hormone therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/8,35\">",
"     8,35",
"    </a>",
"    ]. In a 2010 follow-up analysis of women taking EPT for an average of 5.6 years with subsequent mean follow-up of 7.9 years, the incidence of breast cancer was increased to the same degree as previously reported [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/8\">",
"     8",
"    </a>",
"    ] when compared with women in the placebo group (HR 1.25). The breast cancers diagnosed in the EPT group were similar in grade and histology to those in the placebo group, but were more likely to be node-positive (81 cases [24 percent] versus 43 cases [16 percent], in the hormone and placebo groups, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/35\">",
"     35",
"    </a>",
"    ]. In addition, there were more breast cancer-related deaths in the EPT group (25 deaths [0.03 percent per year] versus 12 deaths [0.01 percent per year]), but with such a small number of events, risk estimates are imprecise. This analysis does not provide insight into the important question of whether hormone therapy-associated breast cancers have a different prognosis or natural history when compared to cancers that develop in women who never took hormone therapy. To address this question, the women with breast cancer in both groups would need to be followed long-term to look at disease-free survival and overall survival.",
"    <br/>",
"   </p>",
"   <p>",
"    In contrast, epidemiologic studies have suggested that breast cancer in women taking estrogen has a relatively good prognosis and improved survival when compared with breast cancer that develops in women not taking estrogen [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/36-40\">",
"     36-40",
"    </a>",
"    ]. In a study of over 1000 postmenopausal breast cancer patients followed for eight years, women who had used hormone therapy before diagnosis were more likely to have smaller tumors (&lt;1 cm) that were node negative, and they had a lower risk of death when compared with those who had not used hormone therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/38\">",
"     38",
"    </a>",
"    ]. Similar results were noted in a second report of 292 postmenopausal breast cancer patients; use of hormone therapy for more than 10 years was associated with improved prognosis and survival [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, the effect of postmenopausal hormone therapy on breast cancer prognosis remains unclear. While observational studies suggest that breast cancer prognosis is better in HT users, the WHI does not. A limitation of the WHI data is the small number of breast cancer cases (too few to look at breast cancer-specific mortality).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H150021291\">",
"    <span class=\"h2\">",
"     Timing of hormone therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether the benefits and risk of hormone therapy (HT) vary with age of initiation relative to women&rsquo;s age at menopause is controversial. For cardiovascular disease, some data suggest that women who start closer to the time of natural menopause may derive more benefit than those who start later. However, limited data on breast cancer suggest that women who start hormone therapy around the time of menopause may be at greater risk of developing breast cancer than those who start later after menopause. For example, a prospective cohort study that included over 7000 cases of breast cancer in current users of hormone therapy observed that the risk of breast cancer was higher in women who started hormone therapy before or soon after menopause compared with women who started more than five years after menopause [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/41\">",
"     41",
"    </a>",
"    ]. This pattern was true for both combined estrogen-progestin users and unopposed estrogen users (RR 2.0 and 1.53 for combined hormone therapy users who started &le; or &ge; five years after menopause, respectively; RR 1.43 and 1.05 for unopposed estrogen users starting &le; or &ge; five years after menopause, respectively).",
"   </p>",
"   <p>",
"    Of note, the overall risks associated with HT in this study were generally higher than other studies observed. For example, these investigators report an increase in breast cancer risk with short-term unopposed estrogen use, which other studies have generally not observed. The WHI also observed greater breast cancer risk with initiation of estrogen-progestin therapy (EPT) close to menopause [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/35\">",
"     35",
"    </a>",
"    ]. However, all of the studies that have evaluated time since menopause to date have not been able to fully adjust for the fact that women who start closer to age at menopause generally have longer durations of use, or for differences in screening between HT users and nonusers. Given the overall increased risk of breast cancer associated with EPT use in the WHI, it is not clear if starting it later after menopause would be &ldquo;safer,&rdquo; so all women are counseled to consider breast cancer risk before initiating therapy. As noted above, no increased risk of breast cancer was seen in the WHI with unopposed estrogen use. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Unopposed estrogen'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H150020341\">",
"    <span class=\"h1\">",
"     OTHER ISSUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H615546153\">",
"    <span class=\"h2\">",
"     Women with a family history of cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overall, the available epidemiologic evidence suggests that the magnitude of risk conferred by postmenopausal hormone therapy in women with and without a family history of breast cancer is similar [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. However, women with a positive family history already have a higher baseline risk than women without a family history and may also be more concerned about behaviors that would modify their breast cancer risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H150020386\">",
"    <span class=\"h2\">",
"     Effect of testosterone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Addition of exogenous testosterone therapy to estrogen may also contribute to breast cancer risk. In the Nurses' Health Study, the risk of breast cancer was 2.5-fold higher in current users of combined estrogen-testosterone users compared with nonusers (RR 2.48, 95% CI 1.53-4.04) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/44\">",
"     44",
"    </a>",
"    ]. This risk also appeared to be higher when compared with unopposed estrogen users. However, it is important to realize that these data are limited since only a few patients were evaluated (29 women used estrogen and testosterone, while three used testosterone alone among the breast cancer cases).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H615546104\">",
"    <span class=\"h2\">",
"     Effect of alcohol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postmenopausal women on postmenopausal hormone therapy (HT) who also drink alcohol may be at considerably higher risk for breast cancer. As an example, in the prospective Nurses' Health Study, the risk of breast cancer was significantly increased in women who took HT for more than five years but did not consume alcohol (RR 1.32) and for those who drank at least 1.5 to 2 drinks per day but did not take HT (RR 1.28) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/45\">",
"     45",
"    </a>",
"    ]. For women who used HT for more than five years",
"    <strong>",
"     and",
"    </strong>",
"    drank at least 1.5 to 2 drinks daily, the relative risk was even higher at 1.99. Thus, postmenopausal women on HT should be cautioned about the added risk of alcohol. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/61/38874?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of the risks and benefits of alcohol consumption\", section on 'Breast cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H150020322\">",
"    <span class=\"h2\">",
"     Women with premature ovarian failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from the WHI should not be extrapolated to women with premature ovarian failure (primary ovarian insufficiency; menopause before age 40 years) in whom postmenopausal hormone therapy is generally initiated at a much younger age. Issues in these women are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/63/37880?source=see_link\">",
"     \"Management of spontaneous primary ovarian insufficiency (premature ovarian failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Effect of race on risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;The increase in risk of breast cancer associated with postmenopausal hormone therapy appears to be similar in black and white women as illustrated by data from the WHI and the larger Black Women's Health Study [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/8,46\">",
"     8,46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Personal history of breast cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traditionally, a personal history of breast cancer has been considered a contraindication to the use of postmenopausal hormone therapy. However, management of menopausal symptoms is an important clinical problem, particularly in premenopausal women who develop ovarian failure secondary to adjuvant chemotherapy. While most observational studies had reported no increase in the risk of recurrence with estrogen therapy, randomized clinical trial data suggest that estrogen therapy may be associated with excessive risk. We recommend that estrogen therapy not be given to women with a history of breast cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Observational data",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anecdotal case series, multiple observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/47-52\">",
"     47-52",
"    </a>",
"    ], a systematic review of four studies [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/53\">",
"     53",
"    </a>",
"    ], and a subsequent large case-control study [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/54\">",
"     54",
"    </a>",
"    ] suggested that postmenopausal hormone therapy in women with adequately treated breast cancer did not increase the risk of recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/47-53\">",
"     47-53",
"    </a>",
"    ], and may even be beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/54\">",
"     54",
"    </a>",
"    ], but there was considerable selection bias regarding which breast cancer survivors took postmenopausal hormone therapy.",
"   </p>",
"   <p>",
"    Given the results of a randomized clinical trial discussed below, it is likely that these observational studies still did not account completely for residual confounding with hormone users being overall healthier and at lower risk of recurrence than nonusers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Clinical trial data",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two larger randomized clinical trials have been conducted among breast cancer survivors and the results are conflicting. The larger, more powerful study was the HABITS trial with follow-up data on 442 women randomized to either postmenopausal hormone therapy (the majority used estradiol",
"    <span class=\"nowrap\">",
"     +/-",
"    </span>",
"    norethisterone acetate depending upon the presence of a uterus) versus non-hormonal symptom management. The HABITS trial was stopped early due to an increase in breast cancer events in the HT arm.",
"   </p>",
"   <p>",
"    With median follow-up of four years, new breast cancer events occurred almost twice as often in the hormone group compared with the non-hormone group (39 of 221 versus 17 of 221; HR 2.4) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/55\">",
"     55",
"    </a>",
"    ]. The cumulative incidence of a breast cancer event in the hormone and non-hormone groups at five years was estimated at 22 and 8 percent, respectively.",
"   </p>",
"   <p>",
"    A similar trial in Stockholm was started at the same time as HABITS and also terminated in December 2003, based upon the results of the HABITS trial as well as anticipated difficulties in recruitment. Unlike the HABITS trial, after 10.8 years of follow-up, there was no significant difference in new breast cancer events overall with 60 in the hormone therapy group and 48 in the controls (HR 1.3; 95% CI 0.9-1.9), but there was an increased risk of contralateral breast cancer with HT (RR 3.6) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Possible explanations include the use of different progestins (norethisterone acetate in HABITS,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    in Stockholm study), the small number of events in both trials, and a lower-risk patient population with greater use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    in the Stockholm trial compared to HABITS.",
"   </p>",
"   <p>",
"    Although the data are not entirely consistent, the increase in risk observed in the HABITS trial is of great concern [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/57\">",
"     57",
"    </a>",
"    ]. Thus, we agree with expert guidelines that recommend the use of non-estrogen therapies for controlling symptoms before considering estrogen therapy in these women [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/58\">",
"     58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/53/25434?source=see_link&amp;anchor=H12#H12\">",
"     \"Menopausal hot flashes\", section on 'Other therapies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/27/40370?source=see_link\">",
"       \"Patient information: Menopause (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/59/26546?source=see_link\">",
"       \"Patient information: Menopause (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Much of the available evidence supports a causal relationship between endogenous estrogens, exogenous hormone therapy, and breast cancer, with the important exception of the WHI trial of unopposed estrogen. Long-term use has been associated with the highest risk.",
"     </li>",
"     <li>",
"      On the other hand, short-term use of combined estrogen-progestin therapy (less than three years in previous users of estrogen [",
"      <a class=\"abstract\" href=\"UTD.htm?11/11/11449/abstract/8\">",
"       8",
"      </a>",
"      ]) appears not to increase the risk of breast cancer significantly, although it may make mammographic detection more difficult. With longer follow-up, the WHI reported a slightly reduced breast cancer risk in the unopposed estrogen arm (median duration of use 5.9 years), but the observational studies suggest increased risk with longer term use. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Unopposed estrogen'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Duration of use'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some data suggest that starting hormone therapy soon after menopause (less than five years) may be associated with greater breast cancer risk than starting more than five years after menopause. (See",
"      <a class=\"local\" href=\"#H150021291\">",
"       'Timing of hormone therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Data are conflicting on the prognosis of breast cancers that develop in women who take hormone therapy. (See",
"      <a class=\"local\" href=\"#H150020086\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The effects of other types of estrogens, different progestins, or lower hormone doses on breast cancer risk are currently unknown, although most experts now recommend using the lowest hormone doses possible that relieve menopausal symptoms and minimize treatment duration as much as possible. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/42/40615?source=see_link\">",
"       \"Treatment of menopausal symptoms with hormone therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The use of hormone therapy for menopausal symptoms, including hot flashes, is reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/53/25434?source=see_link\">",
"       \"Menopausal hot flashes\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/42/40615?source=see_link\">",
"       \"Treatment of menopausal symptoms with hormone therapy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11449/abstract/1\">",
"      Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1997; 350:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11449/abstract/2\">",
"      Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11449/abstract/3\">",
"      Erlik Y, Meldrum DR, Judd HL. Estrogen levels in postmenopausal women with hot flashes. Obstet Gynecol 1982; 59:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11449/abstract/4\">",
"      Bauer DC, Browner WS, Cauley JA, et al. Factors associated with appendicular bone mass in older women. The Study of Osteoporotic Fractures Research Group. Ann Intern Med 1993; 118:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11449/abstract/5\">",
"      Colditz GA. Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J Natl Cancer Inst 1998; 90:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11449/abstract/6\">",
"      Matthews KA, Kuller LH, Wing RR, et al. Prior to use of estrogen replacement therapy, are users healthier than nonusers? Am J Epidemiol 1996; 143:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11449/abstract/7\">",
"      Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11449/abstract/8\">",
"      Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003; 289:3243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11449/abstract/9\">",
"      Heiss G, Wallace R, Anderson GL, et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 2008; 299:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11449/abstract/10\">",
"      Chlebowski RT, Kuller LH, Prentice RL, et al. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 2009; 360:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11449/abstract/11\">",
"      Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006; 295:1647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11449/abstract/12\">",
"      Prentice RL, Chlebowski RT, Stefanick ML, et al. Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. Am J Epidemiol 2008; 167:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11449/abstract/13\">",
"      Anderson GL, Chlebowski RT, Aragaki AK, et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol 2012; 13:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11449/abstract/14\">",
"      Li CI, Malone KE, Porter PL, et al. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 2003; 289:3254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11449/abstract/15\">",
"      McTiernan A, Martin CF, Peck JD, et al. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial. J Natl Cancer Inst 2005; 97:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11449/abstract/16\">",
"      McTiernan A, Chlebowski RT, Martin C, et al. Conjugated equine estrogen influence on mammographic density in postmenopausal women in a substudy of the women's health initiative randomized trial. J Clin Oncol 2009; 27:6135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11449/abstract/17\">",
"      Chlebowski RT, Anderson G, Pettinger M, et al. Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy. Arch Intern Med 2008; 168:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11449/abstract/18\">",
"      Chlebowski RT, Anderson G, Manson JE, et al. Estrogen alone in postmenopausal women and breast cancer detection by means of mammography and breast biopsy. J Clin Oncol 2010; 28:2690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11449/abstract/19\">",
"      Buist DS, Anderson ML, Reed SD, et al. Short-term hormone therapy suspension and mammography recall: a randomized trial. Ann Intern Med 2009; 150:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11449/abstract/20\">",
"      Chen WY, Manson JE, Hankinson SE, et al. Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Intern Med 2006; 166:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11449/abstract/21\">",
"      Zhang SM, Manson JE, Rexrode KM, et al. Use of oral conjugated estrogen alone and risk of breast cancer. Am J Epidemiol 2007; 165:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11449/abstract/22\">",
"      Schairer C, Lubin J, Troisi R, et al. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000; 283:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11449/abstract/23\">",
"      Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000; 92:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11449/abstract/24\">",
"      Olsson HL, Ingvar C, Bladstr&ouml;m A. Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. Cancer 2003; 97:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11449/abstract/25\">",
"      Stahlberg C, Pedersen AT, Lynge E, et al. Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe. Int J Cancer 2004; 109:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11449/abstract/26\">",
"      Fournier A, Berrino F, Riboli E, et al. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 2005; 114:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11449/abstract/27\">",
"      Tj&oslash;nneland A, Christensen J, Thomsen BL, et al. Hormone replacement therapy in relation to breast carcinoma incidence rate ratios: a prospective Danish cohort study. Cancer 2004; 100:2328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11449/abstract/28\">",
"      Bakken K, Fournier A, Lund E, et al. Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2011; 128:144.",
"     </a>",
"    </li>",
"    <li>",
"     Clarke C, Sutherland R. Progestin regulation of cellular proliferation: Update 1993. In: Endocrine Reviews, Horwitz K (Ed), Endocrine Society, Bethesda, MD 1993. p.132.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11449/abstract/30\">",
"      Greendale GA, Reboussin BA, Sie A, et al. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators. Ann Intern Med 1999; 130:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11449/abstract/31\">",
"      Hofseth LJ, Raafat AM, Osuch JR, et al. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 1999; 84:4559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11449/abstract/32\">",
"      Cline JM, Soderqvist G, von Schoultz E, et al. Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques. Am J Obstet Gynecol 1996; 174:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11449/abstract/33\">",
"      Wren, B. Hormonal replacement therapy and breast cancer. Eur Menopause J 1995; 2:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11449/abstract/34\">",
"      Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008; 107:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11449/abstract/35\">",
"      Chlebowski RT, Anderson GL, Gass M, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 2010; 304:1684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11449/abstract/36\">",
"      Nanda K, Bastian LA, Schulz K. Hormone replacement therapy and the risk of death from breast cancer: a systematic review. Am J Obstet Gynecol 2002; 186:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11449/abstract/37\">",
"      Brewster AM, Do KA, Thompson PA, et al. Relationship between epidemiologic risk factors and breast cancer recurrence. J Clin Oncol 2007; 25:4438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11449/abstract/38\">",
"      Sener SF, Winchester DJ, Winchester DP, et al. The effects of hormone replacement therapy on postmenopausal breast cancer biology and survival. Am J Surg 2009; 197:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11449/abstract/39\">",
"      Christante D, Pommier S, Garreau J, et al. Improved breast cancer survival among hormone replacement therapy users is durable after 5 years of additional follow-up. Am J Surg 2008; 196:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11449/abstract/40\">",
"      Slanger TE, Chang-Claude JC, Obi N, et al. Menopausal hormone therapy and risk of clinical breast cancer subtypes. Cancer Epidemiol Biomarkers Prev 2009; 18:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11449/abstract/41\">",
"      Beral V, Reeves G, Bull D, et al. Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst 2011; 103:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11449/abstract/42\">",
"      Sellers TA, Mink PJ, Cerhan JR, et al. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. Ann Intern Med 1997; 127:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11449/abstract/43\">",
"      Colditz GA, Rosner BA, Speizer FE. Risk factors for breast cancer according to family history of breast cancer. For the Nurses' Health Study Research Group. J Natl Cancer Inst 1996; 88:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11449/abstract/44\">",
"      Tamimi RM, Hankinson SE, Chen WY, et al. Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women. Arch Intern Med 2006; 166:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11449/abstract/45\">",
"      Chen WY, Colditz GA, Rosner B, et al. Use of postmenopausal hormones, alcohol, and risk for invasive breast cancer. Ann Intern Med 2002; 137:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11449/abstract/46\">",
"      Rosenberg L, Palmer JR, Wise LA, Adams-Campbell LL. A prospective study of female hormone use and breast cancer among black women. Arch Intern Med 2006; 166:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11449/abstract/47\">",
"      Cobleigh MA, Berris RF, Bush T, et al. Estrogen replacement therapy in breast cancer survivors. A time for change. Breast Cancer Committees of the Eastern Cooperative Oncology Group. JAMA 1994; 272:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11449/abstract/48\">",
"      Vassilopoulou-Sellin R, Theriault R, Klein MJ. Estrogen replacement therapy in women with prior diagnosis and treatment for breast cancer. Gynecol Oncol 1997; 65:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11449/abstract/49\">",
"      Vassilopoulou-Sellin R, Asmar L, Hortobagyi GN, et al. Estrogen replacement therapy after localized breast cancer: clinical outcome of 319 women followed prospectively. J Clin Oncol 1999; 17:1482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11449/abstract/50\">",
"      DiSaia PJ, Grosen EA, Kurosaki T, et al. Hormone replacement therapy in breast cancer survivors: a cohort study. Am J Obstet Gynecol 1996; 174:1494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11449/abstract/51\">",
"      Natrajan PK, Soumakis K, Gambrell RD Jr. Estrogen replacement therapy in women with previous breast cancer. Am J Obstet Gynecol 1999; 181:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11449/abstract/52\">",
"      Beckmann MW, Jap D, Djahansouzi S, et al. Hormone replacement therapy after treatment of breast cancer: effects on postmenopausal symptoms, bone mineral density and recurrence rates. Oncology 2001; 60:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11449/abstract/53\">",
"      Col NF, Hirota LK, Orr RK, et al. Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk. J Clin Oncol 2001; 19:2357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11449/abstract/54\">",
"      O'Meara ES, Rossing MA, Daling JR, et al. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl Cancer Inst 2001; 93:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11449/abstract/55\">",
"      Holmberg L, Iversen OE, Rudenstam CM, et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst 2008; 100:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11449/abstract/56\">",
"      Fahl&eacute;n M, Fornander T, Johansson H, et al. Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. Eur J Cancer 2013; 49:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11449/abstract/57\">",
"      Colditz GA. Menopausal hormone therapy after breast cancer. Breast Cancer Res 2005; 7:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11449/abstract/58\">",
"      North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010; 17:242.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7392 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-201.211.0.116-33F4385FB5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_11_11449=[""].join("\n");
var outline_f11_11_11449=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ENDOGENOUS HORMONES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Obesity and weight gain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EXOGENOUS HORMONE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H150019706\">",
"      Epidemiologic data",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Women's Health Initiative",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Combination therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H150019616\">",
"      Post-WHI rates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Unopposed estrogen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H150020278\">",
"      - Absolute risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H150019838\">",
"      - Mammographic density",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Abnormal mammography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Duration of use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H150020558\">",
"      Effect of progestins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H150020565\">",
"      - Type of progestin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H150020086\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H150021291\">",
"      Timing of hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H150020341\">",
"      OTHER ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H615546153\">",
"      Women with a family history of cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H150020386\">",
"      Effect of testosterone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H615546104\">",
"      Effect of alcohol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H150020322\">",
"      Women with premature ovarian failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Effect of race on risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Personal history of breast cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Observational data",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Clinical trial data",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7392\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7392|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/26/17838\" title=\"figure 1\">",
"      HRT invasive breast CA WHI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/27/13759\" title=\"figure 2\">",
"      Risk of breast cancer with ERT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/26/35246\" title=\"figure 3\">",
"      Hormones and menses",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28954?source=related_link\">",
"      Factors that modify breast cancer risk in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/63/37880?source=related_link\">",
"      Management of spontaneous primary ovarian insufficiency (premature ovarian failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/53/25434?source=related_link\">",
"      Menopausal hot flashes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/61/38874?source=related_link\">",
"      Overview of the risks and benefits of alcohol consumption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/59/26546?source=related_link\">",
"      Patient information: Menopause (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/27/40370?source=related_link\">",
"      Patient information: Menopause (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=related_link\">",
"      Postmenopausal hormone therapy: Benefits and risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16218?source=related_link\">",
"      Preparations for postmenopausal hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41754?source=related_link\">",
"      Screening for breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/42/40615?source=related_link\">",
"      Treatment of menopausal symptoms with hormone therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_11_11450="Epidemiology, risk factors, pathogenesis and natural history of abdominal aortic aneurysm";
var content_f11_11_11450=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, risk factors, pathogenesis and natural history of abdominal aortic aneurysm",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/11/11450/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/11/11450/contributors\">",
"     Emile R Mohler III, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/11/11450/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/11/11450/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/11/11450/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/11/11450/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/11/11450/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/11/11450/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H431205718\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal aortic aneurysm (AAA), which is a focal dilation (",
"    <a class=\"graphic graphic_figure graphicRef60682 \" href=\"UTD.htm?9/29/9683\">",
"     figure 1",
"    </a>",
"    ) 50 percent greater than the normal diameter of the aorta, is a common but potentially lethal condition. The abdominal aorta is the most common site of true arterial aneurysm affecting predominantly the segment of aorta below the renal arteries (infrarenal aorta) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Well-defined risk factors are associated with the development of AAA and include older age, male gender, Caucasian race, a positive family history, smoking, the presence of other large vessel aneurysms and atherosclerosis. The natural history of AAA is one of progressive dilation, and although expansion rates vary, large aneurysms generally expand at a faster rate than small aneurysms. Many pathogenic mechanisms have been proposed for the development, expansion, and rupture of AAA, and some have been validated in animal models; however, the relative contribution of these mechanisms to AAA expansion and rupture in humans is unclear. The main risk factors associated with expansion and rupture of AAA include large aneurysm diameter, faster aortic expansion rate, and female gender.",
"   </p>",
"   <p>",
"    The epidemiology, risk factors, pathogenesis, and natural history of AAA are reviewed here. The diagnosis, management, and treatment of AAA are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32010?source=see_link\">",
"     \"Clinical features and diagnosis of abdominal aortic aneurysm\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38746?source=see_link&amp;anchor=H611107773#H611107773\">",
"     \"Management of asymptomatic abdominal aortic aneurysm\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1428624\">",
"    <span class=\"h1\">",
"     ANEURYSM TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;An abdominal aorta with a maximal diameter &gt;3.0 cm is considered aneurysmal in most adult patients. Abdominal aortic aneurysm (AAA) most often affects the segment of aorta below the renal arteries (",
"    <a class=\"graphic graphic_figure graphicRef60682 \" href=\"UTD.htm?9/29/9683\">",
"     figure 1",
"    </a>",
"    ); approximately 5 percent involve the renal (pararenal) or visceral arteries (suprarenal).",
"   </p>",
"   <p>",
"    For the purposes of this discussion:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Small aneurysms have a diameter &lt;4.0 cm",
"     </li>",
"     <li>",
"      Medium aneurysms have a diameter between 4.0 and 5.5 cm",
"     </li>",
"     <li>",
"      Large aneurysms have a diameter &ge;5.5 cm",
"     </li>",
"     <li>",
"      Very large aneurysms have a diameter &ge;6.0 cm",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1460375\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound screening studies have shown that 4 to 8 percent of older men have an occult AAA [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/4-9\">",
"     4-9",
"    </a>",
"    ]. Abdominal aortic aneurysm occurs four to five times more commonly in men than women [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/5,7-12\">",
"     5,7-12",
"    </a>",
"    ]. Because the incidence of AAA rises sharply in individuals over 60 years of age, the future prevalence of AAA could increase substantially in association with the aging population. On the other hand, some suggest that a reduction in the prevalence of smoking could have the opposite effect [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/12\">",
"     12",
"    </a>",
"    ]. A screening study in Sweden found a prevalence of 1.7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/13\">",
"     13",
"    </a>",
"    ], the lowest reported in a predominantly Caucasian population.",
"   </p>",
"   <p>",
"    The annual incidence of AAA is difficult to measure. Screening studies in the United States and the United Kingdom have estimated the incidence of AAA in men over 50 to be 3.5 to 6.5 per 1000 person-years [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. These studies also found that new AAAs develop in 2 to 2.6 percent of at-risk men 4 to 5.5 years after an initially normal study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91207428\">",
"    <span class=\"h2\">",
"     Rupture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rupture of AAA is estimated to occur in 12,000 to 15,000 patients per year in the United States. Data from the National Inpatient Sample identified 6241 patients in 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/16\">",
"     16",
"    </a>",
"    ]. However, the incidence of hospitalized patients with ruptured AAA underestimates the overall incidence because only about half of patients with ruptured AAA survive long enough for treatment, and not all patients with sudden death undergo autopsy to confirm the cause of death.",
"   </p>",
"   <p>",
"    From 1993 to 2005, the incidence of ruptured AAA declined about 29 percent, which could be attributed to improved diagnosis from more widespread use of abdominal imaging leading to earlier repair. The contribution of endovascular aneurysm repair (EVAR) is probably more important in reducing the incidence of ruptured AAA due to the ability to offer repair to patients who were unwilling to undergo open surgery and to those who were not candidates for open AAA repair [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. The decline in the incidence of ruptured AAA over this time period was less in women (12 versus 29 percent decline) compared with men [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/16\">",
"     16",
"    </a>",
"    ]. Although a smaller percentage of women have aneurysms (approximately 20 percent of all AAA diagnoses), women present with rupture more often than men [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91204704\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Well-defined clinical risk factors are associated with the development of AAA [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/19\">",
"     19",
"    </a>",
"    ]. These include advancing age, male gender, smoking, Caucasian race, a family history of AAA, the presence of other large aneurysms, and atherosclerosis.",
"   </p>",
"   <p>",
"    Female gender, non-Caucasian race, and diabetes mellitus are associated with a decreased risk for developing AAA. Although diabetes mellitus is consistently a strong risk factor for atherosclerosis, it is negatively associated with AAA [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/8,20\">",
"     8,20",
"    </a>",
"    ]. In the Aneurysm Detection and Management (ADAM) trial, for example, the odds ratio in patients with diabetes mellitus relative to non-diabetic patients was 0.52 (95% CI 0.45-0.61) for AAA &gt;4.0 cm in diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/8\">",
"     8",
"    </a>",
"    ]. This trend was also seen in the Life Line Screening cohort, in which the risk of AAA in patients with diabetes was significantly lower compared with those without diabetes (odds ratio 0.75, 95% CI 0.73-0.77).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91204711\">",
"    <span class=\"h2\">",
"     Older age/male gender",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of AAAs is negligible in individuals under the age of 60 but thereafter increases dramatically with age [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/2,7,21,22\">",
"     2,7,21,22",
"    </a>",
"    ]. The prevalence of AAA increases with age in both men and women, but the age-related increase is more pronounced in men [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/7,21,23\">",
"     7,21,23",
"    </a>",
"    ]. Autopsy studies in Sweden found that the prevalence in men peaks at age 80; however, the prevalence continues to increase with age in women [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/24\">",
"     24",
"    </a>",
"    ]. The relationship of age and AAA is illustrated in the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a population study from Norway that involved 6386 patients (Tr&oslash;mso study), there were no AAAs in subjects under the age of 48 years. No person under the age of 55 had an aortic diameter above 3.9 cm [",
"      <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/7,25\">",
"       7,25",
"      </a>",
"      ]. In men aged 55 to 64 years, 6 percent had a maximal aortic diameter &gt;2.9 cm but clinically relevant aneurysms (&gt;4.0 cm) were found in only 1 percent. The prevalence increased with each decade thereafter such that clinically relevant aneurysms were present in 4 percent of men aged 65 to 74, and 8.6 percent of those aged 75 to 84.",
"     </li>",
"     <li>",
"      In a study of 5356 patients (male and female) aged 65 to 79 years, the prevalence of AAA increased steadily with age, from 2.7 percent at 65 to 69 years to 4.4 percent at 75 to 79 years [",
"      <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Aneurysms are rare in women under the age of 55 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/5,7\">",
"     5,7",
"    </a>",
"    ]. However, prevalence studies often use the same definition of an abnormal maximum external diameter (&gt;3 cm) for both men and women [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/27\">",
"     27",
"    </a>",
"    ]. This definition probably underestimates the prevalence of AAA in women given gender differences in body size. In addition, for aneurysms of similar size, the risk of rupture is increased in women since it reflects a greater increase in aortic diameter above normal [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/18\">",
"     18",
"    </a>",
"    ]. In the United Kingdom Small Aneurysm Trial, for example, the rate of aneurysm rupture was three times higher in women than in men [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H91211810\">",
"     'Female Gender'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91207198\">",
"    <span class=\"h2\">",
"     Race/ethnicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;AAAs are approximately more common in Caucasian compared with non-Caucasian populations. In the Veterans Affairs study, AAA occurred approximately twice as frequently in whites compared with blacks [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/8\">",
"     8",
"    </a>",
"    ]. In the ADAM trial, the risk of developing AAA in black Americans compared with white Americans was significantly lower with an odds ratio of 0.62 for AAA 3.0 to 3.9 cm in diameter and 0.53 for aneurysms at least 4.0 cm in diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/8\">",
"     8",
"    </a>",
"    ]. The Life Line Screening cohort study also showed a reduced risk for Hispanic- (odds ratio 0.69) and Asian-Americans (odds ratio 0.72), in addition to black-Americans (odds ratio 0.72) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91204718\">",
"    <span class=\"h2\">",
"     Smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Smoking is a major risk factor for aneurysm formation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/19,29\">",
"     19,29",
"    </a>",
"    ]. A history of cigarette smoking is one of the strongest independent risk factors for AAA.",
"   </p>",
"   <p>",
"    Smoking predicts a larger aortic diameter at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/30\">",
"     30",
"    </a>",
"    ], and in screening studies, 18 to 52 percent of patients with small AAAs are current smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/5,7,31\">",
"     5,7,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once an aneurysm has formed, active smoking is associated with the highest risk of aneurysm progression and rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/8,21,22,28\">",
"     8,21,22,28",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1428712\">",
"     'Natural history'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The magnitude of the effect of smoking is best illustrated in the Aneurysm Detection and Management (ADAM) Study Screening program conducted by the Veterans Affairs Cooperative Study Group [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/8\">",
"     8",
"    </a>",
"    ]. The study included 126,196 patients, mostly men, aged 50 to 79 years [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/8\">",
"     8",
"    </a>",
"    ]. The likelihood of finding AAA was significantly higher in smokers compared with nonsmokers (odds ratio [OR] 2.97 for AAA 3.0 to 3.9 cm, 95% CI 2.65-3.32; OR 5.07 for AAA &gt;4.0 cm, 95% CI 4.13-6.21). The excess prevalence associated with smoking accounted for 75 percent of all aneurysms that were &gt;4.0 cm in diameter. &nbsp;",
"   </p>",
"   <p>",
"    The risk of AAA increases with the duration of smoking and number of cigarettes smoked per day [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/5,22,25\">",
"     5,22,25",
"    </a>",
"    ]. Compared with never-smokers, the risk of AAA is increased by sevenfold for those who have smoked for more than 30 years and by more than 12-fold for those who currently smoke more than 20 cigarettes per day [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/25\">",
"     25",
"    </a>",
"    ]. There is also a linear dose-response relationship with the duration of smoking, with each year of smoking increasing the relative risk of AAA by 4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/22\">",
"     22",
"    </a>",
"    ]. A decrease in the prevalence of smoking is likely responsible for a decreasing incidence in AAA reported in some countries [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/13,32,33\">",
"     13,32,33",
"    </a>",
"    ]. With smoking cessation, the risk of AAA slowly declines over time, thus [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/19,22\">",
"     19,22",
"    </a>",
"    ], smoking cessation is an essential component of risk reduction in patients with AAA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38746?source=see_link&amp;anchor=H91192084#H91192084\">",
"     \"Management of asymptomatic abdominal aortic aneurysm\", section on 'Potentially beneficial therapies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91204748\">",
"    <span class=\"h2\">",
"     Family history/genetic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A family history of abdominal aneurysm increases the risk of developing the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/2,3,8\">",
"     2,3,8",
"    </a>",
"    ]. A genetic predisposition for the development of AAA has been suspected since the first report of three brothers who each underwent surgery for ruptured AAA [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/34\">",
"     34",
"    </a>",
"    ]. The identification of other familial clusters further suggests a genetic predisposition for aneurysmal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/11,35-40\">",
"     11,35-40",
"    </a>",
"    ]. In one referral surgery practice, three-fourths of operated aneurysms were familial and multiple, rather than associated with atherosclerotic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/41\">",
"     41",
"    </a>",
"    ]. AAA can also occur with monogenetic disorders such as Marfan syndrome (fibrillin-1 defect) or Ehlers-Danlos syndrome type IV (abnormal type III procollagen); however, these more typically involve the thoracoabdominal aorta [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20538?source=see_link\">",
"     \"Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among individuals who have undergone aneurysm repair, 12 to 19 percent have a first-degree relative with AAA [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/11,42,43\">",
"     11,42,43",
"    </a>",
"    ]. In a Swedish nationwide survey, the relative risk of developing AAA for a first-degree relative of a person diagnosed with AAA was approximately double that of a person with no family history of AAA [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/37\">",
"     37",
"    </a>",
"    ]. In a study of 238 first-degree relatives of patients who underwent surgery for AAA and 281 controls, a family history increased the risk of having an aneurysm 4.3-fold; the highest risk was among brothers older than 60 years of age, in whom the prevalence was 18 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A study that evaluated 313 multigenerational pedigrees highlighted the role of genetic factors in the multifactorial pathogenesis of AAA [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/39\">",
"     39",
"    </a>",
"    ]. The relative risk for AAA was 18 in male siblings of an affected male patient relative to siblings without AAA, which could be explained by a single gene defect showing dominant inheritance. A genome scan of 36 families with AAA identified a possible gene locus on chromosome 19q13 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/40\">",
"     40",
"    </a>",
"    ]. Several genetic polymorphisms are known or suspected to increase the risk for AAA including genes controlling angiotensin converting enzyme, methylene tetrahydrofolate reductase, and matrix metalloproteinase-9 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/44\">",
"     44",
"    </a>",
"    ]. Other chromosomes linked to AAA include the long arm of chromosome 16, and chromosomes 4q32-34, 11q24, and 9p21 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/44-46\">",
"     44-46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The inheritance of specific HLA alleles may favor the development of an inflammatory aneurysm. One study found that the incidence of HLA-DRB1 alleles B1*15 and B1*0404 was enhanced in patients with inflammatory AAAs compared with control subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91208494\">",
"    <span class=\"h2\">",
"     Other large vessel aneurysm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a large vessel peripheral aneurysm (eg, iliac, femoral, popliteal, carotid) have an increased risk for AAA, which, in different studies, has been found in 85 percent of patients with a femoral aneurysm and in about 60 percent of those with a popliteal aneurysm [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. In a retrospective review of patients with AAA, more than 25 percent were found to have a concomitant thoracic aortic aneurysm (TAA) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/50\">",
"     50",
"    </a>",
"    ]. Significantly more women had combined AAA and TAA compared with men (48 versus 28 percent). The association between AAA and other large vessel aneurysms is likely related to common pathogenic mechanisms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91208501\">",
"    <span class=\"h2\">",
"     Association with atherosclerosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A positive correlation between cardiovascular disease and AAA has been found in numerous studies [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/5,7,8,19,26,51-56\">",
"     5,7,8,19,26,51-56",
"    </a>",
"    ]. Patients with AAA have a significantly higher prevalence of risk factors for atherosclerosis compared with age and gender-matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/2,57\">",
"     2,57",
"    </a>",
"    ]. The prevalence of AAA is about 5 percent in patients with known coronary heart disease, and approximately 10 percent in those with peripheral artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/51-54\">",
"     51-54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the ADAM trial and Life Line Screening cohorts, coronary heart disease, cerebrovascular disease, hypertension and high cholesterol levels were associated with an increased risk for AAA &gt;4.0 cm in diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/8,19\">",
"     8,19",
"    </a>",
"    ]. Another cohort study of over 104,000 patients confirmed that major atherosclerotic risk factors (except diabetes and obesity) are related to AAA [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/20\">",
"     20",
"    </a>",
"    ]. Conversely, data from the United Kingdom Small Aneurysm Trial showed that lipid levels and elevated blood pressure were not significantly associated with aneurysm expansion [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These findings led to the traditional view that AAA is caused by atherosclerotic disease; however, the formation of AAA, and AAA expansion and rupture involves multiple intertwined pathogenic processes, and atherosclerosis may be a consequence rather than the cause of this process. (See",
"    <a class=\"local\" href=\"#H1428675\">",
"     'Pathogenesis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H491541309\">",
"    <span class=\"h2\">",
"     Aortic infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aneurysmal degeneration of the arterial wall can be the result of aortic wall infection. Risk factors for infected aortic aneurysm include arterial injury, or antecedent infection with the aorta becoming involved due to bacteremic seeding of atherosclerotic aortic plaques, septic embolization typically from infected heart valves, or by contiguous spread from adjacent structures. These risk factors and the pathogenesis of infected aortic aneurysms are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/17/35098?source=see_link\">",
"     \"Overview of infected (mycotic) arterial aneurysm\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1428675\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aneurysmal degeneration of the abdominal aorta is a multifactorial, systemic process generally felt to be due to alterations in vascular wall biology leading to a loss of vascular structural proteins and wall strength [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although atherosclerotic changes frequently coexist with AAA [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/5,8,51-54\">",
"     5,8,51-54",
"    </a>",
"    ], and the risk factors for aneurysmal and atherosclerotic aortic disease overlap to some extent, contemporary research suggests that atherosclerosis is not causal [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/60-63\">",
"     60-63",
"    </a>",
"    ]. Aneurysmal degeneration of the aortic wall is pathologically distinguished from atherosclerosis. Whereas atherosclerotic changes are limited to inner layers of the aortic wall, AAAs are characterized by transmural inflammatory change, abnormal collagen remodeling and cross-linking, and loss of elastin and smooth muscle cells [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. These changes result in aortic wall thinning and progressive aortic expansion.",
"   </p>",
"   <p>",
"    A role for inflammation in the pathogenesis of AAA was first speculated because of a clinical entity called an inflammatory aneurysm, which represents approximately 5 percent of patients with AAA [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. Inflammatory aneurysms are characterized by marked aortic wall thickening with increased vascularity and associated with elevated erythrocyte sedimentation (ESR) levels, indicative of inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/68-70\">",
"     68-70",
"    </a>",
"    ]. This type of aneurysm has distinct clinical and pathologic characteristics that may represent an extreme manifestation of the inflammatory processes present in all aortic aneurysms [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/67\">",
"     67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32010?source=see_link&amp;anchor=H22323992#H22323992\">",
"     \"Clinical features and diagnosis of abdominal aortic aneurysm\", section on 'Infected versus inflammatory AAA'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Aneurysm formation is also associated with other circulating markers of inflammation such as C-reactive protein (CRP), and interleukins. A positive association between serum CRP and aneurysm diameter, and the presence of CRP mRNA in aneurysmal tissue is consistent with a causal hypothesis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/71\">",
"     71",
"    </a>",
"    ]. Tissue cultures of biopsied aneurysm wall tissue secrete large amounts of cytokines, including interleukin-6 (IL-6), in aneurysm patients. In a study of 466 patients with small aneurysms, high concentrations of circulating IL-6 signaled rapid aneurysm expansion [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chronic inflammation of the aortic wall likely mediates aortic wall elastin and collagen degradation through proteases, including plasmin (formed from plasminogen by urokinase plasminogen activator and tissue type plasminogen activator), matrix metalloproteinases (MMPs), and cathepsin S and K [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/62,73-82\">",
"     62,73-82",
"    </a>",
"    ]. These factors are derived from endothelial and smooth muscle cells and inflammatory cells infiltrating the media and adventitia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/40/28297?source=see_link\">",
"     \"Vascular endothelial function and fundamental mechanisms of fibrinolysis (thrombolysis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following observations in animal models are consistent with an important role for proteases in the development of AAA:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Blocking plasmin formation by overexpression of plasminogen activator inhibitor-1 prevents the formation of aneurysms by inhibiting metalloproteinase activation [",
"      <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/74\">",
"       74",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Macrophage elastase (MMP-12) or calcium chloride-induced aneurysmal degeneration is suppressed or prevented by treatment with a nonselective MMP inhibitor (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      ) and by targeted gene disruption of MMP-2 (gelatinase A) or MMP-9 (gelatinase B) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/75,76\">",
"       75,76",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The expression of MMP-3 (stromelysin-1) and the tissue inhibitor of MMP-3 in AAA aortic tissue are significantly higher compared with tissue obtained from the aorta in aortic occlusive disease [",
"      <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/77\">",
"       77",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The elastolytic cysteine proteases cathepsin S and K are overexpressed at sites of arterial elastin damage [",
"      <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/79\">",
"       79",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cystatin C, the most abundant endogenous local inhibitor of these proteases, which is normally expressed in vascular wall smooth muscle cells, is severely reduced in atherosclerotic and aneurysmal aortic lesions. Among patients with AAA, the diameter measured on ultrasound is inversely related to serum cystatin C levels.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The pathologic factors responsible for aneurysm rupture have been less well studied. In an animal model, aneurysm rupture correlated with an increase in MMP-2 and MMP-9 levels [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/78\">",
"     78",
"    </a>",
"    ]. Local overexpression of tissue inhibitor of MMP-1, produced by retrovirally infected smooth muscle cells, prevented aneurysmal degeneration and rupture. These findings are consistent with a study in humans in which biopsies were taken from the walls of ruptured and nonruptured AAAs [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/83\">",
"     83",
"    </a>",
"    ]. Only MMP-8 (collagenase-2) and MMP-9 were significantly increased at the rupture site compared with the nonruptured anterior wall.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1428712\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of AAA is one of progressively increasing diameter; however, expansion rates vary. The main risk factors associated with AAA expansion and rupture include large aneurysm diameter, faster aortic expansion rate, current smoking, and female gender.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91206665\">",
"    <span class=\"h2\">",
"     Aortic expansion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rate of aortic expansion is greater for larger compared with smaller diameter AAA [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/30,58,84-86\">",
"     30,58,84-86",
"    </a>",
"    ]. This pattern of differential expansion over time related to baseline AAA diameter was illustrated in an analysis from the United Kingdom Small Aneurysm Trial in which the following annual expansion rates were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/58\">",
"     58",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      1.9 mm per year for aneurysms 2.8 to 3.9 cm in baseline diameter",
"     </li>",
"     <li>",
"      2.7 mm per year for those 4.0 to 4.5 cm in baseline diameter",
"     </li>",
"     <li>",
"      3.5 mm per year for those 4.6 to 8.5 cm in baseline diameter",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The cumulative evidence from studies that prospectively followed the size of AAAs suggests that small and medium-sized AAAs (&lt;5.5 cm) expand at an average rate of 2 to 3",
"    <span class=\"nowrap\">",
"     mm/year,",
"    </span>",
"    while larger aneurysms expand at about 3 to 4 mm per year [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/30,58,84-86\">",
"     30,58,84-86",
"    </a>",
"    ]. Some aneurysms, for unclear reasons, remain relatively fixed in size for a period of time and then undergo rapid expansion, which is thought to increase the risk for rupture, and is defined as an increase in maximal aortic diameter &ge;5 mm over a six-month period of time or &gt;10 mm over a year [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Aneurysm expansion tends to be more rapid in smokers, and less rapid in patients with diabetes mellitus or peripheral artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/58\">",
"     58",
"    </a>",
"    ]. Active smoking is associated with the highest risk of aneurysm expansion and rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/8,21,22,28,87-89\">",
"     8,21,22,28,87-89",
"    </a>",
"    ]. It has been estimated that active smoking increases the aneurysm expansion rate by 20 to 25 percent per year [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/21,90\">",
"     21,90",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1428719\">",
"    <span class=\"h2\">",
"     Risk of rupture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aneurysm diameter is the most important factor predisposing to rupture, with risk increasing markedly at aneurysm diameters greater than 5.5 cm (",
"    <a class=\"graphic graphic_figure graphicRef57275 \" href=\"UTD.htm?43/25/44445\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/21,85,91-96\">",
"     21,85,91-96",
"    </a>",
"    ]. In addition to diameter, a faster rate of expansion (highest in smokers), gender, and other factors play a role [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/21,85,91,93-96\">",
"     21,85,91,93-96",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1428726\">",
"    <span class=\"h3\">",
"     Aneurysm diameter",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aneurysm diameter is one of the strongest predictors of aneurysm rupture, with risk increasing markedly with aneurysm diameters greater than 5.5 cm (",
"    <a class=\"graphic graphic_figure graphicRef57275 \" href=\"UTD.htm?43/25/44445\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/3,21,85,91-95\">",
"     3,21,85,91-95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relationship of aneurysm diameter to aortic rupture was first demonstrated in a seminal study in which patients with aneurysms &gt;6 cm had a much higher rate of rupture at five years compared with aneurysms &lt;6.0 cm (43 versus 20 percent), and lower rate of survival (6 versus 48 percent). Virtually identical differences in survival rates have been noted in other series [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/28,91,97\">",
"     28,91,97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A statement from the Joint Council of the American Association for Vascular Surgery and Society for Vascular Surgery estimated the annual rupture risk according to AAA diameter as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/3,96\">",
"     3,96",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Zero for AAA &lt;4.0 cm in diameter",
"     </li>",
"     <li>",
"      0.5 to 5 percent for AAA 4.0 to 4.9 cm in diameter",
"     </li>",
"     <li>",
"      3 to 15 percent for AAA 5.0 to 5.9 cm in diameter",
"     </li>",
"     <li>",
"      10 to 20 percent for AAA 6.0 to 6.9 cm in diameter",
"     </li>",
"     <li>",
"      20 to 40 percent for AAA 7.0 to 7.9 cm in diameter",
"     </li>",
"     <li>",
"      30 to 50 percent for AAA &ge;8.0 cm in diameter",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91211796\">",
"    <span class=\"h3\">",
"     Rate of expansion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rate of aneurysm expansion may also be an important determinant of rupture risk [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/84,98\">",
"     84,98",
"    </a>",
"    ]. A small (&lt;4.0 cm) or medium (4 to 5.5 cm) AAA that expands &ge;0.5 cm over six months of follow-up is considered to be at high risk for rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/2\">",
"     2",
"    </a>",
"    ]. One study, for example, found mean expansion rates of ruptured versus nonruptured aneurysms of 0.82 and 0.42",
"    <span class=\"nowrap\">",
"     cm/year,",
"    </span>",
"    respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Active smoking is associated with the highest rates of aneurysm expansion and rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/8,21,22,28\">",
"     8,21,22,28",
"    </a>",
"    ]. In the United Kingdom Small Aneurysm Trial, active smokers were at an increased risk for aneurysm rupture relative to nonsmokers and former smokers (odds ratio [OR] 2.1, 95% CI 0.95-4.67), and had a poorer prognosis related to worse pulmonary function [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/28,99\">",
"     28,99",
"    </a>",
"    ]. In the women&rsquo;s health initiative that enrolled more than 160,000 women, current smoking was associated with the highest risk of having an AAA event defined as development of AAA requiring intervention (symptomatic or ruptured) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91211810\">",
"    <span class=\"h3\">",
"     Female Gender",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of AAA rupture is increased in women compared with men for the same aortic diameter. Although the prevalence of AAA is 4 to 6 times lower for women compared with men [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/4-8,26,101-103\">",
"     4-8,26,101-103",
"    </a>",
"    ], about a third of admissions for ruptured AAA are women [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the United Kingdom Small Aneurysm Trial, the risk for AAA rupture in women relative to men for a given diameter was increased fourfold (odds ratio 4.5, 95% CI 1.98-10.2) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/28,104\">",
"       28,104",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      In another review, the rupture rate for AAA &ge;5.0 cm was 19 percent for women and 12 percent for men [",
"      <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These differences may reflect the smaller &lsquo;normal&rsquo; diameter of the female aorta. Thus, a diameter of 5.0 to 5.5 cm represents a greater degree of dilatation in women [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/21,27\">",
"     21,27",
"    </a>",
"    ]. This concept is supported by the results of a study in which the mean diameter of the aorta at the time of rupture was 5 mm smaller for women compared with men [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/105\">",
"     105",
"    </a>",
"    ]. Mortality rates following repair are also higher for women [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91211817\">",
"    <span class=\"h3\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the main risk factors for aneurysm rupture discussed above (aneurysm diameter, rate of expansion, female gender), other factors that may influence the risk of rupture include medical factors and recent surgery; the configuration of the aneurysm may also play a role.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H491541181\">",
"    <span class=\"h4\">",
"     Medical factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United Kingdom Small Aneurysm Trial, medical risk factors for AAA rupture included mean arterial blood pressure &gt;110 mmHg (OR 1.04, 95% CI 1.02-1.07) and lower FEV1. Low FEV1 measurements correlated with the presence of severe chronic pulmonary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/28,96\">",
"     28,96",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H491541195\">",
"    <span class=\"h4\">",
"     Recent surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rupture rates as high as 33 percent are reported in prospective studies of patients undergoing coronary artery revascularization prior to aneurysm repair [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/106,107\">",
"     106,107",
"    </a>",
"    ]. AAA rupture has been reported following other types of surgery, but no causal etiology has been proven. One prospective study found a 3 percent rupture rate after unrelated noncardiac surgery in patients with AAA diameter &gt;5 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/108\">",
"     108",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H491541209\">",
"    <span class=\"h4\">",
"     Aneurysm configuration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies using advanced mechanical modeling (eg, finite element analysis), to more accurately evaluate the stresses on the aortic wall have identified that the highest mechanical stress is located at the transition zone from normal aortic tissue to the dilated region [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/109,110\">",
"     109,110",
"    </a>",
"    ]. Some have speculated that saccular aneurysms have higher risk for rupture compared with fusiform aneurysms. Although saccular aneurysms have a very abrupt transition zone, saccular aneurysms are not necessarily associated with an increased risk of rupture, particularly if the configuration is concentric [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/105\">",
"     105",
"    </a>",
"    ]. On the other hand, asymmetric saccular aortic aneurysm may be a manifestation of aortic infection, and these do appear to have an increased risk for rupture. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/17/35098?source=see_link\">",
"     \"Overview of infected (mycotic) arterial aneurysm\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1428755\">",
"    <span class=\"h2\">",
"     Long-term outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the risk of rupture, patients with AAA (any diameter) are more likely to have cardiovascular disease and more likely to experience a cardiovascular event. In a screening study of 4734 subjects over the age of 65, 8.8 percent were found to have an aortic aneurysm, of which 88 percent were smaller than 3.5 cm in diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?11/11/11450/abstract/102\">",
"     102",
"    </a>",
"    ]. During a 4.5-year follow-up, patients with an aneurysm had a higher rate of overall mortality compared with subjects without an aneurysm, an effect that was more pronounced if the aneurysm was &gt;3.5 cm in diameter. After adjusting for age, sex, race, height, weight, smoking, lipid levels, family history, and history of a cardiovascular disease event, mortality risk remained significantly elevated (relative risk [RR] 1.47, 95% CI 1.18 to 1.83). However, further adjustment for disease in other vascular beds by measuring carotid wall thickness, presence of major electrocardiographic abnormalities, or an abnormal ankle&ndash;brachial index, reduced the risk (RR 1.32, 95% CI 1.04-1.67). The differences in mortality rates were due predominantly to other associated cardiovascular disease in participants with aneurysm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1428813\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abdominal aortic aneurysm (AAA), which is a focal dilation (",
"      <a class=\"graphic graphic_figure graphicRef60682 \" href=\"UTD.htm?9/29/9683\">",
"       figure 1",
"      </a>",
"      ) more than 50 percent greater than the normal diameter of the aorta, is a common but potentially lethal condition. The abdominal aorta is the most common site of true arterial aneurysm affecting predominantly the segment of aorta below the renal arteries (infrarenal aorta). For the majority of patients, an infrarenal aorta with a maximum diameter &ge;3.0 cm is aneurysmal. (See",
"      <a class=\"local\" href=\"#H431205718\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ultrasound screening studies have found that 4 to 8 percent of older men have an occult AAA. Although the prevalence of AAA is 4 to 6 times lower for women compared with men, women present with rupture more often than men. (See",
"      <a class=\"local\" href=\"#H1460375\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk factors for AAA include advancing age, smoking, hypertension, male gender, Caucasian race, family history, other large vessel aneurysm, and, rarely, aortic infection. Although diabetes mellitus is consistently a strong risk factor for atherosclerosis, it is negatively associated with AAA. (See",
"      <a class=\"local\" href=\"#H91204704\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Aneurysmal degeneration of the abdominal aorta is a multifactorial, systemic process due to alterations in vascular wall biology. AAAs are characterized by transmural inflammatory changes, abnormal collagen remodeling and cross-linking, and loss of elastin and smooth muscle cells, which results in progressive thinning and weakening of the aortic wall and enlargement of the aortic diameter. (See",
"      <a class=\"local\" href=\"#H1428675\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Multiple factors influence aortic expansion and the risk of rupture, the most important of which are aortic diameter and ongoing smoking. Small and medium-sized AAAs (&lt;5.5 cm) expand at an average rate of 2 to 3",
"      <span class=\"nowrap\">",
"       mm/year",
"      </span>",
"      while larger AAAs expand at about 3 to 4 mm per year. AAA that expands &ge;0.5 cm over six months of follow-up is considered at high risk for rupture. (See",
"      <a class=\"local\" href=\"#H1428712\">",
"       'Natural history'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/1\">",
"      Johnston KW, Rutherford RB, Tilson MD, et al. Suggested standards for reporting on arterial aneurysms. Subcommittee on Reporting Standards for Arterial Aneurysms, Ad Hoc Committee on Reporting Standards, Society for Vascular Surgery and North American Chapter, International Society for Cardiovascular Surgery. J Vasc Surg 1991; 13:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/2\">",
"      Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006; 113:e463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/3\">",
"      Chaikof EL, Brewster DC, Dalman RL, et al. SVS practice guidelines for the care of patients with an abdominal aortic aneurysm: executive summary. J Vasc Surg 2009; 50:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/4\">",
"      Scott RA, Ashton HA, Kay DN. Abdominal aortic aneurysm in 4237 screened patients: prevalence, development and management over 6 years. Br J Surg 1991; 78:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/5\">",
"      Lederle FA, Johnson GR, Wilson SE, et al. Prevalence and associations of abdominal aortic aneurysm detected through screening. Aneurysm Detection and Management (ADAM) Veterans Affairs Cooperative Study Group. Ann Intern Med 1997; 126:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/6\">",
"      Boll AP, Verbeek AL, van de Lisdonk EH, van der Vliet JA. High prevalence of abdominal aortic aneurysm in a primary care screening programme. Br J Surg 1998; 85:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/7\">",
"      Singh K, B&oslash;naa KH, Jacobsen BK, et al. Prevalence of and risk factors for abdominal aortic aneurysms in a population-based study : The Troms&oslash; Study. Am J Epidemiol 2001; 154:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/8\">",
"      Lederle FA, Johnson GR, Wilson SE, et al. The aneurysm detection and management study screening program: validation cohort and final results. Aneurysm Detection and Management Veterans Affairs Cooperative Study Investigators. Arch Intern Med 2000; 160:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/9\">",
"      Graham M, Chan A. Ultrasound screening for clinically occult abdominal aortic aneurysm. CMAJ 1988; 138:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/10\">",
"      Darling RC, Messina CR, Brewster DC, Ottinger LW. Autopsy study of unoperated abdominal aortic aneurysms. The case for early resection. Circulation 1977; 56:II161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/11\">",
"      Salo JA, Soisalon-Soininen S, Bondestam S, Mattila PS. Familial occurrence of abdominal aortic aneurysm. Ann Intern Med 1999; 130:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/12\">",
"      Lederle FA. The rise and fall of abdominal aortic aneurysm. Circulation 2011; 124:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/13\">",
"      Svensj&ouml; S, Bj&ouml;rck M, G&uuml;rtelschmid M, et al. Low prevalence of abdominal aortic aneurysm among 65-year-old Swedish men indicates a change in the epidemiology of the disease. Circulation 2011; 124:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/14\">",
"      Wilmink AB, Hubbard CS, Day NE, Quick CR. The incidence of small abdominal aortic aneurysms and the change in normal infrarenal aortic diameter: implications for screening. Eur J Vasc Endovasc Surg 2001; 21:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/15\">",
"      Lederle FA, Johnson GR, Wilson SE, et al. Yield of repeated screening for abdominal aortic aneurysm after a 4-year interval. Aneurysm Detection and Management Veterans Affairs Cooperative Study Investigators. Arch Intern Med 2000; 160:1117.",
"     </a>",
"    </li>",
"    <li>",
"     file://hcupnet.ahrq.gov/HCUPnet (Accessed on May 11, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/17\">",
"      Giles KA, Pomposelli F, Hamdan A, et al. Decrease in total aneurysm-related deaths in the era of endovascular aneurysm repair. J Vasc Surg 2009; 49:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/18\">",
"      Dillavou ED, Muluk SC, Makaroun MS. A decade of change in abdominal aortic aneurysm repair in the United States: Have we improved outcomes equally between men and women? J Vasc Surg 2006; 43:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/19\">",
"      Kent KC, Zwolak RM, Egorova NN, et al. Analysis of risk factors for abdominal aortic aneurysm in a cohort of more than 3 million individuals. J Vasc Surg 2010; 52:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/20\">",
"      Iribarren C, Darbinian JA, Go AS, et al. Traditional and novel risk factors for clinically diagnosed abdominal aortic aneurysm: the Kaiser multiphasic health checkup cohort study. Ann Epidemiol 2007; 17:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/21\">",
"      Powell JT, Greenhalgh RM. Clinical practice. Small abdominal aortic aneurysms. N Engl J Med 2003; 348:1895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/22\">",
"      Wilmink TB, Quick CR, Day NE. The association between cigarette smoking and abdominal aortic aneurysms. J Vasc Surg 1999; 30:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/23\">",
"      Collin J, Araujo L, Walton J, Lindsell D. Oxford screening programme for abdominal aortic aneurysm in men aged 65 to 74 years. Lancet 1988; 2:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/24\">",
"      Bengtsson H, Sonesson B, Bergqvist D. Incidence and prevalence of abdominal aortic aneurysms, estimated by necropsy studies and population screening by ultrasound. Ann N Y Acad Sci 1996; 800:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/25\">",
"      Forsdahl SH, Singh K, Solberg S, Jacobsen BK. Risk factors for abdominal aortic aneurysms: a 7-year prospective study: the Troms&oslash; Study, 1994-2001. Circulation 2009; 119:2202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/26\">",
"      Vardulaki KA, Walker NM, Day NE, et al. Quantifying the risks of hypertension, age, sex and smoking in patients with abdominal aortic aneurysm. Br J Surg 2000; 87:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/27\">",
"      Norman PE, Powell JT. Abdominal aortic aneurysm: the prognosis in women is worse than in men. Circulation 2007; 115:2865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/28\">",
"      Brown LC, Powell JT. Risk factors for aneurysm rupture in patients kept under ultrasound surveillance. UK Small Aneurysm Trial Participants. Ann Surg 1999; 230:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/29\">",
"      Sugamura K, Keaney JF Jr. Nicotine: linking smoking to abdominal aneurysms. Nat Med 2012; 18:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/30\">",
"      Lederle FA, Johnson GR, Wilson SE, et al. Relationship of age, gender, race, and body size to infrarenal aortic diameter. The Aneurysm Detection and Management (ADAM) Veterans Affairs Cooperative Study Investigators. J Vasc Surg 1997; 26:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/31\">",
"      Lederle FA, Nelson DB, Joseph AM. Smokers' relative risk for aortic aneurysm compared with other smoking-related diseases: a systematic review. J Vasc Surg 2003; 38:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/32\">",
"      Sandiford P, Mosquera D, Bramley D. Trends in incidence and mortality from abdominal aortic aneurysm in New Zealand. Br J Surg 2011; 98:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/33\">",
"      Norman PE, Spilsbury K, Semmens JB. Falling rates of hospitalization and mortality from abdominal aortic aneurysms in Australia. J Vasc Surg 2011; 53:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/34\">",
"      Clifton MA. Familial abdominal aortic aneurysms. Br J Surg 1977; 64:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/35\">",
"      Johansen K, Koepsell T. Familial tendency for abdominal aortic aneurysms. JAMA 1986; 256:1934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/36\">",
"      Tilson MD, Seashore MR. Fifty families with abdominal aortic aneurysms in two or more first-order relatives. Am J Surg 1984; 147:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/37\">",
"      Larsson E, Granath F, Swedenborg J, Hultgren R. A population-based case-control study of the familial risk of abdominal aortic aneurysm. J Vasc Surg 2009; 49:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/38\">",
"      Tilson MD, Seashore MR. Human genetics of the abdominal aortic aneurysm. Surg Gynecol Obstet 1984; 158:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/39\">",
"      Verloes A, Sakalihasan N, Koulischer L, Limet R. Aneurysms of the abdominal aorta: familial and genetic aspects in three hundred thirteen pedigrees. J Vasc Surg 1995; 21:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/40\">",
"      Shibamura H, Olson JM, van Vlijmen-Van Keulen C, et al. Genome scan for familial abdominal aortic aneurysm using sex and family history as covariates suggests genetic heterogeneity and identifies linkage to chromosome 19q13. Circulation 2004; 109:2103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/41\">",
"      Sterpetti AV, Feldhaus RJ, Schultz RD, Blair EA. Identification of abdominal aortic aneurysm patients with different clinical features and clinical outcomes. Am J Surg 1988; 156:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/42\">",
"      Darling RC 3rd, Brewster DC, Darling RC, et al. Are familial abdominal aortic aneurysms different? J Vasc Surg 1989; 10:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/43\">",
"      van Vlijmen-van Keulen CJ, Pals G, Rauwerda JA. Familial abdominal aortic aneurysm: a systematic review of a genetic background. Eur J Vasc Endovasc Surg 2002; 24:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/44\">",
"      Thompson AR, Drenos F, Hafez H, Humphries SE. Candidate gene association studies in abdominal aortic aneurysm disease: a review and meta-analysis. Eur J Vasc Endovasc Surg 2008; 35:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/45\">",
"      Powell JT, Bashir A, Dawson S, et al. Genetic variation on chromosome 16 is associated with abdominal aortic aneurysm. Clin Sci (Lond) 1990; 78:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/46\">",
"      Ruigrok YM, Elias R, Wijmenga C, Rinkel GJ. A comparison of genetic chromosomal loci for intracranial, thoracic aortic, and abdominal aortic aneurysms in search of common genetic risk factors. Cardiovasc Pathol 2008; 17:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/47\">",
"      Rasmussen TE, Hallett JW Jr, Metzger RL, et al. Genetic risk factors in inflammatory abdominal aortic aneurysms: polymorphic residue 70 in the HLA-DR B1 gene as a key genetic element. J Vasc Surg 1997; 25:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/48\">",
"      Graham LM, Zelenock GB, Whitehouse WM Jr, et al. Clinical significance of arteriosclerotic femoral artery aneurysms. Arch Surg 1980; 115:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/49\">",
"      Whitehouse WM Jr, Wakefield TW, Graham LM, et al. Limb-threatening potential of arteriosclerotic popliteal artery aneurysms. Surgery 1983; 93:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/50\">",
"      Larsson E, Vishnevskaya L, Kalin B, et al. High frequency of thoracic aneurysms in patients with abdominal aortic aneurysms. Ann Surg 2011; 253:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/51\">",
"      Allardice JT, Allwright GJ, Wafula JM, Wyatt AP. High prevalence of abdominal aortic aneurysm in men with peripheral vascular disease: screening by ultrasonography. Br J Surg 1988; 75:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/52\">",
"      Bengtsson H, Ekberg O, Aspelin P, et al. Ultrasound screening of the abdominal aorta in patients with intermittent claudication. Eur J Vasc Surg 1989; 3:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/53\">",
"      Cabellon S Jr, Moncrief CL, Pierre DR, Cavanaugh DG. Incidence of abdominal aortic aneurysms in patients with atheromatous arterial disease. Am J Surg 1983; 146:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/54\">",
"      Thurmond AS, Semler HJ. Abdominal aortic aneurysm: incidence in a population at risk. J Cardiovasc Surg (Torino) 1986; 27:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/55\">",
"      Pleumeekers HJ, Hoes AW, van der Does E, et al. Aneurysms of the abdominal aorta in older adults. The Rotterdam Study. Am J Epidemiol 1995; 142:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/56\">",
"      Alcorn HG, Wolfson SK Jr, Sutton-Tyrrell K, et al. Risk factors for abdominal aortic aneurysms in older adults enrolled in The Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 1996; 16:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/57\">",
"      Rodin MB, Daviglus ML, Wong GC, et al. Middle age cardiovascular risk factors and abdominal aortic aneurysm in older age. Hypertension 2003; 42:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/58\">",
"      Brady AR, Thompson SG, Fowkes FG, et al. Abdominal aortic aneurysm expansion: risk factors and time intervals for surveillance. Circulation 2004; 110:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/59\">",
"      Wassef M, Baxter BT, Chisholm RL, et al. Pathogenesis of abdominal aortic aneurysms: a multidisciplinary research program supported by the National Heart, Lung, and Blood Institute. J Vasc Surg 2001; 34:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/60\">",
"      Kuivaniemi H, Tromp G, Prockop DJ. Genetic causes of aortic aneurysms. Unlearning at least part of what the textbooks say. J Clin Invest 1991; 88:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/61\">",
"      Reed D, Reed C, Stemmermann G, Hayashi T. Are aortic aneurysms caused by atherosclerosis? Circulation 1992; 85:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/62\">",
"      MacSweeney ST, Powell JT, Greenhalgh RM. Pathogenesis of abdominal aortic aneurysm. Br J Surg 1994; 81:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/63\">",
"      Tilson MD. Aortic aneurysms and atherosclerosis. Circulation 1992; 85:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/64\">",
"      Miller FJ Jr, Sharp WJ, Fang X, et al. Oxidative stress in human abdominal aortic aneurysms: a potential mediator of aneurysmal remodeling. Arterioscler Thromb Vasc Biol 2002; 22:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/65\">",
"      L&oacute;pez-Candales A, Holmes DR, Liao S, et al. Decreased vascular smooth muscle cell density in medial degeneration of human abdominal aortic aneurysms. Am J Pathol 1997; 150:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/66\">",
"      Eagleton MJ. Inflammation in abdominal aortic aneurysms: cellular infiltrate and cytokine profiles. Vascular 2012; 20:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/67\">",
"      Rasmussen TE, Hallett JW Jr. Inflammatory aortic aneurysms. A clinical review with new perspectives in pathogenesis. Ann Surg 1997; 225:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/68\">",
"      Cavallaro A, Sapienza P, di Marzo L, et al. [Inflammatory aneurysm of the abdominal aorta. Study of 355 patients with aortic aneurysm]. Recenti Prog Med 2001; 92:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/69\">",
"      Pennell RC, Hollier LH, Lie JT, et al. Inflammatory abdominal aortic aneurysms: a thirty-year review. J Vasc Surg 1985; 2:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/70\">",
"      Bonamigo TP, Bianco C, Becker M, Puricelli Faccini F. Inflammatory aneurysms of infra-renal abdominal aorta. A case-control study. Minerva Cardioangiol 2002; 50:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/71\">",
"      Vainas T, Lubbers T, Stassen FR, et al. Serum C-reactive protein level is associated with abdominal aortic aneurysm size and may be produced by aneurysmal tissue. Circulation 2003; 107:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/72\">",
"      Jones KG, Brull DJ, Brown LC, et al. Interleukin-6 (IL-6) and the prognosis of abdominal aortic aneurysms. Circulation 2001; 103:2260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/73\">",
"      Sukhova GK, Shi GP, Simon DI, et al. Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J Clin Invest 1998; 102:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/74\">",
"      Allaire E, Hasenstab D, Kenagy RD, et al. Prevention of aneurysm development and rupture by local overexpression of plasminogen activator inhibitor-1. Circulation 1998; 98:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/75\">",
"      Pyo R, Lee JK, Shipley JM, et al. Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J Clin Invest 2000; 105:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/76\">",
"      Longo GM, Xiong W, Greiner TC, et al. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest 2002; 110:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/77\">",
"      Carrell TW, Burnand KG, Wells GM, et al. Stromelysin-1 (matrix metalloproteinase-3) and tissue inhibitor of metalloproteinase-3 are overexpressed in the wall of abdominal aortic aneurysms. Circulation 2002; 105:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/78\">",
"      Allaire E, Forough R, Clowes M, et al. Local overexpression of TIMP-1 prevents aortic aneurysm degeneration and rupture in a rat model. J Clin Invest 1998; 102:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/79\">",
"      Shi GP, Sukhova GK, Grubb A, et al. Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J Clin Invest 1999; 104:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/80\">",
"      Koch AE, Haines GK, Rizzo RJ, et al. Human abdominal aortic aneurysms. Immunophenotypic analysis suggesting an immune-mediated response. Am J Pathol 1990; 137:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/81\">",
"      Walton LJ, Franklin IJ, Bayston T, et al. Inhibition of prostaglandin E2 synthesis in abdominal aortic aneurysms: implications for smooth muscle cell viability, inflammatory processes, and the expansion of abdominal aortic aneurysms. Circulation 1999; 100:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/82\">",
"      Newman KM, Jean-Claude J, Li H, et al. Cytokines that activate proteolysis are increased in abdominal aortic aneurysms. Circulation 1994; 90:II224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/83\">",
"      Wilson WR, Anderton M, Schwalbe EC, et al. Matrix metalloproteinase-8 and -9 are increased at the site of abdominal aortic aneurysm rupture. Circulation 2006; 113:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/84\">",
"      Gadowski GR, Pilcher DB, Ricci MA. Abdominal aortic aneurysm expansion rate: effect of size and beta-adrenergic blockade. J Vasc Surg 1994; 19:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/85\">",
"      Mortality results for randomised controlled trial of early elective surgery or ultrasonographic surveillance for small abdominal aortic aneurysms. The UK Small Aneurysm Trial Participants. Lancet 1998; 352:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/86\">",
"      Vega de C&eacute;niga M, G&oacute;mez R, Estallo L, et al. Growth rate and associated factors in small abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2006; 31:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/87\">",
"      MacSweeney ST, Ellis M, Worrell PC, et al. Smoking and growth rate of small abdominal aortic aneurysms. Lancet 1994; 344:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/88\">",
"      Chang JB, Stein TA, Liu JP, Dunn ME. Risk factors associated with rapid growth of small abdominal aortic aneurysms. Surgery 1997; 121:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/89\">",
"      Lindholt JS, Heegaard NH, Vammen S, et al. Smoking, but not lipids, lipoprotein(a) and antibodies against oxidised LDL, is correlated to the expansion of abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2001; 21:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/90\">",
"      Powell JT, Brady AR. Detection, management, and prospects for the medical treatment of small abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2004; 24:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/91\">",
"      Foster JH, Bolasny BL, Gobbel WG Jr, Scott HW Jr. Comparative study of elective resection and expectant treatment of abdomianl aortic aneurysm. Surg Gynecol Obstet 1969; 129:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/92\">",
"      Thompson AR, Cooper JA, Ashton HA, Hafez H. Growth rates of small abdominal aortic aneurysms correlate with clinical events. Br J Surg 2010; 97:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/93\">",
"      Szilagyi DE, Elliott JP, Smith RF. Clinical fate of the patient with asymptomatic abdominal aortic aneurysm and unfit for surgical treatment. Arch Surg 1972; 104:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/94\">",
"      Katz DA, Littenberg B, Cronenwett JL. Management of small abdominal aortic aneurysms. Early surgery vs watchful waiting. JAMA 1992; 268:2678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/95\">",
"      Nevitt MP, Ballard DJ, Hallett JW Jr. Prognosis of abdominal aortic aneurysms. A population-based study. N Engl J Med 1989; 321:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/96\">",
"      Brewster DC, Cronenwett JL, Hallett JW Jr, et al. Guidelines for the treatment of abdominal aortic aneurysms. Report of a subcommittee of the Joint Council of the American Association for Vascular Surgery and Society for Vascular Surgery. J Vasc Surg 2003; 37:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/97\">",
"      Lederle FA, Johnson GR, Wilson SE, et al. Rupture rate of large abdominal aortic aneurysms in patients refusing or unfit for elective repair. JAMA 2002; 287:2968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/98\">",
"      Bengtsson H, Bergqvist D, Ekberg O, Ranstam J. Expansion pattern and risk of rupture of abdominal aortic aneurysms that were not operated on. Eur J Surg 1993; 159:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/99\">",
"      Smoking, lung function and the prognosis of abdominal aortic aneurysm. The UK Small Aneurysm Trial Participants. Eur J Vasc Endovasc Surg 2000; 19:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/100\">",
"      Lederle FA, Larson JC, Margolis KL, et al. Abdominal aortic aneurysm events in the women's health initiative: cohort study. BMJ 2008; 337:a1724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/101\">",
"      Wilmink AB, Quick CR. Epidemiology and potential for prevention of abdominal aortic aneurysm. Br J Surg 1998; 85:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/102\">",
"      Newman AB, Arnold AM, Burke GL, et al. Cardiovascular disease and mortality in older adults with small abdominal aortic aneurysms detected by ultrasonography: the cardiovascular health study. Ann Intern Med 2001; 134:182.",
"     </a>",
"    </li>",
"    <li>",
"     National statistics based on the National Inpatient Sample. file://hcupnet.ahrq.gov/HCUPnet.jsp (Accessed on June 20, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/104\">",
"      United Kingdom Small Aneurysm Trial Participants. Long-term outcomes of immediate repair compared with surveillance of small abdominal aortic aneurysms. N Engl J Med 2002; 346:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/105\">",
"      Fillinger MF, Racusin J, Baker RK, et al. Anatomic characteristics of ruptured abdominal aortic aneurysm on conventional CT scans: Implications for rupture risk. J Vasc Surg 2004; 39:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/106\">",
"      Blackbourne LH, Tribble CG, Langenburg SE, et al. Optimal timing of abdominal aortic aneurysm repair after coronary artery revascularization. Ann Surg 1994; 219:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/107\">",
"      Paty PS, Darling RC 3rd, Chang BB, et al. Repair of large abdominal aortic aneurysm should be performed early after coronary artery bypass surgery. J Vasc Surg 2000; 31:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/108\">",
"      Durham SJ, Steed DL, Moosa HH, et al. Probability of rupture of an abdominal aortic aneurysm after an unrelated operative procedure: a prospective study. J Vasc Surg 1991; 13:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/109\">",
"      Li ZY, Sadat U, U-King-Im J, et al. Association between aneurysm shoulder stress and abdominal aortic aneurysm expansion: a longitudinal follow-up study. Circulation 2010; 122:1815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/11/11450/abstract/110\">",
"      Gasser TC, Auer M, Labruto F, et al. Biomechanical rupture risk assessment of abdominal aortic aneurysms: model complexity versus predictability of finite element simulations. Eur J Vasc Endovasc Surg 2010; 40:176.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15190 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-CAE5397922-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_11_11450=[""].join("\n");
var outline_f11_11_11450=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1428813\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H431205718\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1428624\">",
"      ANEURYSM TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1460375\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H91207428\">",
"      Rupture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H91204704\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H91204711\">",
"      Older age/male gender",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H91207198\">",
"      Race/ethnicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H91204718\">",
"      Smoking",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H91204748\">",
"      Family history/genetic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H91208494\">",
"      Other large vessel aneurysm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H91208501\">",
"      Association with atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H491541309\">",
"      Aortic infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1428675\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1428712\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H91206665\">",
"      Aortic expansion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1428719\">",
"      Risk of rupture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1428726\">",
"      - Aneurysm diameter",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H91211796\">",
"      - Rate of expansion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H91211810\">",
"      - Female Gender",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H91211817\">",
"      - Other factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H491541181\">",
"      Medical factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H491541195\">",
"      Recent surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H491541209\">",
"      Aneurysm configuration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1428755\">",
"      Long-term outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1428813\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/15190\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15190|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/29/9683\" title=\"figure 1\">",
"      Anatomy abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/25/44445\" title=\"figure 2\">",
"      Risk of rupture of AAA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32010?source=related_link\">",
"      Clinical features and diagnosis of abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20538?source=related_link\">",
"      Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38746?source=related_link\">",
"      Management of asymptomatic abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/17/35098?source=related_link\">",
"      Overview of infected (mycotic) arterial aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/40/28297?source=related_link\">",
"      Vascular endothelial function and fundamental mechanisms of fibrinolysis (thrombolysis)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_11_11451="Criteria schizoid personality";
var content_f11_11_11451=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F62678&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F62678&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnostic criteria for schizoid personality disorder",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Four or more of following plus general criteria for personality disorder:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1. Neither desires nor enjoys close relationships, including being part of a family",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2. Almost always chooses solitary activities",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3. Has little if any interest in having sexual experiences with another person",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4. Takes pleasure in few, if any, activities",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       5. Lacks close friends or confidants other than first-degree relatives",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       6. Appears indifferent to praise or criticism",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       7. Shows emotional coldness, detachment, or flattened affectivity",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed, Text revision (DSM-IV-TR). American Psychiatric Association, Washington, DC, 2000.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_11_11451=[""].join("\n");
var outline_f11_11_11451=null;
var title_f11_11_11452="Grading system SVC synd";
var content_f11_11_11452=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F72401&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F72401&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Proposed grading system for superior vena cava syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Grade",
"      </td>",
"      <td class=\"subtitle1\">",
"       Category",
"      </td>",
"      <td class=\"subtitle1\">",
"       Estimated incidence, percent",
"      </td>",
"      <td class=\"subtitle1\">",
"       Definition*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       Asymptomatic",
"      </td>",
"      <td>",
"       10",
"      </td>",
"      <td>",
"       Radiographic superior vena cava obstruction in the absence of symptoms",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       Mild",
"      </td>",
"      <td>",
"       25",
"      </td>",
"      <td>",
"       Edema in head or neck (vascular distention), cyanosis, plethora",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       Moderate",
"      </td>",
"      <td>",
"       50",
"      </td>",
"      <td>",
"       Edema in head or neck with functional impairment (mild dysphagia, cough, mild or moderate impairment of head, jaw or eyelid movements, visual disturbances caused by ocular edema)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       Severe",
"      </td>",
"      <td>",
"       10",
"      </td>",
"      <td>",
"       Mild or moderate cerebral edema (headache, dizziness) or mild/moderate laryngeal edema or diminished cardiac reserve (syncope after bending)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4",
"      </td>",
"      <td>",
"       Life-threatening",
"      </td>",
"      <td>",
"       5",
"      </td>",
"      <td>",
"       Significant cerebral edema (confusion, obtundation) or significant laryngeal edema (stridor) or significant hemodynamic compromise (syncope without precipitating factors, hypotension, renal insufficiency)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       5",
"      </td>",
"      <td>",
"       Fatal",
"      </td>",
"      <td>",
"       &lt;1",
"      </td>",
"      <td>",
"       Death",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Each sign or symptom must be thought due to superior vena cava obstruction and the effects of cerebral or laryngeal edema or effects on cardiac function. Symptoms caused by other factors (eg, vocal cord paralysis, compromise of the tracheobronchial tree, or heart as a result of mass effect) should not be considered as they are due to mass effect on other organs and not superior vena cava obstruction.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Yu JB, Wilson LD, Detterbeck FC. Superior vena cava syndrome-a proposed classification system and algorithm for management. J Thorac Oncol 2008; 3:811. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_11_11452=[""].join("\n");
var outline_f11_11_11452=null;
var title_f11_11_11453="Radiographic patterns in ILD";
var content_f11_11_11453=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F59082&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F59082&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Helpful radiographic patterns in the differential diagnosis of interstitial lung disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Normal*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hypersensitivity pneumonitis (common in population studies, rare in isolated chronic cases)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sarcoidosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Connective tissue disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bronchiolitis obliterans",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            IPF (especially early \"cellular\" stage)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Asbestosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lymphangioleiomyomatosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Airspace opacities",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pulmonary hemorrhage",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chronic or acute eosinophilic pneumonia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bronchiolitis obliterans with organizing pneumonia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Alveolar proteinosis",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Reticular or linear opacities",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Peripheral lung zone predominance",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Bronchiolitis obliterans with organizing pneumonia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Eosinophilic pneumonia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Upper zone predominance",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            Granulomatous disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Sarcoidosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Pulmonary Langerhans cell histiocytosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Chronic hypersensitivity pneumonitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Chronic infectious diseases (eg, tuberculosis, histoplasmosis)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            Pneumoconiosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Silicosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Berylliosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Coal miners' pneumoconiosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Hard metal disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            Miscellaneous",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Rheumatoid arthritis (necrobiotic nodular form)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Ankylosing spondylitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Radiation fibrosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Drug-induced (amiodarone, gold)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Lower zone predominance",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Idiopathic pulmonary fibrosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Rheumatoid arthritis (associated with usual interstitial pneumonia)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Asbestosis",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The HRCT scan is abnormal in most of these cases.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_11_11453=[""].join("\n");
var outline_f11_11_11453=null;
var title_f11_11_11454="Extended cylinder life";
var content_f11_11_11454=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F59690&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F59690&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cylinder life extended with conserving devices",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 392px; height: 315px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Calculated extended cylinder life using oxygen conserving devices of various delivery efficacies. The \"1X\" curve is the comparison curve without a conserving device. As the efficacy improves, the smallest oxygen cylinders become feasible for portable oxygen therapy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_11_11454=[""].join("\n");
var outline_f11_11_11454=null;
var title_f11_11_11455="Risk classific exercise class A";
var content_f11_11_11455=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F50753%7ECARD%2F60012%7ECARD%2F72809%7ECARD%2F52847%7ECARD%2F80110&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F50753%7ECARD%2F60012%7ECARD%2F72809%7ECARD%2F52847%7ECARD%2F80110&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk classification for exercise training: class A: apparently healthy individuals",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        This classification includes:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Children, adolescents, men &lt;45 years, and women &lt;55 years who have no symptoms or known presence of heart disease or major coronary risk factors.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Men &ge;45 years and women &ge;55 years who have no symptoms or known presence of heart disease and with &lt;2 major cardiovascular risk factors.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Men &ge;45 years and women &ge;55 years who have no symptoms or known presence of heart disease and with &ge;2 major cardiovascular risk factors.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Activity guidelines:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No restrictions other than basic guidelines.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Supervision required",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        ECG and blood pressure monitoring:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Not required",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * It is suggested that persons classified as Class A-2 and particularly Class A-3 undergo a medical examination and possibly a medically supervised exercise test before engaging in vigorous exercise.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fletcher GF, Balady GJ, Amsterdam EA, et al. Circulation 2001; 104:1694. Copyright &copy; 2001 Lippincott Williams and Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk classification for exercise training: class B: presence of known, stable cardiovascular disease with low risk for complications with vigorous exercise, but slightly greater than for apparently healthy individuals",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        This classification includes individuals with any of the following diagnoses:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Coronary artery disease (myocardial infarction, bypass surgery, angioplasty, angina pectoris, abnormal exercise test, and abnormal coronary angiograms) whose condition is stable and who have the clinical characteristics outlined below.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Valvular heart disease, excluding severe valvular stenosis or regurgitation with the clinical characteristics as outlined below.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Congenital heart disease; risk stratification for patients with congenital heart disease should be guided by the 36th Bethesda Conference recommendations.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Cardiomyopathy: ejection fraction &le;30 percent; includes stable patients with heart failure with clinical characteristics as outlined below but not hypertrophic cardiomyopathy or recent myocarditis.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        5. Exercise test abnormalities that do not meet any of the high risk criteria outlined in class C below.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Clinical characteristics (must include all of the following)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. New York Heart Association class 1 or 2.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Exercise capacity &le;6 METs.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. No evidence of heart failure.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        4. No evidence of myocardial ischemia or angina at rest or on the exercise test at or below 6 METs.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Appropriate rise in systolic blood pressure during exercise.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. Absence of sustained or nonsustained ventricular tachycardia at rest or with exercise.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7. Ability to satisfactorily self-monitor intensity of activity.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Activity guidelines:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Activity should be individualized, with exercise prescription provided by qualified individuals and approved by primary healthcare provider.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Supervision required:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Medical supervision during initial prescription session is beneficial.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Supervision by appropriate trained nonmedical personnel for other exercise sessions should occur until the individual understands how to monitor his or her activity.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Medical personnel should be trained and certified in Advanced Cardiac Life Support. Nonmedical personnel should be trained and certified in Basic Life Support (which includes cardiopulmonary resuscitation).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        ECG and blood pressure monitoring:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Useful during the early prescription phase of training, usually 6 to 12 sessions.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fletcher GF, Balady GJ, Amsterdam EA, et al. Circulation 2001; 104:1694. Copyright &copy; 2001 Lippincott Williams and Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk classification for exercise training: class C: those at moderate-to-high risk for cardiac complications during exercise and/or unable to self-regulate activity or to understand recommended activity level",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        This classification includes",
"individuals with any of the following diagnoses:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Coronary artery disease with the clinical",
"characteristics outlined below.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Valvular heart disease,",
"excluding severe valvular stenosis or regurgitation with the clinical",
"characteristics as outlined below.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Congenital heart disease; risk",
"stratification for patients with congenital heart disease should be",
"guided by the 27th Bethesda Conference recommendations.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Cardiomyopathy: ejection",
"fraction &lt;30 percent; includes stable patients with heart",
"failure with clinical characteristics as outlined below but not",
"hypertrophic cardiomyopathy or recent myocarditis.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Complex ventricular arrhythmias not well controlled.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Clinical characteristics (any",
"of the following):",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. NYHA class 3 or 4.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        2. Exercise test results",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Exercise capacity",
"&lt;6 METs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Angina or ischemic ST",
"depression at a workload &lt;6 METs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Fall in systolic blood",
"pressure below resting levels during exercise",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Nonsustained",
"ventricular tachycardia with exercise",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Previous episode of primary",
"cardiac arrest (ie, cardiac arrest that did not occur in the presence",
"of an acute myocardial infarction or during a cardiac procedure).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. A medical problem that the physician believes may",
"be life-threatening.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Activity guidelines:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Activity should be individualized, with exercise",
"prescription provided by qualified individuals and approved by primary",
"healthcare provider.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Supervision",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Medical supervision during all exercise sessions",
"until safety is established.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        ECG and blood pressure",
"monitoring:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Continuous during exercise sessions until safety is",
"established, usually &ge;12",
"sessions.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NYHA: New York Heart Association.",
"     <br>",
"      * Class C patients who have successfully completed a series of supervised exercise sessions may be reclassified to Class B providing that the safety of exercise at the prescribed intensity is satisfactorily established by appropriate medical personnel and that the patient has demonstrated the ability to self-monitor.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fletcher GF, Balady GJ, Amsterdam EA, et al. Circulation 2001; 104:1694. Copyright &copy; 2001 Lippincott Williams and Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk classification for exercise training: class D: unstable disease with activity restriction*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        This classification includes individuals with any of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Unstable ischemia.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Severe and symptomatic valvular stenosis or regurgitation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Congenital heart disease; criteria for risk that would prohibit exercise conditioning in patients with congenital heart disease should be guided by the 27th Bethesda Conference recommendations.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Heart failure that is not compensated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Uncontrolled arrhythmias.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. Other medical conditions that could be aggravated by exercise.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Activity guidelines:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. No activity is recommended for conditioning purposes.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Attention should be directed to treating the patient and restoring the patient to Class C or better.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Daily activities must be prescribed on the basis of individual assessment by the patient's personal physician.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Exercise for conditioning purposes is not recommended.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fletcher GF, Balady GJ, Amsterdam EA, et al. Circulation 2001; 104:1694. Copyright &copy; 2001 Lippincott Williams and Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Absolute and relative contraindications to exercise treadmill testing",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Absolute",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute myocardial infarction (within two days)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unstable angina",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uncontrolled cardiac arrhythmias causing symptoms or hemodynamic compromise",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Symptomatic severe aortic stenosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uncontrolled symptomatic heart failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute pulmonary embolus or pulmonary infarction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute myocarditis or pericarditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Active endocarditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute aortic dissection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute noncardiac disorder that may affect exercise performance or be aggravated by exercise (eg, infection, renal failure, thyrotoxicosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inability to obtain consent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Relative*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Left main coronary stenosis or its equivalent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Moderate stenotic valvular heart disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Electrolyte abnormalities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe hypertension (systolic &ge;200 mmHg and/or diastolic &ge;110 mmHg)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tachyarrhythmias or bradyarrhythmias, including atrial fibrillation with uncontrolled ventricular rate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypertrophic cardiomyopathy and other forms of outflow tract obstruction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mental or physical impairment leading to inability to cooperate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        High-degree atrioventricular block",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Relative contraindications can be superseded if benefits outweigh risks of exercise.",
"    </div>",
"    <div class=\"reference\">",
"     Data from Fletcher GF, Balady GJ, Amsterdam EA, et al. Exercise standards for testing and training: a statement for healthcare professionals from the American Heart Association. Circulation 2001; 104:1694; and Gibbons, RJ, Balady, GJ, Bricker, JT, et al. ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). Circulation 2002; 106:1883.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_11_11455=[""].join("\n");
var outline_f11_11_11455=null;
